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General Introduction
1BACKGROUND
Gastrointestinal symptoms stem from organs that constitute the gastrointestinal tract, 
from the mouth to the rectum. These symptoms have a broad spectrum, and include 
nausea, abdominal fullness, vomiting, regurgitation, diarrhoea, constipation and bloody 
stools. Symptoms originating from the upper gastrointestinal tract can be described as 
‘dyspepsia’. This word has been derived from the Greek words “įȣı” (dus = bad) and 
“ʌİʌĲȚİȞ” (peptien = to digest), and refers to problems with digestion of food and chronic 
or recurrent discomfort or pain in the upper abdomen. Patients can present with any 
combination of upper gastrointestinal symptoms, making the variation in clinical presen-
tation of patients with dyspepsia very broad. 
Causes of dyspepsia can be classified into two main categories: “organic” and “functional”. 
Gastroesophageal reflux disease (GERD) and peptic ulcer disease are the most common 
organic causes and are present in 25-40% of patients with dyspeptic symptoms in primary 
care.1,2 The prevalence of gastric or oesophageal cancer in patients with dyspepsia 
without alarm symptoms is less than 1%.3-5 Dyspepsia is called “functional”, in case 
diagnostic workup does not yield any abnormalities. 
EPIDEMIOLOGY
The prevalence of dyspepsia in western countries varies between 10% and 40% (Figure 
1).6-22 Reasons for the large range in reported prevalence include variations in: time period, 
definition used, country of origin and method of data collection. 
 
Figure 1: Prevalence of dyspepsia
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During the last 20 years, prevalence of risk factors for gastrointestinal symptoms has 
changed dramatically. New causes of gastrointestinal symptoms, e.g. widespread non-
steroidal anti-inflammatory drug (NSAID) and aspirin use, have emerged, while other 
factors, as the prevalence of Helicobacter pylori, have significantly declined.23,24 Due 
to these changes an update of the current population prevalence is warranted. The 
importance for a critical reconsideration regarding the current prevalence is emphasised 
by the large burden on our healthcare system, healthcare budget and individual health-
related quality of life.25-27 This is caused by the high prevalence and by the chronic, 
recurring symptom pattern of many gastrointestinal symptoms. 
PATHOGENESIS 
Functional dyspepsia is assumed to be a multifactorial disease, resulting from the inter-
action of biological, psychological and social factors.28 Studies in patients with functional 
dyspepsia have found that impaired gastric accommodation is present in approximately 
40% of patients.29,30 It is hypothesized that due to impaired relaxation, the gastric wall 
tension increases, which is associated with dyspeptic symptoms.31
Delayed gastric emptying is also a mechanism that has been associated with functional 
dyspepsia. In a meta-analysis, delayed gastric emptying was found in more than 35% of 
patients with dyspepsia.32 On the other hand there are also indications that rapid and not 
delayed gastric emptying causes dyspeptic symptoms.33 It is thought that visceral hyper-
sensitivity also plays a role in patients with functional dyspepsia. Visceral hypersensitivity 
is defined as an increased perception to visceral stimuli. Several studies have demon-
strated an abnormal visceral sensory function in patients with functional dyspepsia.34-37
Anxiety disorders, depression and somatoform disorders are more frequently diagnosed 
in patients with functional dyspepsia and the association between psychosocial factors 
and presence of gastrointestinal symptoms has been reported in multiple studies.38-40 
This association is present in the dyspepsia population that visits secondary and tertiary 
care centers, but also among the general population.38,41,42
Helicobacter pylori infection is a cause of organic dyspepsia. Since the initial discovery 
of H. pylori in 1982 by Robin Warren and Barry Marshall, the prevalence of  H. pylori has 
decreased from 38% to 11% of the general Dutch population.2,43  A higher prevalence 
is found in older patients and in patients from non-western countries.23-43
Simultaneous with the decreasing prevalence of H. pylori infection, the prevalence of reflux 
disease in the western world has increased.44 Gastroesophageal reflux disease (GERD) 
is defined by frequent symptoms of heartburn and / or regurgitation, which arise when 
reflux of stomach contents causes symptoms. The prevalence of GERD in Western 
countries is 10%-20%.16,45 GERD symptoms are included in some definitions of dyspepsia, 
while other classifications consider these symptoms as a separate entity. 
CLINICAL EVALUATION
The Dutch guideline “dyspepsia” is recently updated and recommends the following 
assessment of upper gastrointestinal symptoms (Figure 2).46
Figure 2: Clinical evaluation according to the Dutch guideline
H2RA: H2-receptor antagonist, NSAID: nonsteroidal anti-inflammatory drug, PPI: proton pump inhibitor
If a patient presents with upper gastrointestinal symptoms without alarm symptoms, use 
of gastrotoxic medication has to be evaluated. If this medication is not used, empirical 
treatment with acid suppressants can be initiated. The Dutch guideline recommends a 
step-up approach preserving the potent proton pump inhibitors (PPIs) for patients with 
persistent upper gastrointestinal symptoms, despite antacids and/or H2-receptor antago-
nists (H2RAs). A H. pylori test and treat strategy can be followed for patients originating from 
countries with a high H. pylori prevalence, or in patients with persistent or recurrent upper 
gastrointestinal symptoms.47-50 If alarm symptoms are present, such as unintentional 
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weight loss and/ or dysphagia, an upper endoscopy should be performed directly. Routine 
laboratory testing is not recommended. 
Additional investigations are being performed in less than 25% of patients who present with 
upper gastrointestinal symptoms in primary care.51-53 In primary care studies, 60%-70% 
of patients with upper gastrointestinal symptoms who undergo endoscopy, no or irrelevant 
abnormalities will be found.1,2
In the international medical literature, Rome criteria are used to categorise functional 
gastrointestinal disorders.54 The definition of functional dyspepsia according to the most 
recent Rome III criteria consists of at least one of the following symptoms: bothersome 
postprandial fullness, early satiety, epigastric pain or epigastric burning without evidence 
of structural disease (including upper endoscopy) that is likely to explain the symptoms. 
These symptoms must be present for the last 3 months; and the onset was at least 6 
months prior to diagnosis.55
THERAPEUTIC OPTIONS
If functional dyspepsia is suspected, treatment with an antacid or H2RA may be initiated 
according to the Dutch guideline. However, the current daily practice is that a PPI is the 
most frequently prescribed medication in patients with upper gastrointestinal symptoms 
(data from the Dutch Foundation for Pharmaceutical Statistics, SFK). The beneficial 
effects of PPIs have been widely proven in the treatment of GERD.56-59 In dyspepsia, the 
PPI efficacy is less obvious. A meta-analysis that compared PPIs with placebo in patients 
with functional dyspepsia found that PPIs were more effective with an estimated number 
needed to treat of 15 (95% CI, 8.7 - 57.1).60 H2RAs are also superior to placebo in the 
treatment of functional dyspepsia, but the evidence is weaker.61
Prokinetics, as domperidon, are also used in the treatment of dyspepsia. This is based 
on the hypothesis that decreased motility is one of the contributing factors in dyspepsia. 
Most studies that assessed prokinetic drugs in functional dyspepsia have been performed 
with cisapride and which demonstrated that cisapride was more effective than placebo.62 
However, these studies have limited methodological quality and cisapride was withdrawn 
from the Dutch market in 2009 due to cardiovascular side effects (i.e. QT prolongation).63 
In patients with functional dyspepsia not responding to the previously described treatment 
options, treatment with antidepressants can be considered.64-66
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- Medication use
Environmental factors (e.g. 
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Prevalence of gastrointestinal 
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RESEARCH AGENDA
We have chosen to study gastrointestinal symptoms at an epidemiological level. As 
depicted in Figure 3, this thesis aims to assess health determinants, such as demographic 
and lifestyle factors, and behaviour. As outcome we will assess presence of gastrointestinal 
symptoms and health-related quality of life, both overall and disease-specific. 
There are a number of known risk factors that contribute to presence of gastrointestinal 
symptoms. Prevalence of gastrointestinal symptoms decreases with increasing age.7,21 
The effects of smoking and alcohol on gastrointestinal symptoms are contradictory.7,12,15,17-19 
Medication can be a cause of gastrointestinal symptoms. The best-known examples are 
the use of NSAIDs and aspirin and their relation to gastrointestinal complications, such 
as dyspeptic symptoms and gastrointestinal bleeding.67-73 For other drugs the association 
with gastrointestinal symptoms is not studied or less certain.
In case of gastrointestinal symptoms, only around 25% of individuals will visit a healtcare 
provider.20,21,74 Irrespective of initiation of treatment or diagnostic tests, patients should always 
be adequately informed regarding possible causes and consequences of gastrointestinal 
symptoms. Nowadays, Internet is a frequently used source of information by patients. Based 
on information from the Internet and/ or a healthcare provider treatment can be initiated. 
Figure 3: Factors that determine risk for gastrointestinal symptoms 
RESEARCH QUESTIONS 
To gain a critical assessment regarding the current prevalence of gastrointestinal symptoms 
and associated factors at an epidemiological level, we composed the following questions 
as guiding themes. The most important components are prevalence, health-related quality 
of life and medications, both as cause of gastrointestinal symptoms and as treatment.
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1RESEARCH QUESTIONS IN THIS 
THESIS
1  What is the current prevalence of gastrointestinal symptoms in the Dutch general 
population? 
1a What is the current prevalence of gastrointestinal symptoms in general in the general 
population? (Chapter 2)
1b What is the prevalence of GERD symptoms in a sample of Dutch internet users? 
(Chapter 3)
1c What is the behaviour of GERD over time, assessed in an Internet population? 
(Chapter 4)
1d What is the gastrointestinal symptom presence in users of plain low-dose aspirin 
compared to users of buffered aspirin in the general population? (Chapter 8) 
1e What is the association between antidepressant use and presence of gastrointestinal 
symptoms in the general population? (Chapter 9)
2  What is the consequence of gastrointestinal symptom presence on health-related 
quality of life?
2a What is the health-related quality of life in respondents with gastrointestinal symptoms 
in the general adult population? (Chapter 2)
2b What is the health-related quality of life in respondents with GERD in an internet 
population? (Chapter 3)
3  What is the role of NSAIDs on gastrointestinal symptoms and complications?
3a What risk factors for gastrointestinal complications are present in international 
guidelines for NSAID users? (Chapter 5)
3b Is there a difference in prevalence of gastrointestinal symptoms between users of 
prescribed NSAIDs and over-the-counter (OTC) NSAIDs? (Chapter 6) 
4  What is the role of PPIs in the treatment of gastrointestinal symptoms?
4a What is the effectiveness of PPIs in respondents with GERD, followed via the Inter-
net? (Chapter 4)
4b What is the PPI-coprescription rate in NSAID users at increased risk for gastroin-
testinal complications? (Chapter 6)
4c Can PPIs relieve NSAID-associated upper gastrointestinal symptoms? (Chapter 7)
THESIS
In order to address the abovementioned issues we used 3 different study models.
1. QUESTIONNAIRES 
We have chosen to study the general population because gastrointestinal symptoms are 
frequently present and only a subset of persons with gastrointestinal symptoms will end 
up in the healthcare system (see Figure 4). 
Figure 4: Studied populations in this thesis 
We developed a questionnaire to assess presence of symptoms derived from the whole 
gastrointestinal tract. Most questionnaires are focussed on presence of a specific disease, 
like dyspepsia, GERD, irritable bowel syndrome (IBS) etc, while our aim was to assess the 
entire gastrointestinal system.75-79 Our questionnaire was used previously and has been 
adapted over time.80-82 The questionnaire has not yet been validated. However, a first 
step was made, during a study in which the answers of the gastrointestinal symptom as-
sessment on the questionnaire were compared with answers obtained via an interview.82 
This study concluded that the 7-point Likert scale for symptom assessment was compre-
hensible and had a good reproducibility for measuring the presence of gastrointestinal 
symptoms. As main drawback, the symptom severity was consistently rated higher in 
the questionnaire compared to the interview. The questionnaire was subsequently slightly 
adapted and tested in a pilot study involving more than 1500 subjects.81 To assess 
health-related quality of life, we added the widely used general health-related quality of life 
questionnaire “EuroQol EQ-5D” to the questionnaire used in our large general population 
survey.83 We submitted the questionnaire to 5 different communities in the Netherlands 
(Almere: 10,000 questionnaires; Den Haag: 10,000; Nijmegen: 20,000; Heumen: 6,012; 
General population
Subjects with gastrointestinal symptoms
Subjects visiting a general practitioner
Subjects searching the internet for health information
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Wijchen: 5,857). We chose these communities to obtain a representative geographical 
distribution; east versus west, village versus city. 
The advantage of using a paper-based questionnaire is that respondents can complete 
the questionnaire at a moment they prefer. As this is a frequently used method, the vast 
majority of participants know how to complete such a questionnaire. The disadvantage 
is that respondents can skip questions or that answers are unreadable, leading to incom-
plete questionnaires. These disadvantages are not present with internet based surveys. 
The drawback of surveys via the internet is selection bias, which will be higher compared 
to paperbased questionnaires, and the inability of a subset of the general population to 
use to the internet properly.84,85
To acquire a complete and complementary overview of the general population, we 
employed both methods (a web and paperbased questionnaire). By using both methods 
we are able to assess baseline characteristics, medication use, a broad spectrum of 
gastrointestinal symptoms, and health-related quality of life.
2. SYSTEMATIC REVIEW
To assess risk factors for gastrointestinal complications in NSAID users, we performed a 
systematic review of guidelines and consensus agreements that have been published in 
the international literature. As mentioned above, NSAID use is associated with gastroin-
testinal complications. The risk for patients to develop these complications is dependent 
on the presence of risk factors. Advanced age, co-medication and history of peptic ulcer 
disease are established risk factors.70 Although multiple studies have demonstrated a 
large number of risk factors, we still lack in depth quantitative knowledge how to interpret 
these data for the individual patient. For example, age is a well-known risk factor but we 
do not know at which age we should start to advice a gastroprotective strategy.86-89 Ideally 
we should be able to identify only those patients that have an increased risk for gastroin-
testinal complications and actively offer them  a gastroprotective strategy.90 Several guide-
lines were published to help to identify ‘at risk’ patients. We will study the level of agree-
ment in these guidelines. 
3. PROSPECTIVE INTERVENTION STUDY
According to the Dutch guideline, NSAID use is an important cause of upper gastrointestinal 
symptoms and should always be questioned during history taking.74 To assess whether 
PPIs could relieve gastrointestinal symptoms in NSAID users in clinical daily practice, we 
performed a trial in primary care that included NSAID users who presented with upper gas-
trointestinal symptoms. Most studies that assessed PPI efficacy in NSAID users, focused 
on gastrointestinal complications. Only few studies assessed gastrointestinal symptoms 
as primary outcome.91-93 We chose to perform an open-label study in primary care to re-
semble daily clinical practice as closely as possible. The advantage of our study method 
was the lower rate of selection bias, because subjects with comorbidity and co-medication 
were also included. The disadvantage of this study method was that we did not perform 
endoscopy to exclude other causes of symptoms and the study was not blinded and 
placebo controlled. 
OUTLINE OF THE THESIS
In Chapter 1, “the General Introduction”, we depicted a framework and provided background 
for this thesis. In Chapter 2 we will assess the prevalence of gastrointestinal symptoms 
and its association with health-related quality of life in a sample of randomly selected Dutch 
inhabitants. In Chapter 3 we will describe the presence of GERD and persistent symp-
toms in PPI users in website visitors of a dedicated GERD website who completed the 
GerdQ self-assessment questionnaire. We will highlight patterns of healthcare visits and 
symptoms over time of this internet population in Chapter 4. Guidelines and consensus 
agreements regarding gastrointestinal risk factors in NSAID users are systematically 
reviewed in Chapter 5. Chapter 6 describes the prevalence of gastrointestinal symptoms 
in OTC and on prescription NSAID users and assesses concomitant PPI use in those 
NSAID users at increased risk for gastrointestinal complications. The focus of Chapter 7 
is the effectiveness of PPIs on NSAID-induced gastrointestinal symptoms in a daily clinical 
practice setting in primary care. In Chapter 8 we will assess the prevalence of gastrointes-
tinal symptoms in low-dose aspirin users, with a comparison between acetylsalicylic acid 
and carbasalate calcium users. Chapter 9 describes the association between gastrointes-
tinal symptoms and antidepressants use. We complete this thesis by a General Discussion 
(Chapter 10) that summarizes and discusses the main findings of this thesis.
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ABSTRACT
Background Over the last decades important risk factors for gastrointestinal symptoms 
have shifted, which may have changed its population prevalence. The aim of this study 
was to assess the current prevalence of gastrointestinal symptoms, appraise associated 
factors and assess health-related quality of life in the general population.
Methods A total of 51,869 questionnaires were sent to a representative sample of the Dutch 
adult general population in December 2008. Demographic characteristics, gastrointestinal 
symptoms, health-related quality of life, medication use and comorbidity were reported. 
We used multivariable logistic regression analysis to determine factors associated with 
gastrointestinal symptoms. 
Results A total of 18,317 questionnaires were returned, and 16,758 were eligible for 
analysis. Prevalence of gastrointestinal symptoms was 26%. Most frequent symptoms 
were bloating (63%), borborygmi (60%) and flatulence (71%). Female gender (adjusted 
OR (aOR) 1.59, 95% CI 1.43 - 1.77), asthma/COPD (aOR 1.47, 95% CI 1.21 - 1.79), use of 
paracetamol (aOR 1.33, 95% CI 1.20 - 1.47), antidepressants (aOR 1.56, 95% CI 1.22 - 2.00) 
and acid-suppressive medication were independently associated with presence of 
gastrointestinal symptoms. Age over 65 years (aOR 0.75, 95% CI 0.65 - 0.87), and use 
of statins (aOR 0.75, 95% CI 0.61 - 0.93) were associated with a lower prevalence of 
gastrointestinal symptoms. Respondents with gastrointestinal symptoms had a lower 
mean health-related quality of life of 0.81 (SD=0.21) compared to 0.92 (SD=0.14) for 
persons without gastrointestinal symptoms (p < 0.01).
Conclusions Prevalence of gastrointestinal symptoms in the Dutch community is high 
and associated with decreased health-related quality of life. 
INTRODUCTION
Gastrointestinal symptoms are highly prevalent in the general population and are a frequent 
cause for consultation of a general practitioner.1 Individuals with gastrointestinal symptoms 
contribute heavily to healthcare utilization and budgeting. The yearly costs for individual 
patients with gastrointestinal symptoms are steep. For example, in the United States 
average direct healthcare costs for a number of symptoms such as constipation ($7522), 
functional abdominal pain ($7646) and irritable bowel syndrome ($5049) are considerable.2 
Large population studies in Western countries reported a widely ranging prevalence of 
dyspepsia from 10% to more than 50%.1,3-12 However, these studies were performed 
about 20 years ago and the risk factor profile for gastrointestinal symptoms has shifted 
since. For example, the incidence of Helicobacter pylori has rapidly decreased in the 
industrialized world,13,14 while use of proton pump inhibitors (PPIs) has been on the 
rise.15-17 Simultaneously, use of gastrotoxic medication, e.g. non-steroidal anti-inflam-
matory drugs (NSAIDs) and low-dose aspirin, is high.18 Finally, there is a global epidemic 
of obesity, which is associated with gastrointestinal symptoms and disorders, especially 
gastroesophageal reflux disease (GERD).19,20 The overall prevalence of upper gastroin-
testinal symptoms ranged from 24% to 45% in a recent study in 13 European countries.21 
Although performed in the current era, this study emphasized on socioeconomic factors, 
and did not report associations between gastrointestinal symptoms and modifiable factors 
such as BMI and smoking on an individual level.21 
Health-related quality of life is an important parameter in modern medicine and refers to 
the extent that an individual’s physical, emotional and social well-being is affected by a 
medical condition and its treatment. Individuals with gastrointestinal symptoms report a 
lower health-related quality of life,22-24 but this has been mainly studied in a subgroup of 
patients that have presented to a healthcare provider, which may not be a representative 
group. The exact impact of gastrointestinal symptoms on all domains of health-related 
quality of life in the general – including non-healthcare visiting – population remains unclear.
Given abovementioned considerations, new data on the prevalence of gastrointestinal 
symptoms in the general population are warranted. We hypothesize that the prevalence, 
despite all changes, has remained stable. The aims of our study were to assess: 1) the 
prevalence of gastrointestinal symptoms in the general population; 2) factors associated 
with presence of gastrointestinal symptoms; and 3) the effect of gastrointestinal symptom 
presence on health-related quality of life.
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MATERIAL AND METHODS 
STUDY POPULATION
We sent 51,869 questionnaires by postal mail to a sample of the Dutch population in 
December 2008. Invited subjects were at least 18 years and randomly selected from 
municipal databases of five different municipalities. These villages and cities were selected 
on their geographical location in The Netherlands, in order to fetch a representative sample. 
We included returned questionnaires until the end of March 2009. We excluded returned 
questionnaires with (1) missing of all baseline variables, (2) missing of all gastrointestinal 
symptoms, (3) missing of the primary outcome measure, or (4) unreadable input about 
medication use. 
The Medical Ethical Committee of the Radboud University Nijmegen assessed the proposal 
of this study and concluded that it could be waived for ethical review, as questionnaires 
were returned and stored anonymously, and (non-)responders would not be contacted 
again. For this reason, we did not obtain written informed consent of all participants.
QUESTIONNAIRE
The questionnaire we used was specifically designed to assess demographic information, 
gastrointestinal symptoms, medication use, healthcare visits, and health-related quality 
of life, and has been used before.15,25,26 Respondents were asked whether they suffer from 
gastrointestinal symptoms in general and subsequently for presence of 26 gastrointestinal 
symptoms including nausea, early satiety, bloating, constipation and diarrhoea. Severity 
of gastrointestinal symptoms was assessed on a seven-point Likert scale (0 = absent, 1 
= almost absent, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe, 6 = very 
severe) during the preceding four weeks.27 A symptom was considered to be present 
when scored t 2. 
Our primary outcome was the presence or absence of gastrointestinal symptoms, which 
was assessed with the question: “Do you experience gastrointestinal complaints?” and had 
to be answered with either “yes” or “no”. Secondary outcomes were type of gastrointes-
tinal symptoms experienced in the preceding four weeks and health-related quality of 
life, which was assessed with the validated EQ-5D questionnaire.28 The EQ-5D comprises 
5 domains of health status: mobility, self-care, usual activities, pain/ discomfort and anxiety/ 
depression. Each domain has 3 degrees of severity: no problems, some problems or 
extreme problems. The EQ-5D tariffs were calculated by using Dutch coefficients for 
Time Trade Off tariffs.29 The EQ-5D questionnaire also contains a visual analogue scale 
(EQ VAS), ranging from the worst imaginable health status to the best imaginable health 
status. 
We defined excessive consumption of alcohol as t 14 units (women) or t 21 units (men) 
per week.30 Body mass index (BMI in kg/m2) was categorized in < 25 (normal weight) 
and 25 or more (overweight or obese). 31 Excessive coffee consumption was defined as 
42 cups or more per week.25,32
STATISTICAL ANALYSIS
We analyzed data using Statistical Package for the Social Sciences (SPSS), version 16.0 
(IBM Corporation, New York, United States). Frequency tables were provided for respon-
dents’ characteristics and for secondary outcomes. Pearson’s chi-square (Ȥ2) analysis was 
used to compare categorical variables between respondents with and without presence 
of gastrointestinal symptoms. Continuous variables were compared between the two 
groups using Student’s t-test or Mann-Whitney U method whenever appropriate. We 
calculated presence of various symptoms at various ages by calculating symptom pres-
ence per 10 years. Univariable and multivariable logistic regression analysis were per-
formed to identify factors associated with gastrointestinal symptoms. Odds ratios and 
95% confidence intervals were stated. Covariates were included in multivariable regression 
analysis based on a predefined conceptual model that was based on published literature. 
We also included covariates if they were univariably associated with the primary outcome 
(p < 0.01).
Health-related quality of life was compared between respondents with and without 
gastrointestinal symptoms. The 5 domains of the EQ-5D questionnaire were compared 
using chi-square (Ȥ2) analysis. Dutch utility scores for every individual symptom in 
persons reporting gastrointestinal symptoms were calculated to assess the impact of an 
individual symptom on health-related quality of life. Correlation between gastrointestinal 
symptom score (VAS) and health-related quality of life (EQ VAS) was calculated with a 
Spearman correlation. A p-value < 0.01 was assumed to be statistically significant. 
RESULTS
A total of 18,317 (35%) questionnaires were returned, of which 742 returned unopened 
and uncompleted. After applying our predetermined exclusion criteria, a total of 16,758 
questionnaires were included in our analyses (Figure 1). In total, 4,315 persons (26%) 
reported gastrointestinal symptoms, with a median symptom duration of 8 years (inter-
quartile range 3-18 years). Compared to participants not reporting symptoms, those 
with gastrointestinal symptoms were younger (48.9 ± 16 vs. 50.2 ± 16 years), more of-
ten female (66% vs. 53%), and reported more frequently use of any medication (overall 
80% vs. 67%; Table 1).
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51,869 questionnaires sent
17,575 completed questionnaires 
received
817 questionnaires excluded* 
     284 all baseline variables missing
     308 primary outcome missing
     413 gastrointestinal symptoms missing
     111 medication unreadable     
742 questionnaires returned to sender
     360 no reason
     298 moved
       47 deceased
       37 not interested 
16,758 questionnaires analysed
The most frequently reported upper gastrointestinal symptoms were bloating (63%) 
and belching (45%; Table 2). Flatulence (71%) and borborygmi (60%) were the most 
frequently reported lower gastrointestinal tract symptoms (Table 3). Distribution of 
symptom presence among different age categories is depicted in Table 4.
The overall prevalence of gastrointestinal symptoms decreased with ageing. This was 
apparent in females (p<0.01), but not in males (p=0.22; Supplementary Table 1). There 
was no effect of Body mass index on upper versus lower gastrointestinal symptoms 
(data not shown).
Figure 1: Flowchart
* Some respondents fulfilled more than 1 exclusion criterion
Table 1: Population characteristics and factors associated with gastrointestinal symptom presence
Respondents 
with
gastrointestinal 
symptoms
Respondents 
without 
gastrointestinal 
symptoms
Unadjusted OR Adjusted ORa 
n/N n/N (95% CI) (95% CI)
Mean age (±SD) 48.9 (16) 50.2 (16) -- --
t 65 years (%) 747/4,300 (17) 2,451/12,389 (20) 0.85 (0.78 – 0.93) 0.75 (0.65 – 0.87)
Female (%) 2,784 /4,217 (66) 6,448/12,079 (53) 1.70 (1.58 – 1.83) 1.59 (1.43 – 1.77)
Body mass index  
t 25 kg/m2 (%)
2,067/4,224 (49) 5,549/12,213 (45) 1.15 (1.07 – 1.23) 1.02 (0.92 – 1.13)
Smoking (%) 840/4,247 (20) 2,089/12,242 (17) 1.20 (1.10 – 1.31) 1.12 (0.98 – 1.27)
Excessive alcohol  
consumptiona (%)
394/2,919 (14) 1,229/9,266 (13) 1.02 (0.90 – 1.15) 0.93 (0.81 – 1.07)
Excessive coffee  
consumptionb (%)
352/3,612 (10) 1,241/10,828 (12) 0.83 (0.74 – 0.95) 0.87 (0.74 – 1.02)
Comorbidity (%)
Diabetes mellitus 238/4,315 (6) 639/12,443 (5) 1.08 (0.93 – 1.26) 0.85 (0.64 – 1.13)
Rheumatoid arthritis 316/4,315 (7) 457/12,443 (4) 2.07 (1.79 - 2.40) 1.27 (0.99 – 1.62)
Asthma/COPD 393/4,315 (9) 651/12,443 (5) 1.82 (1.59 – 2.07) 1.47 (1.21 – 1.79)
Medication use (%)
PPIs 1,161/4,315 (27) 610/12,443 (5) 7.14 (6.43 – 7.94) 9.28 (7.91 – 10.9)
H2RAs 212/4,315 (5) 75/12,443 (1) 8.52 (6.53 – 11.1) 9.93 (6.72 – 14.7)
Antacids 588/4,315 (14) 437/12,443 (4) 4.33 (3.81 – 4.93) 4.22 (3.53 – 5.05)
Paracetamol 2,529/4,315 (59) 5,763/12,443 (46) 1.64 (1.53 – 1.76) 1.33 (1.20 – 1.47)
NSAIDs 1,076/4,315 (25) 2,157/12,443 (17) 1.58 (1.46 – 1.72) 1.02 (0.90 – 1.15)
Antiplatelet therapyc  462/4,315 (11)  1,221/12,443 (10) 1.10 (0.98 – 1.23) 1.08 (0.89 – 1.30)
Antidepressants 278/4,315 (6) 423/12,443 (3) 1.96 (1.68 – 2.29) 1.56 (1.22 – 2.00)
Statins 435/4,315 (10) 1,285/12,443 (10) 0.97 (0.87 – 1.09) 0.75 (0.61 – 0.93)
Oral contraceptives 339/4,315 (8) 716/12,443 (6) 1.40 (1.22 – 1.60) 1.22 (0.99 – 1.51)
Beta blockers 487/4,315 (11) 1,286/12,443 (10) 1.10 (0.99 – 1.23) 0.87 (0.71 – 1.06)
ACE inhibitors 227/4,315 (5) 727/12,443 (6) 0.90 (0.77 – 1.04) 0.81 (0.62 – 1.06)
Angiotensin-receptor 
antagonist
186/4,315 (4) 517/12,443 (4) 1.04 (0.88 – 1.23) 0.77 (0.58 – 1.03)
Diuretics 390/4,315 (9) 1,052/12,443 (9) 1.08 (0.95 – 1.22) 0.85 (0.68 – 1.06)
 
ACE: angiotensin converting enzyme, COPD: chronic obstructive pulmonary disease, H2RA: H2-receptor  
antagonist, NSAID: nonsteroidal anti-inflammatory drug, PPI: proton pump inhibitor 
aAdjusted for all variables depicted in this table 
bExcessive alcohol consumption is 14 units or more a week for women and 21 units or more a week for men 
cExcessive coffee consumption was defined as 42 cups a week and more  
dLow-dose acetylsalicylic acid, carbasalate calcium, clopidogrel and dipyridamol are taken together 
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Table 2: Type and frequency of upper gastrointestinal symptoms in respondents experiencing gastrointestinal 
symptoms
Number of respondents
n/N (%) 
Epigastric pain
In general 1,407/3,842 (36.6) 
During daytime 1,422/3,565 (39.9)
At night 867/3,452 (25.1)
Heartburn 
In general 1,366/3,916 (34.9)
During daytime 1,250/3,537 (35.3)
At night 953/3,494 (27.3)
Regurgitation 1,545/4,012 (38.5)
Belching 1,884/4,166 (45.2)
Empty feeling 1,008/4,039 (25.0)
Bloating 2,627/4,164 (63.1)
Nausea 1,278/4,139 (30.9)
Vomiting 327/4,109 (8.0)
Loss of appetite 796/4,119 (19.3)
Early satiety 1,409/4,121 (34.2)
Haematemesis 36/4,091 (0.9)
Dysphagia 
For liquids 141/4,088 (3.4)
For solid food 257/3,957 (6.5)
Table 3: Type and frequency of lower gastrointestinal symptoms in respondents experiencing gastrointestinal 
symptoms
Number of respondents
n/N (%) 
Lower abdominal pain
In general 1,755/4,075 (43.1)
Postprandial 1,176/3,477 (33.8)
Pre-prandial 726/3,379 (21.5)
No reduction after defecation 867/3,338 (26.0)
Flatulence 2,965/4,193 (70.7)
Borborygmi 2,479/4,138 (59.9)
Number of respondents
n/N (%) 
Abnormal defecation
Black stools 338/3,714 (9.1)
Blood 187/3,708 (5.0)
Mucous 557/3,751 (14.8)
Frequently hard 1,418/3,810 (37.2)
Diarrhoea 1,330/3,812 (34.9)
Constipation 1,060/3,859 (27.5)
Alternately solid or loose 1,939/3,979 (48.7)
Frequently painful 908/3,818 (23.8)
Strong urgency 1,541/3,853 (40.0)
Incomplete 1,143/3,811 (30.0)
Fatty stools 1,012/3,882 (26.1)
Table 4: Symptom presence in respondents with gastrointestinal symptoms at various age categories 
Age categories (years)
18 - 30 31 - 40 41 - 50 51 - 60 61 - 70 t 71
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Epigastric pain 
in general
257/650 
(39.5)
238/627 
(38.0)
303/799 
(37.9)
323/856 
(37.7)
196/594 
(33.0)
88/305  
(28.9)
Belching 335/672  
(49.9)
288/651 
(44.2)
396/870 
(45.5)
428/932 
(45.9)
278/678 
(41.0)
153/349 
(43.8)
Bloating 486/667 
(72.9)
441/647 
(68.2)
579/865 
(66.9)
583/942 
(61.9)
351/678 
(51.8)
181/352 
(51.4)
Heartburn  
in general
184/666 
(27.6)
223/636 
(35.1)
321/822 
(39.1)
324/853 
(38.0)
200/614 
(32.6)
108/314 
(34.4)
Borborygmi 511/669 
(76.4)
411/644 
(63.8)
523/864 
(60.5)
518/930 
(55.7)
331/669 
(49.5)
179/350 
(51.1)
Constipation 237/654 
(36.2)
194/618 
(31.4)
224/808 
(27.7)
203/851 
(23.9)
111/604 
(18.4)
86/311 
(27.7)
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FACTORS ASSOCIATED WITH GASTROINTESTINAL SYMPTOMS
We found that respondents with gastrointestinal symptoms more frequently reported ac-
id-suppressive medication use. Other factors that were also more frequently reported in 
respondents with gastrointestinal symptoms are depicted in Table 1. 
After adjustment, female gender (adjusted OR (aOR) 1.59, 95% CI 1.43 - 1.77), asthma/ 
COPD (aOR 1.47, 95% CI 1.21 - 1.79), use of paracetamol (aOR 1.33, 95% CI 1.20 - 1.47), 
antidepressants (aOR 1.56, 95% CI 1.22 - 2.00) and use of acid-suppressive medication 
(antacids aOR 4.22, 95% CI 3.53 - 5.05, H2RAs aOR 9.93, 95% CI 6.72 - 14.7, PPIs 
aOR 9.29, 95% CI 7.91 - 10.9) remained independently associated with a higher risk for 
presence of gastrointestinal symptoms (Table 1). Age t 65 years (aOR 0.75, 95% CI 0.65 - 
0.87), and use of statins (aOR 0.75, 95% CI 0.61 - 0.93) were independently associated 
with a lower risk for presence of gastrointestinal symptoms. In the univariable analysis 
obesity was associated with presence of gastrointestinal symptoms (OR 1.15, 95% CI 
1.10 - 1.31), but this association was lost after adjustment (aOR 1.02, 95% CI 0.92 - 1.13).
HEALTH-RELATED QUALITY OF LIFE
The mean utility for health-related quality of life was statistically significantly lower for 
respondents with gastrointestinal symptoms (0.81, SD 0.21) compared to respondents 
without gastrointestinal symptoms (0.92, SD 0.14, p < 0 .01). This difference was statis-
tically significant (p < 0.01) for all dimensions, and most pronounced for dimensions “pain/ 
discomfort”, “anxiety/ depression”, and “usual activities” (Table 5). The gastrointestinal 
symptom score (VAS) correlated negatively with health-related quality of life (EQ VAS) 
with a Spearman correlation of -0.57 (p < 0.01), indicating that persons with more severe 
gastrointestinal symptoms reported a lower health-related quality of life. The following 
individual symptoms were associated with the lowest health-related quality of life: 
haematemesis (0.54, SD 0.32), dysphagia for liquid (0.59, SD 0.32) and solid intake 
(0.62, SD 0.30) and vomiting (0.66, SD 0.30; Supplementary Table 2).
Table 5: Health-related quality of life in respondents with and without gastrointestinal symptoms
EQ-5D dimension
Respondents 
with 
gastrointestinal 
symptoms
n/N (%)
Respondents 
without 
gastrointestinal 
symptoms
n/N (%) P-value
Mobility < 0.001
No problems 3,440/4,203 (81.8) 10,880/12,194 (89.2)
Some problems 745/4,203 (17.7) 1,290/12,194 (10.6)
Extreme problems 18/4,203 (0.4) 24/12,194 (0.2)
Self-care < 0.001
No problems 4,039/4,191 (96.4) 11,904/12,154 (97.9)
Some problems 134/4,191 (3.2) 219/12,154 (1.8)
Extreme problems 18/4,191 (0.4) 31/12,154 (0.3)
Usual activities < 0.001
No problems 3,179/4,213 (75.5) 11,029/12,173 (90.6)
Some problems 952/4,213 (22.6) 1,065/12,173 (8.7)
Extreme problems 82/4,213 (1.9) 79/ 12,173 (0.6)
Pain/discomfort < 0.001
No problems 1,715/4,209 (40.7) 9,424/12,128 (77.7)
Some problems 2,263/4,209 (53.8) 2,559/12,128 (21.1)
Extreme problems 231/4,209 (5.5) 145/12,128 (1.2)
Anxiety/depression < 0.001
No problems 2,893/4,215 (68.6) 10,559/12,131 (87.0)
Some problems 1,185/4,215 (28.1) 1,485/12,131 (12.2)
Extreme problems 137/4,215 (3.3) 87/12,131 (0.7)
DISCUSSION
We found that 26% of the general population reported gastrointestinal symptoms, with 
a median duration of eight years. Our study identifies female gender, asthma/ COPD, 
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use of paracetamol, antidepressants and acid-suppressive medication use as risk factors 
that were independently associated with a higher prevalence of gastrointestinal symptoms. 
Older age and statin use protected against gastrointestinal symptoms. Respondents with 
gastrointestinal symptoms had an impaired health-related quality of life. In comparison 
to other, older, studies in the field,1,3-12 we found a similar prevalence of gastrointestinal 
symptoms in the community. This suggests that the effect of time is limited, although 
there are a plethora of differences between our study and others, most importantly the 
definitions used to assess prevalence of gastrointestinal symptoms. 
We found that females more frequently reported gastrointestinal symptoms, which is in 
line with other studies regarding gastrointestinal symptoms.9,25,33 In our study, presence 
of asthma or COPD was an independent risk factor. Presence of asthma is associated with 
GERD,34,35 and recent studies indicate an increased prevalence of GERD symptoms in 
patients with COPD.36-38 Medication use, and especially paracetamol, antidepressants, 
and acid-suppressive medication contributed significantly to presence of gastrointestinal 
symptoms in our large population-based survey. The independent association found for 
paracetamol, probably stems from the use of paracetamol as a panacea for gastrointes-
tinal symptoms. We surmise that this hypothesis also applies to the relation between 
acid-suppressive medication and gastrointestinal symptoms. The association between 
antidepressants and gastrointestinal symptoms is complex due to the interactions 
between: 1) depression and gastrointestinal symptoms; 2) depression and antidepressant 
use, and 3) antidepressant use and gastrointestinal symptoms.39-48
A total of 11% of our studied population reported PPI use, 2% H2RA use and 6% antacid 
use. This is much lower than the use of so-called ‘indigestion remedies’ in a study by Jones 
et al. prior to the PPI era, in which 47-55% of respondents reported any use of this med-
ication class.3 Use of PPIs was strongly associated with gastrointestinal symptom pres-
ence in our study (adjusted OR 9.28, 95% CI 7.91 - 10.9). This can by explained by a 
combination of indication bias, partial responsiveness on PPI therapy and assessment 
of both upper and lower gastrointestinal symptom presence. However, the prevalence of 
gastrointestinal symptoms would be even higher if we would include respondents with 
acid-suppressive medication without current gastrointestinal symptoms in our prevalence. 
In a recently published study, the prevalence of upper gastrointestinal symptoms in The 
Netherlands, the country where our study was performed, was 24%.21 We found an almost 
similar prevalence (26%), but we assessed both upper and lower gastrointestinal symp-
toms. We found that the majority of respondents with gastrointestinal symptoms had 
both upper and lower gastrointestinal symptoms. Respondents with upper gastrointes-
tinal symptoms have a higher risk for associated lower gastrointestinal symptoms. This 
is in line with a Japanese study that reported overlap of GERD, functional dyspepsia and 
IBS in 45% of their studied population.23 Moreover, in the natural history of functional 
gastrointestinal disorders many patients frequently switch between upper and lower 
gastrointestinal symptoms.49
We also reported the impact of gastrointestinal symptoms on health-related quality of 
life. Gastrointestinal symptoms were associated with a disutility of 0.11, which was in 
line with a disutility for dyspeptic symptoms of 0.09 in another study.50 Furthermore, we 
observed that more severe symptoms correlated with a lower health-related quality of 
life (Supplementary Table 2). By presenting a wide variety of utilities, we have delivered 
input for cost-utility studies. These studies become more and more important, and are 
incorporated in clinical guidelines, e.g. by the National Institute for Health and Care and 
Excellence (NICE).
The major strength of our study is that we examined commonly experienced symptoms 
in the community by use of a broad definition. Second, in order to attain a representa-
tive sample, persons were randomly selected via databases of local authorities without 
stringent in- and exclusion criteria. Third, we studied gastrointestinal symptoms overall 
and per symptom instead of in clusters of gastrointestinal symptoms.
Our study design comes with limitations. We cannot exclude response bias, as our response 
rate was 35%. Response rates in epidemiological studies are declining the last decades 
and this problem is faced by multiple researchers.51,52 A study by Galea et al. describes 
that a low response rate is not inevitably leading to substantial changes in outcomes.51 
Since our study was performed with postal questionnaires, in comparison to digital surveys, 
our response rate is actually not that low and still within the range of an acceptable 
response rate according to Galea et al. Due to concealment we were not able to perform 
non-responder research. We tried to minimize this bias by inviting all subjects with a 
personalized cover letter, and we asked explicitly to return the questionnaire, irrespective 
of presence of gastrointestinal symptoms. Seventy-four percent of all responders did 
not report the presence of gastrointestinal symptoms. Furthermore, the prevalence of 
co-morbidities in our study cohort resembles the prevalence in the general population.53 
Therefore, we assume that response bias might be limited. We also cannot exclude 
that bias was introduced by exclusion of individuals with incomplete information about 
gastrointestinal symptoms. 
The results of our study will refresh awareness among healthcare providers on the high 
prevalence of gastrointestinal symptoms in the general population. Future research 
should focus on new targets to effectively treat patients with gastrointestinal symptoms, 
as we have shown that even many users of acid-suppressive medication still report 
presence of symptoms. 
In conclusion, despite increased treatment options and alterations in risk factors, the 
prevalence of gastrointestinal symptoms in the western community remains high and is 
associated with a considerable decrease in health-related quality of life. 
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Supplementary Table 1: Prevalence of gastrointestinal symptoms per age category and gender
Age categories (years)
18 - 30 31 - 40 41 - 50 51 - 60 61 - 70 t 71
n/N (%) n/N (%) n/N (%) n/ N (%) n/N (%) n/N (%)
Male 
gender
161/764 
(21.1)
201/996 
(20.2)
290/1,404 
(20.7)
360/1,712 
(21.0)
274/1,408 
(19.5)
143/756 
(18.9)
Female 
gender 
505/1,513 
(33.4)
448/1,512 
(29.6)
576/1,886 
(30.5)
581/1,932 
(30.1)
432/1,493 
(28.9)
233/862 
(27.0)
 
Supplementary Table 2: Impact of individual gastrointestinal symptoms on health-related quality of life
Symptom EQ-5D Utility score
Mean (SD)
Epigastric pain
In general 0.74 (0.24)
During daytime  0.81 (0.19)
At night 0.72 (0.26)
Heartburn 
In general 0.78 (0.23)
During daytime 0.78 (0.23)
At night 0.77 (0.25)
Regurgitation 0.77 (0.23)
Belching 0.78 (0.22)
Empty feeling  0.75 (0.24)
Bloating 0.78 (0.22)
Nausea 0.71 (0.26)
Vomiting  0.66 (0.30)
Loss of appetite  0.67 (0.27)
Early satiety 0.73 (0.25)
Haematemesis 0.53 (0.32)
Dysphagia 
For liquids  0.59 (0.32)
For solid food 0.62 (0.30)
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Symptom EQ-5D Utility score
Mean (SD)
Lower abdominal pain
In general 0.74 (0.24)
Postprandial 0.75 (0.24)
Pre-prandial 0.71 (0.26)
No reduction after defecation 0.73 (0.25)
Flatulence 0.79 (0.21)
Borborygmi 0.78 (0.22)
Abnormal defecation
Black stools 0.71 (0.27)
Blood 0.73 (0.26)
Mucous 0.73 (0.25)
Frequently hard 0.76 (0.23)
Diarrhoea 0.76 (0.23)
Constipation 0.73 (0.25)
Alternately solid or loose 0.78 (0.22)
Frequently painful 0.70 (0.26)
Strong urgency 0.76 (0.23)
Incomplete 0.74 (0.24)
Fatty stools 0.74 (0.24)
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3ABSTRACT
Background Persons with gastroesophageal reflux disease (GERD) frequently search 
online for information about causes and treatment options. The GerdQ self-assessment 
questionnaire can be used for diagnosis of GERD and follow-up of symptoms.
Objectives To assess whether it is feasible (1) to study the prevalence and impact of GERD 
in persons visiting a GERD information website, and (2) to identify partial responsiveness 
to proton pump inhibitor (PPI) therapy using the GerdQ.
Methods All visitors (aged 18–79 years) to a GERD information website between November 
2008 and May 2011 were invited to complete the GerdQ online. The GerdQ questionnaire 
consists of 6 questions (score per question: 0–3). In respondents who did not use PPIs, 
we used the questionnaire to identify those with GERD (total score t8) and assess the 
influence of these symptoms on their daily life, divided into low (total score <3 on impact 
questions) and high impact (total score t3 on impact questions). In PPI users, we used 
the GerdQ to quantify partial responsiveness by any report of heartburn, regurgitation, 
sleep disturbance, or over-the-counter medication use for more than 1 day in the preceding 
week. We subsequently asked GerdQ respondents scoring t8 to complete the disease-
specific Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire.
Results A total of 131,286 visitors completed the GerdQ, of whom 80.23% (n = 105,329) 
did not use a PPI. Of these, we identified 67,379 respondents (63.97%) to have GERD 
(n = 32,935; 48.88% high impact). We invited 14,028 non-PPI users to complete the 
QOLRAD questionnaire, of whom 1231 (8.78%) completed the questionnaire. Mean 
total QOLRAD scores were 5.14 (SEM 0.04) for those with high-impact GERD and 5.77 
(SEM 0.04) for those with low-impact GERD (p < 0.001). In PPI users, 22,826 of 25,957 
respondents (87.94%) reported partial responsiveness. We invited 6238 PPI users to 
complete the QOLRAD questionnaire, of whom 599 (9.60%) completed the disease-
specific quality-of-life questionnaire. Mean total QOLRAD scores were 4.62 (SEM 0.05) 
for partial responders and 5.88 (SEM 0.14) for adequate responders (p < 0.001).
Conclusions The GerdQ identified GERD in many website respondents and measured 
partial responsiveness in the majority of PPI users. Both non-PPI users with GERD and 
PPI users with partial responsiveness were associated with a decreased health-related 
ife. We have shown the feasibility of GERD patient identification online.
INTRODUCTION
The Internet has gained major influence in the information supply for both physicians and 
patients in the last decades and has generated new opportunities to study healthcare and 
diseases.1-4 Traditionally, medical literature, treatment guidelines, and patient brochures on 
gastroesophageal reflux disease (GERD) have been available mainly at the general prac-
titioner’s office, and only 5%–30% of patients with GERD consult a general practitioner 
for their symptoms.5,6 A recent study found that more than half of online health information 
seekers searched the Internet without prior medical consultation.4
GERD is a chronic relapsing and remitting disorder with heartburn and regurgitation as 
cardinal symptoms. It is associated with a decreased health-related quality of life.7-9 
The prevalence of GERD in Western countries is 10%–20%5,10 and the disease accounts 
for 3%–5% of general practitioner visits.11,12 The main treatment focus is gastric acid 
suppression, for which proton pump inhibitors (PPIs) are most effective and are proven 
to be cost effective.13
The majority of persons with GERD symptoms are underreported in the literature, 
because prior studies regarding GERD were mainly conducted in primary care14. Most 
persons with GERD symptoms do not visit a primary care physician, which is a potential 
limitation in the understanding of symptom prevalence and treatment response. A 
German study assessed gastrointestinal symptoms and quality of life via an Internet 
questionnaire in 5256 individuals between 2002 and 2005.15 This study concluded that 
the generated data were in general comparable with non-Internet studies, with the 
exception that the Internet population was younger. Since then, only a few studies have 
been conducted on the prevalence of a condition in the general population via the Internet. 
The majority of Internet-based studies invite participants by email, for example, selected 
by clinicians or Internet panels,16,17 thereby preselecting participants.
The aims of the current study were to assess whether it is feasible to study the prevalence 
and impact of GERD in persons visiting a GERD information website and to identify partial 
responsiveness to PPI therapy using the GerdQ self-assessment questionnaire. Symptom 
scores were compared with a validated health-related quality-of-life instrument. We hypo-
thesized that the prevalence of GERD in our Internet population would be high and that 
a higher GerdQ score would reflect a lower health-related quality of life.
METHODS
STUDY POPULATION
The website www.maagzuur.nl contains information regarding GERD symptoms, possible 
causes, lifestyle advice, and treatment and diagnostic options. In May 2008, the Dutch 
translation of the GerdQ self-assessment questionnaire was launched on this website 
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and could be completed by all website visitors. After a preparatory period of 6 months, 
questionnaires completed between 24 November 2008 and 4 May 2011 were included 
in this study. We excluded respondents younger than 18 and older than 79 years. In the 
case of duplicate GerdQ questionnaires—defined as having an identical Internet protocol 
address, birth year, and gender—we included only the first completed GerdQ question-
naire. Respondents who scored t8 on the GerdQ were subsequently asked to complete 
the Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire.
THE GERDQ SELF-ASSESSMENT QUESTIONNAIRE
The GerdQ is a short and validated self-assessment questionnaire that assesses presence 
of GERD and determines the influence of symptoms on a patient’s daily life18. The GerdQ 
comprises six questions reflecting symptoms in the previous 7 days, and has been devel-
oped with questions from the Reflux Disease Questionnaire, the Gastrointestinal Symptom 
Rating Scale, and the Gastrointestinal Symptom Scale, all of which are validated disease-
specific questionnaires19-21. The GerdQ consists of the following questions referring to the 
previous week: (1) How often did you have a burning feeling behind your breastbone (heart-
burn)?, (2) How often did you have stomach contents (liquid or food) moving upward to 
your throat or mouth (regurgitation)?, (3) How often did you have a pain in the center of the 
upper stomach?, (4) How often did you have nausea?, (5) How often did you have difficulty 
getting a good night’s sleep because of your heartburn and/or regurgitation?, and (6) How 
often did you take additional medication for your heartburn and/or regurgitation, other than 
what the physician told you to take (such as Maalox)? (see Supplementary Table).
The first two questions (1 and 2) are positive predictors of GERD, where a higher symptom 
frequency is indicated by a higher score. Questions 3 and 4 address dyspeptic symptoms 
that decrease the probability of having GERD – that is, they are negative predictors of 
GERD. The two final questions (5 and 6) assess the impact of symptoms on a person’s 
daily life and are also positive predictors of GERD. The score on every question ranges 
from 0 to 3 for the four positive predictors of GERD (0 days is a score of 0; 1 day scores 
1; 2–3 days scores 2, and 4–7 days scores 3, or in reversed order for the two negative 
predictors of GERD). In people who do not use a PPI, a GerdQ score of t8 indicates a 
high probability of having GERD. A cut-off of t3 on the GERD-impact questions 5 and 6 
indicates a high impact of symptoms on a person’s daily life. 
We defined partial responsiveness in PPI users as more than 1 day of having heartburn 
(question 1), regurgitation (question 2), sleep disturbance (question 5), or over-the-counter 
acid-suppressive medication use (question 6), all during the preceding week. We also 
analyzed partial responsiveness using a more stringent definition of persistence of heartburn, 
regurgitation, sleep disturbances, or over-the-counter medication use for at least 4 days 
during the preceding week. The questionnaire was shown to respondents together with a 
figure of a human torso with the breastbone and center of the upper stomach being marked.
QOLRAD QUESTIONNAIRE
The validated disease-specific QOLRAD questionnaire was developed to monitor health-
related quality of life in patients with heartburn and dyspepsia. It contains 25 questions 
clustered in five domains: emotional distress, sleep disturbance, food and drink problems, 
physical and social functioning, and vitality.22,23 Every question was assessed on a 7-point 
Likert scale, with a lower score indicating a more severe impact on daily functioning (1 = 
always, 2 = usually, 3 = frequently, etc, to 7 = never).24
DATA ANALYSIS
Questionnaires were stored online in a specially designed website content management 
system (TripTic bv, Eindhoven, The Netherlands). Data were analyzed using SPSS version 
16.0 (IBM Corporation, Somers, NY, USA). We calculated total GerdQ score by summing 
scores for all of the GerdQ questions. The mean age of respondents with high-impact 
GERD and low-impact GERD were analyzed using the Student’s t-test. The mean age of 
PPI users with adequate relief and partial responders were also compared by Student‘s t-
test. We compared dichotomous variables, such as gender, by chi-square (Ȥ2) analysis. 
Over-the-counter medication use and duration of symptoms were analyzed using descrip-
tive statistics. An overall mean QOLRAD score was calculated by summing scores for all 
QOLRAD questions, divided by 25 for subgroups of PPI users and non-PPI users. We 
also calculated a mean score for each domain for respondents with high-impact GERD, 
low-impact GERD, PPI users with adequate relief, and partial responders to PPI therapy. 
In respondents with partial responsiveness, we analyzed subgroups of respondents with 
symptoms persisting at least 4 days per week versus those with less frequent symptoms. 
Using the Mann-Whitney U test, we compared mean scores in each QOLRAD domain 
between non-PPI users with low impact and those with high impact, and between PPI 
users with relief and those with partial response. We also compared mean scores in 
each QOLRAD domain between partial responders with symptoms persisting at least 4 
days per week and those with symptoms persisting at most 3 days per week. A p-value 
of < 0.05 was considered statistically significant.
RESULTS
The GerdQ self-assessment questionnaire was completed 153,415 times between 
November 2008 and May 2011. After removing duplicate entries (n = 16,447) and 
excluding respondents aged less than 18 years or 80 years and over (n = 5682), we 
entered 131,286 GerdQ questionnaires into our analysis (Figure 1). A total of 105,329 
respondents (80.23%) reported no use of PPIs and 25,957 respondents (19.77%) 
reported PPI use (Figure 1).
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Figure 1: Flowchart of participants
GERD: gastroesophageal reflux disease, PPI: proton pump inhibitor, QOLRAD: Quality of Life in Reflux and Dyspepsia
RESPONDENTS WITHOUT PROTON PUMP INHIBITOR USE
The mean age of the 105,329 respondents who did not use PPIs was 41.6 (SD 14) 
years, and 49.72% (n = 52,369) were male. A total of 37,950 respondents (36.03%) 
scored <8 on the GerdQ, indicating a low probability for GERD. The remainder (n = 
67,379; 64.0%) scored t8, of whom half (n = 32,935; 48.88%) reported GERD with a 
high impact on the respondent’s daily life. Respondents with GERD were older than 
those without GERD, and the mean age was even higher in respondents with GERD with 
high impact (Table 1).
 
Total study population
n = 153,415
PPI use
n = 25,957
Excluded n = 5682
      < 18 years, n = 4,773 
      > 79 years, n = 909
n = 131,286
No PPI use
n = 105,329
Partial response
n = 22,826
Adequate relief
n = 3,131
GERD high impact
n = 32,935
GERD low impact
n = 34,444
GerdQ < 8
n = 37,950
GerdQ  8
n = 67,379
QOLRAD
n = 16
QOLRAD
n = 583
QOLRAD
n = 735
QOLRAD
 n = 496
n = 136,968
Duplicates n = 16,447
Table 1: Baseline characteristics of respondents with and without proton pump inhibitor (PPI) use
Characteristic No PPI use PPI use
 
No GERD
(n = 37,950)
Low-impact
GERD
(n = 34,444)
High-impact
GERD
(n = 32,935)
Adequate
relief
(n = 3,131)
Partial
responsea
(n = 22,826)
Male, n (%) 17,562 
(46.28%)
18,035 
(52.36%)b
16,772 
(50.92%)
1,539 
(49.15%)c
10,132 
(44%)
Age (years), 
mean (SD)
39.2 
(14)
41.7 
(14)b
44.3 
(14)
49.9 
(14)c
48.3 
(14)
Age categories (years), n (%)
18 – 30 12,937 
(34.09%)
9,346 
(27.13%)b
6,500 
(19.74%)
349 
(11.15%)c
2,719 
(12%)
31 – 40 7,953 
(20.96%)
7,096 
(20.60%)
6,721 
(20.41%)
437 
(13.96%)
3,821 
(17%)
41 – 50 8,157 
(21.49%)
8,051 
(23.37%)
8,252 
(25.06%)
717 
(22.90%)
5,787 
(25%)
51 – 60 5,833 
(15.37%)
6,237 
(18.11%)
7,217 
(21.91%)
861 
(27.50%)
5,815 
(26%)
61 – 70 2,575 
(6.79%)
3,038 
(8.82%)
3,527 
(10.71%)
603 
(19.26%)
3,644 
(16%)
71 – 79 495 
(1.30%)
676 
(1.96%)
718 
(2.18%)
164 
(5.24%)
1,040 
(5%)
GERD: gastroesophageal reflux disease, PPI: proton pump inhibitor
aPartial response: heartburn, regurgitation, sleep disturbance, or over-the-counter medication use for >1 day 
during the preceding week
bp < 0.001 comparing low-impact GERD versus high-impact GERD
cp < 0.001 comparing adequate relief versus partial response in PPI users
Of respondents with low-impact GERD, 61.59% (n = 21,215) took over-the-counter 
medication less than once per week, compared with 8.64% (n = 2,846) of respondents 
with high-impact GERD (Table 2).
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Table 2: Frequency of over-the-counter medication use in respondents with and without proton pump
inhibitor (PPI) use
Frequency
(days/week)
No PPI use PPI use
No GERD
(n = 37,950)
Low-impact
GERD
(n = 34,444)
High-impact
GERD
(n = 32,935)
Adequate
relief
(n = 3,131)
Partial
responsea
(n = 22,826)
< 1 31,673 
(83.46%)
21,215 
(61.59%)
2,846 
(8.64%)
2,221 
(70.94%)
8,352 
(36.59%)
1 4,086 
(10.77%)
9,128 
(26.50%)
3,169 
(9.62%)
910 
(29.06%)
2,195 
(9.62%)
2 – 3 1,692 
(4.46%)
4,101 
(11.91%)
13,427 
(40.77%)
0 
(0%)
4,587 
(20.10%)
4 – 7 499 
(1.31%)
0 
(0%)
13,493 
(40.97%)
0 
(0%)
7,692 
(33.70%)
 
GERD: gastroesophageal reflux disease 
aPartial response: heartburn, regurgitation, sleep disturbance, or over-the-counter medication use for >1 day 
during the preceding week
In a subset of respondents we inquired about duration of symptoms. Of those with low-
impact GERD, 45.6% (n = 554) reported symptom duration of 1 year or less, while 
56.3% (n = 930) of those with high-impact GERD reported symptoms for more than 2 
years (Table 3).
Table 3: Duration of symptoms in respondents with and without proton pump inhibitor (PPI) use
Duration 
(months)
No PPI use PPI use
Low-impact 
GERD
(n = 1,215)
High-impact
GERD
(n = 1,652)
Adequate
relief
(n = 185)
Partial
responsea
(n = 1,381)
0 – 6 376 (30.95%) 290 (17.55%)b 34 (18.4%) 190 (13.76%)c
7 – 12 178 (14.65%) 213 (12.89%) 14 (7.6%) 123 (8.91%)
13 – 24 130 (10.70%) 219 (13.26%) 13 (7.0%) 131 (9.49%)
> 24 531 (43.70%) 930 (56.30%) 124 (67.0%) 937 (67.85%)
GERD: gastroesophageal reflux disease 
aPartial response: heartburn, regurgitation, sleep disturbance, or over-the-counter medication use for >1 day 
during the preceding week 
bp < 0.001 comparing low-impact GERD versus high-impact GERD 
cp = 0.28 comparing adequate relief versus partial response
A total of 14,028 respondents were eligible for (ie, GerdQ score t8) and invited to complete 
the QOLRAD questionnaire, of whom 1,231 (8.78%) completed the questionnaire. The 
total mean QOLRAD score in respondents with GERD with low impact on daily life was 5.77 
(SEM 0.04), compared with 5.14 (SEM 0.04) in those with high-impact GERD (p < .001; 
Figure 2). Quality of life was most impaired in the food/drink domain, and the differences 
in scores between high-impact and low-impact GERD were most pronounced in sleep 
disturbances and food/drink problems.
Figure 2: Quality of Life in Reflux and Dyspepsia (QOLRAD) scores by domain in respondents with 
gastroesophageal reflux disease (GERD) who did not use proton pump inhibitors (PPIs) 
Error bars indicate standard error of mean (SEM), *p < 0.001
PROTON PUMP INHIBITOR USERS
The mean age of PPI users was 48.5 (SD 14) years, and 44.96% (n = 11,671) were male. 
A total of 22,826 PPI users (87.94%) reported having heartburn or regurgitation, sleep 
disturbances due to GERD symptoms, or intake of over-the-counter acid-suppressive 
medication for more than 1 day per week. We classified these PPI users as partial respond-
ers, and this subgroup was younger and had a higher proportion of women (Table 1). 
Over-the-counter medication use for at least 4 days per week was reported by 33.70% 
(n = 7,692) of PPI users with partial response, whereas the majority of adequate responders 
(n = 2,221, 70.94%) reported over-the-counter acid suppression medication use of less 
than once per week (Table 2). 
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After applying a more stringent definition of partial response, of symptoms persisting at 
least 4 days per week, we obtained a total of 15,975 individuals (61.54%) reporting partial 
response.
A total of 6238 PPI users were eligible for and invited to complete the QOLRAD question-
naire, of whom 599 (9.60%) completed the disease-specific quality of life questionnaire. 
The total mean QOLRAD score over all domains was 5.88 (SEM 0.14) in PPI users with 
adequate relief and 4.62 (SEM 0.05) in PPI users with partial response (p < .001; Figure 3).
Figure 3: Quality of Life in Reflux and Dyspepsia (QOLRAD) scores by domain in proton pump inhibitor (PPI) users 
Error bars indicate standard error of mean (SEM) 
ap < 0.001, bp = 0.003, cp = 0.001, dp = 0.002
In both groups of PPI users, scores in the vitality and food/drink domains were lowest, 
with a consistently lower score in those with partial response. The total mean QOLRAD 
scores in the two subgroups of partial responders were 5.14 (SEM 0.09) for responders 
with symptoms persisting at most 3 days per week and 4.43 (SEM 0.06) for responders 
with symptoms persisting at least 4 days per week (p < 0.001 for all domains; Figure 4).
Figure 4: Quality of Life in Reflux and Dyspepsia (QOLRAD) scores by domain in proton pump inhibitor (PPI) 
users with subdivision of partial responders 
*p < 0.001 for the comparison between partial responders with symptoms persisting at most 3 days per week 
and those with symptoms persisting at least 4 days per week 
Error bars indicate standard error of mean (SEM)
DISCUSSION
PRINCIPAL RESULTS
We found that the prevalence of GERD in website visitors was high, as over 60% of 
responders without PPI use scored at or above the predefined cut-off on the GerdQ 
questionnaire. Of the respondents with GERD who did not use a PPI, 49% reported that 
their symptoms had a great influence on their daily life, in the form of sleep disturbances, 
and that they needed over-the-counter medications. This was associated with a decreased 
health-related quality of life. Almost 90% of PPI users reported persistent GERD symptoms 
for at least 1 day per week. Partial responders taking PPI therapy had a lower health-related 
quality of life than those who did not use PPIs and those with adequate symptom relief 
obtained from PPI therapy.
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We used the validated self-assessment questionnaire GerdQ to assess the prevalence 
of GERD among website visitors. Research via the Internet has several advantages and 
generates new possibilities. As only a minority of patients with GERD visit a healthcare 
provider, we can use the Internet to study people who are normally out of the scope of 
traditional research methods.25 Another advantage is that missing answers can be directly 
supplemented during completion of the questionnaire. Data are directly stored electronically, 
avoiding unreadable handwriting and subsequent mistakes.26 Data processing via Internet 
research saves time, especially in studies with many participants. Respondents are able 
to complete an Internet questionnaire at any time of day, anywhere.
We have shown that it is possible to detect patients with GERD symptoms through a 
dedicated website. This method can also be used for other conditions. We found that over 
150,000 respondents completed the GerdQ questionnaire made accessible online on a 
health information website, emphasizing the need for disease information on the Internet. 
However, the skills of the general population to adequately seek health information on 
the Internet have been shown to be insufficient.27 These deficiencies varied from problems 
with opening various common file formats and using hyperlinks embedded in different 
formats, to problems with appropriately evaluating the information they found.27
In our study, only 10% of invited respondents completed the QOLRAD questionnaire. We 
consider the low response rate on completing the QOLRAD questionnaire to be the main 
drawback of research via an open access questionnaire. Respondents lack face-to-face 
contact and miss any relationship with the researchers, reducing their willingness to com-
plete a questionnaire without any expected personal gain. A previous study by McCambridge 
et al. assessed the effect of length and relevance of questionnaires on completion rates.28 
They found that only relevance, and not length of the questionnaire, influenced response 
rate. Another limitation of Internet research is that researchers are unaware of the accuracy 
of the given information. However, this also applies partly to telephone surveys and paper-
based questionnaires.
PARTIAL RESPONSIVENESS IN PROTON PUMP INHIBITOR USERS
We used the GerdQ self-assessment questionnaire to identify partial responsiveness in 
PPI users. This is a novel and very promising feature of the GerdQ. We found that almost 
90% of all PPI users had heartburn or regurgitation, sleep problems, or over-the-counter 
acid-suppressive medication use for more than 1 day per week. Of the PPI users, 62% 
reported persistent symptoms on at least 4 days during the preceding week. Respondents 
with symptoms persisting at least 4 days per week reported the lowest health-related 
quality of life in our survey.
A recently published systematic review found that reflux symptoms during PPI therapy 
persisted in 17%–45% of patients in primary care and the general population.14 We 
found a higher proportion of partial responders. This may be due to three independent 
elements. First, the definitions used in the included articles of the systematic review were 
not uniform and did not take aspects of quality of life into account. Second, in our study, all 
website visitors could complete the GerdQ, including those with comorbidity, who are 
normally excluded from trials. To obtain a maximal treatment effect in clinical trials, respon-
dents with a high risk for decreased efficacy are normally excluded.29 Third, people with 
incomplete symptom relief are likelier to search the Internet for more information.
STRENGTHS AND LIMITATIONS
Our study has several strengths. We included over 130,000 participants in our study, 
which is the largest population studied for GERD so far.7,8,30 We used a new, innovative 
way to collect data. Online data collection can be adequately used in the Netherlands, 
because more than 85% of Dutch inhabitants already had Internet access in 2008. This 
is the highest Internet coverage in Europe and would only have increased further during 
the last 4 years31. Using the GerdQ as a promising tool to assess the response of GERD 
patients to PPI therapy is a novelty. The GerdQ can be used as an easy and quick ques-
tionnaire to identify people with an incomplete response. Studies have demonstrated that 
most physicians presume that PPI therapy is effective in GERD.32 However, PPIs do not 
help a significant percentage of patients, which is related to a decreased health-related 
quality of life.33,34
Our study also has limitations. First, we have to take selection bias into account. Online 
health information seekers are probably younger and more educated than are people 
who search for health information offline.35 We hypothesize that respondents with more 
severe symptoms might be overrepresented, as they are likely more motivated to search 
for information.36 However, a US survey comparing characteristics of offline and online 
health information seekers found that online seekers reported a better health status.35 
Another aspect of selection bias in our study is that only a minority of respondents 
completed the QOLRAD questionnaire. A second limitation is that information regarding 
comorbidity, medical history, or use of other medications was not available. Third, 
respondents with suspected GERD symptoms did not undergo endoscopy or pH 
recording. However, previous research demonstrated that the GerdQ has a comparable 
sensitivity and specificity as a gastroenterologist in diagnosing GERD.18
IMPLICATIONS
The results of our study have some important implications for clinical practice. Many 
persons searching the Internet for information about reflux have GERD. This generates new 
opportunities for using the Internet to recognize and treat GERD. It is possible to detect 
people with GERD and to advise them at first to adjust their lifestyle and take an over-
the-counter medication. If these measures are ineffective, these people can be advised 
to seek medical treatment. People can also regularly complete the GerdQ self-assessment 
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questionnaire via the Internet to assess the effectiveness of their treatment. If they are 
dissatisfied, they can contact a health care practitioner.
Most PPI users searching the Internet report persistent symptoms or use over-the-counter 
medication in addition to PPI treatment. General practitioners and gastroenterologists 
assume that most patients with GERD are adequately treated,32 while our study showed 
the contrary. Health care providers can now use the GerdQ at every consultation to assess 
persistent symptoms on PPI therapy and the impact of reflux symptoms on daily life. 
When necessary, treatment can be adjusted. Further research should investigate the 
superiority of GerdQ-assisted practice over standard care. The first study to assess 
incorporation of the GerdQ in daily practice was recently published.37 It compared the 
GerdQ with an endoscopy-based approach for diagnosis and initial treatment of GERD, 
and concluded that using the GerdQ reduced health care costs with comparable efficacy.
We have shown that it is feasible to find patients through a dedicated website for GERD. 
This concept will also be applicable to other conditions and diseases.
CONCLUSIONS
The GerdQ self-assessment questionnaire was completed by over 130,000 website 
visitors. Two-thirds of respondents who did not use PPIs obtained a score suggestive of 
GERD. The prevalence of partial responsiveness to PPI therapy was high. Respondents 
reporting a high impact of GERD had a decreased disease-specific health-related quality 
of life. Identification of people with GERD through a GERD information website has been 
shown to be feasible.
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Supplementary Table: The GerdQ Self-assessment questionnaire
Symptoms present in the last 7 days
Symptom presence
0 days 1 day 2-3 days 4-7 days
Question:
1. How often did you have a burning 
feeling behind your breastbone  
(heartburn)?
0 1 2 3
2. How often did you have stomach  
contents (liquid or food) moving  
upwards to your throat or mouth  
(regurgitation)?
0 1 2 3
3. How often did you have a pain in  
the center of the upper stomach?
3 2 1 0
4. How often did you have nausea? 3 2 1 0
5. How often did you have difficulty  
getting a good night’s sleep  
because of your heartburn and/or 
regurgitation? 
0 1 2 3
6. How often did you take additional 
medication for your heartburn and/or 
regurgitation other than what the  
physician told you to take (such as 
Maalox)? 
0 1 2 3
 
GerdQ symptom scores:
GerdQ < 8: low probability for GERD 
GerdQ t 8 and < 3 on questions 5 and 6 (impact questions): GERD with low impact on daily life
GerdQ t 8 and t 3 on questions 5 and 6 (impact questions): GERD with high impact on daily life 
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ABSTRACT
Background Many individuals with gastroesophageal reflux disease (GERD) never visit 
their general practitioner. Therefore, prospective data about GERD and its natural history 
in the general population are scarce. The aims of this study were to assess symptoms 
over time and consultation reasons in an Internet population with GERD.
Methods Visitors (18-79 years) to a GERD information website who completed the 
GerdQ self-assessment questionnaire were invited to participate. Follow-up GerdQ 
questionnaires were sent after 4, 12 and 24 weeks, and those who had a total GerdQ 
score t 8 and responded to at least the baseline and 4-week questionnaires (within 2-7 
weeks) were included in the analyses. Outcome in proton pump inhibitor (PPI) and non-PPI 
users was classified as symptom improvement, symptom persistence / stable symptoms, 
or symptom relapse according to GerdQ scores. 
Results A total of 403 non-PPI users (mean age 48 years; 40% male) and 304 PPI users 
(mean age 51 years, 41% male) were included. After 24 weeks, symptom improvement 
was present in 66% of non-PPI users (45/68) and 8% of PPI users (6/73), while persisting 
symptoms were reported by 24% (16/68) and 89% (65/73) respectively (baseline symp-
toms did not influence outcome at 24 weeks). Fifty-five percent of PPI users (116/210) 
and 37% of non-PPI users (76/207) who intended to visit a healthcare practitioner, 
performed one or more healthcare visits in the interim. Most frequently reported reason 
for consultation was persistence of symptoms. 
Conclusions GERD symptoms were persistent in the majority of PPI users during 
our 24-week follow-up, while almost two thirds of non-PPI users reported symptom 
improvement. Online follow-up of an Internet population with GERD is feasible. 
BACKGROUND 
Gastroesophageal reflux disease (GERD) is a frequent disorder with a prevalence in Western 
countries of around 10-20%.1-3 As GERD is common in the middle-aged population, it 
is associated with decreased work productivity, including work absenteeism, leading to 
substantial indirect healthcare costs. 4-7
Despite the high burden of GERD on available healthcare resources, data about the natural 
course of GERD are scarce.8,9 As ‘second best’, data from placebo groups included in 
randomized therapeutic trials can be evaluated to develop insight into the natural history 
of GERD. However, those studies are mainly performed in primary and secondary care, 
where only around 30% of individuals with GERD symptoms (range: 5 - 56%) ever present 
with their symptoms.10 Consequently, many individuals that suffer from GERD are not 
considered for inclusion in those studies. 
Use of the Internet is nowadays widespread and many individuals use this source for 
healthcare information.11-14 A Dutch website with information about GERD was launched 
and website visitors could complete an online survey about symptoms and proton pump 
inhibitor (PPI) use. Reasons for visiting a general practitioner or to refrain from consultation 
were also asked. This model provides a unique opportunity to evaluate a population that 
have not yet entered the healthcare arena. 
The aims of our study are: 1) to prospectively assess GERD symptoms online; 2) to 
study healthcare practitioner consultation patterns; and 3) to study underlying reasons 
for healthcare visits. 
 
METHODS
STUDY DESIGN AND PARTICIPANTS
The Dutch website www.maagzuur.nl (“maagzuur” is Dutch for “gastric acid”) contains 
information regarding GERD symptoms, possible causes, lifestyle advice, diagnostic 
options and treatment. In May 2008 the Dutch translation of the GerdQ self-assessment 
questionnaire (Table 1) was launched on this website and could be completed by all 
website visitors. After a preparatory period of 6 months, questionnaires completed 
between 5 December 2008 and 2 April 2009 could be included in this study. Follow-up 
GerdQ questionnaires were sent to all participants (aged 18-79 years) who had a baseline 
total GerdQ score t 8 and agreed to be contacted again. Questionnaires were sent to 
eligible respondents after 4, 12 and 24 weeks after completion of the baseline questionnaire. 
Those who did not complete the first follow-up survey within 7 weeks were excluded to 
minimize variance. In case of duplicate GerdQ questionnaires entries – defined as: identical 
IP address, birth year and gender – only the first completed GerdQ questionnaire was 
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taken into account. Respondents were regarded PPI users as they stated acid-suppressive 
medication use. The remainder was classified as non-PPI users. 
The Medical Ethical Committee of the Radboud University Nijmegen assessed the research 
proposal of this study and concluded that it could be waived for ethical review, as we did 
not gather information about participants from other sources (e.g. medical records) and 
data storage occurred in accordance with Dutch law. For this reason, we did not obtain 
written informed consent of all participants.
GERDQ SELF-ASSESSMENT QUESTIONNAIRE 
The GerdQ is a short and validated self-assessment questionnaire that assesses presence 
of GERD and determines the impact of symptoms on patients’ daily lives.15-18 The GerdQ 
comprises six questions reflecting symptoms in the previous 7 days, and has been devel-
oped with questions from the Reflux Disease Questionnaire (RDQ), the Gastrointestinal 
Symptom Rating Scale (GSRS), and the Gastrointestinal symptom Scale (GIS), which 
are all validated disease-specific questionnaires.19-21 The first two questions (1 and 2) are 
positive predictors of GERD, and a higher score suggests a higher symptom frequency. 
Questions 3 and 4 address dyspeptic symptoms that lower the probability for GERD, i.e. 
they are negative predictors of GERD. The two final questions (5 and 6) assess the impact 
of GERD symptoms on peoples’ lives and are also positive predictors of GERD. The 
score on every question ranges from 0 to 3 for the four positive predictors of GERD (0 
days is a score of ‘0’, 1 day is ‘1’, 2-3 days is ‘2’, 4-7 days is ‘3’, or in reversed order for 
the two negative predictors of GERD) (Table 1). 
Table 1: GerdQ Self-assessment questionnaire
Symptoms present in the last 7 days
Symptom presence
0 days 1 day 2-3 days 4-7 days
Question:
1. How often did you have a burning feeling behind 
your breastbone (heartburn)?
0 1 2 3
2. How often did you have stomach contents (liquid 
or food) moving upwards to your throat or mouth 
(regurgitation)?
0 1 2 3
3. How often did you have a pain in the center of the 
upper stomach?
3 2 1 0
4. How often did you have nausea? 3 2 1 0
5. How often did you have difficulty getting a good 
night’s sleep because of your heartburn and/ or 
regurgitation? 
0 1 2 3
6. How often did you take additional medication for 
your heartburn and/ or regurgitation other than 
what the physician told you to take (such as 
Maalox)? 
0 1 2 3
OUTCOMES
Our primary outcome in non-PPI users was “symptom improvement”, which was defined 
as a GerdQ score < 8 if the respondent scored t 8 on the previous questionnaire.  “Stable 
symptoms” were defined as GerdQ score t 8 at two subsequent completed questionnaires 
during follow-up. “Relapse” was defined as GerdQ t 8, in case the previous GerdQ 
score had been < 8.
Our primary outcome in PPI users, “symptom improvement”, was defined as a maxi-
mum of one day per week either heartburn (question 1), regurgitation (question 2), sleep 
disturbance (question 5), or over-the-counter (OTC) acid-suppressive medication use 
(question 6), all during the preceding week. Persistence of GERD symptoms in PPI users 
was defined as more than one day per week with either heartburn (question 1), regurgitation 
(question 2), sleep disturbance (question 5), or OTC acid-suppressive medication use 
(question 6), during the preceding week. If respondents reported symptoms more than one 
day per week for at least 2 subsequent GerdQ questionnaires, they fulfilled the criteria 
for “persistent symptoms”. If the participant reported an increase in symptoms from a 
maximum of one day per week to at least two times per week, this was defined as 
“symptom relapse”. 
STATISTICAL ANALYSIS
Data were analyzed with SPSS version 18.0. Baselines variables for respondents without 
PPI use and PPI users were assessed with descriptive statistics. Percentages of symptom 
improvement, stable symptoms, and relapse were assessed separately for PPI and non-
PPI users and were calculated with chi-square (Ȥ2) analysis or Fisher exact, whenever 
appropriate. If one of the follow-up questionnaires was missing, data were compared 
with the previous completed questionnaire (e.g. if Survey C was missing, data of Survey 
D and B were compared). Frequencies of heartburn, regurgitation, sleep disturbances and 
OTC acid-suppressive medication use during follow-up were calculated with frequency 
tables in respondents without PPI use. Mean symptom frequency within individuals during 
follow-up was assessed by paired t-tests in non-PPI users. We analyzed respondents 
according to (non-) PPI use at baseline.
Respondents were asked at baseline whether they intended to visit a healthcare practitioner. 
During follow-up we asked whether they had actually visited a healthcare practitioner. 
Reasons for consultation were assessed with closed questions and presented in frequency 
tables. If respondents performed more than one healthcare visit during follow-up, only 
reasons for the first visit were taken into account. In respondents that did not visit a 
healthcare provider during follow-up, reasons that were reported in the last completed 
questionnaire were included and depicted in frequency tables. 
Associations between outcome at 24 weeks and GerdQ score at baseline and type of 
symptom at baseline were analyzed with chi-square (Ȥ2) analyses. We also analyzed the 
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percentage of respondents that started or stopped their PPI with descriptive statistics. 
For this analysis, we only took the first medication switch into account. A per protocol 
analysis was performed, including only those respondents who did not change their use 
or non-PPI use during the 24-week follow-up. A p-value of < 0.05 was considered to be 
statistically significant.
 
RESULTS 
A total of 707 respondents met the predefined in- and exclusion criteria and completed 
the GerdQ between 5 December 2008 and 2 April 2009. (Figure 1). Forty-three percent 
of respondents (N=304) reported PPI use, the remainder were classified as non-PPI users. 
Mean age of individuals without PPI use was 48 years (SD 13) and 40% was male. Mean 
age of PPI users was 51 years (SD 12) and 41% was male.
Figure 1: Flowchart
*Identical IP-address, birth year and gender
PPI: proton pump inhibitor
In the non-PPI using group, 68 respondents completed follow-up, of which symptom 
improvement was present in 45/68 respondents (66%) and relapse in 7/68 respondents 
(10%, Figure 2). Symptoms were persistent in the remaining 16 respondents (24%). In 
addition, we assessed 4 individual GerdQ questions during follow-up (Table 2). 
N = 140 non-PPI users at week 12
N = 403 non-PPI users at week 4
N = 68 non-PPI users at week 24
N = 135 PPI users at week 12
N = 304 PPI users at week 4
N = 73 PPI users at week 24
Exclusion criteria:
-Age <18 years or >79 years
-No completion of 2nd follow-up questionnaire 
within 2 – 7 weeks
-Duplicate entries in baseline questionnaire*
N = 707
N = 403 non-PPI users at baselineN = 304 PPI users at baseline
Figure 2: Symptoms during follow-up in non-PPI users
* P < 0.05
** See Method section for definitions
GERD: gastroesophageal reflux disease, PPI: proton pump inhibitor
After 24 weeks, heartburn or regurgitation for a maximum of one day per week was 
reported by 44% and 81% of respondents without PPI use, respectively. Mean symptom 
frequencies of heartburn and regurgitation in non-PPI users significantly declined within 
individuals during follow-up from 2.21 at baseline to 1.43 at 24 weeks and from 1.20 
to 0.77, respectively (both p < 0.01). Mean symptom frequencies of sleep disturbance 
and OTC use in non-PPI users declined from 1.52 to 1.20 (p = 0.30) and from 1.58 to 
1.23 (p = 0.67), respectively. 
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Table 2: Individual symptoms during follow-up in respondents without PPI use
Symptom frequency
0 days 1 day 2 - 3 days 4 - 7 days
Heartburn during the preceding week
Baseline (%) 25/403 (6.2) 46/403 (11.4) 152/403 (37.7) 180/403(44.7)
4 weeks (%) 59/403 (14.6) 84/403 (20.8) 142/403 (35.2) 118/403 (29.3)
12 weeks (%) 23/140 (16.4) 40/140 (28.6) 41/140 (29.3) 36/140 (25.7)
24 weeks (%) 15/68 (22.1) 15/68 (22.1) 23/68 (33.8) 15/68 (22.1)
Regurgitation during the preceding week
Baseline (%) 124/403 (30.8) 136/403 (33.7) 82/403 (20.3) 61/403 (19.4)
4 weeks (%) 135/403 (33.5) 125/403 (31.0) 99/403 (24.6) 44/403 (10.9)
12 weeks (%) 61/140 (43.6) 40/140 (28.6) 26/140 (18.6) 13/140 (9.3)
24 weeks (%) 35/68 (51.5) 20/68 (29.4) 10/68 (14.7) 3/68 (4.4)
Sleep disturbance during the preceding week
Baseline (%) 81/403 (20.1) 108/403 (26,8) 136/403 (33.7) 78/403 (19.4)
4 weeks (%) 116/403 (28.8) 96/403 (23.8) 120/403 (29.8) 71/403 (17.6)
12 weeks (%) 49/140 (35.0) 36/140 (25.7) 34/140 (24.3) 21/140 (15.0)
24 weeks (%) 19/68 (27.9) 19/68 (27.9) 21/68 (30.9) 9/68 (13.2)
OTC use during the preceding week
Baseline (%) 107/403 (26.6) 68/403 (16.9) 117/403 (29.0) 111/403 (27.5)
4 weeks (%) 106/403 (26.3) 70/403 (17.4) 107/403 (26.6) 120/403 (29.8)
12 weeks (%) 39/140 (27.9) 30/140 (21.4) 33/140 (23.6) 38/140 (27.1)
24 weeks (%) 25/68 (36.8) 11/68 (16.2) 16/68 (23.5) 16/68 (25.3)
 PPI: proton pump inhibitor, OTC: over-the-counter
In PPI users who completed follow-up, 65/73 (89%) reported persistence of symptoms, 
6/73 (8%) reported symptom improvement and 2/73 (3%) relapse of symptoms (Figure 
3). Neither individual symptoms nor GerdQ scores at baseline were associated with 
symptom improvement at 24 weeks in respondents that did and did not use PPIs. 
During follow-up, 22% started (n = 89/403) and 17% stopped PPI use (n = 53/304). If 
we excluded these individuals from our analyses, we found that 69% of individuals without 
PPI use reported symptom improvement (33/48) at 24 weeks in this ‘per protocol’ analysis. 
In PPI users, 2 participants (2/61; 3%) reported symptom improvement, and the majority 
(58/61; 95%) reported persistent symptoms. 
Figure 3: Symptoms during follow-up in PPI users
GERD: gastroesophageal reflux disease, NS: not significant, PPI: proton pump inhibitor
*p < 0.05
** See Method section for definitions
HEALTHCARE CONSULTATION PATTERNS 
At baseline, 207 respondents without PPI use reported the intention to visit a health-
care provider. A total of 63 (30%) and 76 (37%) respondents who were planning to visit 
a physician had indeed visited a healthcare practitioner after 4 weeks and 24 weeks, 
respectively. A total of 210 PPI users intended this visit, and 116 (55%) with the intention 
to visit a physician had actually done so at the end of the follow-up.
The most reported reason to consult a healthcare provider was persistence of GERD 
symptoms, which was mentioned by 68% of non-PPI users and 73% of PPI users (Table 3). 
Table 3: Reasons for consultation for GERD symptoms* 
Non-PPI users
n = 95
PPI users
n = 134
GERD symptom persistence (%) 65 (68) 98 (73)
Increased GERD symptom severity (%) 34 (36) 54 (40)
No effect previous treatment (%) 8 (8) 49 (37)
Impact on daily life (%) 39 (41) 69 (52)
Someone else advised me to consult (%) 12 (13) 8 (6)
Information (%) 12 (13) 11 (8)
Worried (%) 42 (44) 49 (37)
Anxiety for serious cause (%) 19 (20) 40 (30)
Other reason (%) 2 (2) 4 (3)
GERD: gastroesophageal reflux disease, PPI: proton pump inhibitor
*Respondents could report more than one reason
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For non-PPI users, worries (44%) and impact on daily life (41%) were also frequently 
mentioned. In PPI users, impact on daily life (52%), and increased GERD symptom severity 
(40%) were frequently described reasons. The most reported reason to refrain from 
consultation was insufficient GERD symptom severity in non-PPI users (44%), and in PPI 
users (21%, Table 4). 
Table 4: Reasons to refrain from a healthcare provider visit for GERD symptoms*
Non-PPI users
n = 308
PPI users
n = 170
Expectation of decreasing GERD symptoms (%) 79 (26) 18 (11)
Insufficient GERD symptom severity (%) 136 (44) 35 (21)
Confidence in life style changes (%) 105 (34) 36 (21)
Over-the-counter medication use (%) 104 (34) 10 (6)
Do not want to take medication (%) 24 (8) 5 (3)
Afraid of diagnosis  (%) 9 (3) 1 (1)
Do not rely on the doctor (%) 6 (2) 7 (4)
Do not make time to visit healthcare provider (%) 71 (23) 16 (9)
Other reason (%) 27 (9) 80 (47)
I do not know anymore (%) 6(2) 9 (5)
PPI: proton pump inhibitor, GERD: gastroesophageal reflux disease 
*Respondents could report more than one reason
DISCUSSION
We found that 66% of the individuals without PPI use reported symptom improvement 
at the end of follow-up at 24 weeks. In contrast, only 8% of PPI users reported symptom 
improvement at the end of follow-up and 89% of PPI users reported persistent symptoms. 
Limited data are available about long-term effectiveness of PPI therapy in GERD. Short-term 
studies conclude that 17-45% of patients with GERD do not respond adequately to PPI 
therapy.22 Symptom severity was comparable or had improved in the majority of patients 
after five years in the proGERD study.23 However, patients included in this proGERD 
study were recruited from secondary care, whilst our population was not selected by 
physicians and we did not apply strict inclusion and exclusion criteria. Our population 
probably also contains respondents with functional upper gastrointestinal symptoms 
who are less likely to respond to PPI therapy than those with GERD. These factors, in 
addition to selection bias, could have contributed to the very high rate of persistence of 
symptoms in PPI users.
As we also focused on a different GERD population, namely Internet users with GERD 
symptoms without PPI use, we are not able to directly compare our results with others. 
As second best, we can use placebo responses in clinical trials. A meta-analysis in pa-
tients with GERD concluded that the average placebo response was 19%.24 Follow-up 
of  included studies was short with a maximum of 12 weeks. We found a higher percentage 
of symptom improvement at 4 and 12 weeks. This can be explained by the inclusion of 
patients with more severe symptoms in clinical trials and by the definition we used for 
symptom improvement. 
Because many individuals with GERD symptoms refrain from consultations, it is interesting 
to assess underlying reasons for the decision to visit or not. In a survey among GERD 
patients in primary care, 52% mentioned that “symptoms too uncomfortable to bear” was 
the main reason for consultation.25 The most frequently reported reason for consultation 
in our study was persistence of GERD symptoms (68% in non-PPI users, 73% in PPI users). 
Worries about their symptoms were reported by 44% of non-PPI users and 37% of PPI 
users. Fear is frequently thought to be one of the most important reasons for seeking 
help, but we were not able to confirm this assumption. 
We used the 6-item GerdQ self-assessment questionnaire for follow-up of GERD. The 
GerdQ appears to be a very promising tool to assess GERD symptoms in a structured, 
easy way and it is increasingly being used in clinical practice. A recently published study 
compared a treatment-algorithm based on the GerdQ with common practice of upper 
endoscopy and if indicated, pH metry in patients with GERD symptoms without any 
alarm signs. Use of the GerdQ approach was associated with a decrease in healthcare 
expenses, but had a comparable efficacy.16
We believe that our data adds to the total, diverse population of individuals with GERD, 
of which only a minority visits healthcare practitioners. We were able to demonstrate 
how GERD symptoms evolve on and off PPI treatment. However, including respondents 
online is associated with limitations, most importantly selection bias. We faced a high 
dropout rate, probably related to the noncommittal attitude of an online questionnaire and 
the fact that we asked respondents to complete a total of 4 questionnaires during follow-
up. We also do not have additional information about the medical history, comorbidity 
and reports of any additional investigations, such as upper endoscopy. We therefore 
cannot exclude that we included individuals with other diagnoses than GERD, or with 
concomitant diseases in addition to GERD. Another limitation is that we did not question 
the type and dose of PPI and the duration of use.
IMPLICATIONS
Our study has implications for clinical practice. We have shown that it is feasible to use 
the GerdQ self-assessment questionnaire in PPI users to assess response to acid-
suppressive therapy over time. We observed that two thirds of non-PPI users had symptom 
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improvement after 24 weeks. This supports the guidelines wherein the first treatment 
step is lifestyle advice.26,27 Effectiveness of lifestyle interventions has never been system-
atically studied, but in specific individuals these measures appear to be successful. In 
addition, our respondents reported confidence in lifestyle interventions (Table 4). When 
symptoms persist after lifestyle interventions, PPIs can be prescribed. 
Our unique approach of online incorporation and follow-up of individuals with GERD 
demonstrates that the Internet can be used to trace individuals with specific symptoms. 
The follow-up via the Internet can be used as complementary method to the traditional 
routes. The communication in our study was one directional, but we will foresee an 
increase in online health platforms with direct patient-physician communication by e-mail, 
blog, or message services. 
 
CONCLUSIONS
We found in our 24-week follow-up study via the Internet, that more than half of the 
respondents without PPI use reported symptom improvement. However, the vast majority 
of PPI users reported persistence of symptoms. The most frequently mentioned reason 
for healthcare visits was persistence of symptoms. Based on our results, we support the 
use of the GerdQ to assess GERD symptoms and we agree with current guidelines that 
PPI prescription is not the first treatment step when patients present with symptoms 
suggestive of GERD. We have shown that online follow-up of an Internet population with 
GERD is feasible. 
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ABSTRACT
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most often used drugs 
worldwide. Numerous NSAID users are at risk for developing gastrointestinal complications. 
The purpose of this review was to identify and stratify risk factors for gastrointestinal 
complications in NSAID users documented in guidelines and consensus agreements, 
and to collect recommendations regarding over-the-counter (OTC) NSAID use. To facilitate 
this, a PubMed search from 1 January 1999 until 1 March 2009 was performed, resulting 
in the inclusion of 9 English-language guidelines in our analysis. Risk factors were defined as 
‘definite’ if mentioned in all guidelines; otherwise they were defined as ‘controversial’ risk 
factors.
‘Definite’ risk factors were a history of (complicated) peptic ulcer disease, older age (cut-off 
range: 60-75 years), concomitant anticoagulant or corticosteroid use and multiple NSAID 
use, including low-dose aspirin (acetylsalicylic acid). ‘Controversial’ risk factors were high-
dose NSAID use, concomitant clopidogrel or selective serotonin reuptake inhibitor use, 
history of gastrointestinal symptoms, rheumatoid arthritis disability and cardiovascular 
disease. Infection with Helicobacter pylori was identified as an additive risk factor. Risk 
factors in OTC NSAID users were difficult to identify in the current literature.
Risk factors were not all uniformly present in analyzed guidelines and consensus 
agreements. We identified a history of (complicated) peptic ulcer disease, older age, 
concomitant anticoagulant or corticosteroid use and multiple NSAID use, including 
low-dose aspirin, as definite gastrointestinal risk factors in NSAID users.
 INTRODUCTION
NSAIDs are amongst the most frequently prescribed drugs, but their use can be aggravated 
by adverse effects.1-4 The most commonly reported adverse effects are gastrointestinal, 
cardiovascular and renal complications. Gastrointestinal adverse effects range from 
gastrointestinal complaints without visible mucosal lesions at endoscopy to serious 
gastrointestinal bleeding4. The prevalence of upper gastrointestinal complaints varies 
between 5% and 50% of patients receiving traditional and cyclooxygenase-2 (COX-2) 
selective NSAIDs.5-8 Common symptoms are epigastric pain, heartburn, nausea, regurgita-
tion, bloating and diarrhoea.9 About 1-2% of NSAID users acquire admission to a hospi-
tal for serious complications, such as gastric perforation and bleeding, both of which are 
associated with a high mortality rate.10,11 
A frequently employed method to minimize gastrointestinal risk associated with NSAID 
use is co-prescription of a gastroprotective agent, such as a proton pump inhibitor (PPI) 
or misoprostol.12-20 This strategy, however, is only cost-effective in NSAID users at high 
gastrointestinal risk.21 Therefore, several guidelines and consensus agreements were 
published that designate patients at risk for gastrointestinal complications.12-20 This dis-
tinction is based on patient-related risk factors. Guidelines and consensus agreements 
are not uniform in discussing risk factors or in otherwise attributing the importance of 
risk factors. Some risk factors are undisputed by authors of analyzed guidelines and 
consensus agreements whereas others are considered more controversial. 
Another issue of concern is gastrointestinal risk in the growing population of over-the-
counter (OTC) NSAID users.13 OTC NSAID use is often propagated by general physicians 
and specialists, but is seldom adequately monitored. A questionnaire-based study 
performed in Italy by Motola et al. showed that 23% of 2,738 randomly selected 
subjects had used NSAIDs in the previous week, of which 44% was bought OTC.22 No 
gastrointestinal complication prevention studies in OTC users have yet been reported. 
As a consequence, evidence-based guidelines do not recognize the potential gastroin-
testinal risk in OTC NSAID users. The growing OTC consumption of NSAIDs could well 
contribute to the incidence of gastrointestinal adverse effects and therefore should be 
addressed.
The aim of this study is to systematically review guidelines and consensus agreements 
identifying NSAID users, including those using prescribed NSAIDs and those obtaining 
NSAIDs OTC, who are at risk for gastrointestinal events. The emphasis of this review will 
be on individual risk factors for gastrointestinal adverse effects, the role of OTC availabil-
ity and the recognition of these in guidelines and consensus agreements.
 
Chapter 5
82 83
Identification of NSAID users at risk for gastrointestinal complications
5
METHODS
LITERATURE SEARCH
We conducted a structured search in PubMed to identify English-language clinical guide-
lines or consensus agreements regarding risk management of gastrointestinal adverse 
events in NSAID users, with an emphasis on risk factors and OTC use. Publications from 
1 January 1999 until 1 March 2009 were included. If a group of authors published more 
than one guideline, only the most recent was included. 
In the search strategy, the following subject headings and keywords were used: “Anti-
Inflammatory Agents, Non-Steroidal”[MeSH] or “nonsteroidal anti-inflammatory drugs” 
or “NSAID” and “guideline” or “consensus”. The following limits within PubMed were used: 
published in the last 10 years, Humans, Meta-Analysis, Practice Guideline, Consensus 
Development Conference. The reviewers (MT and TE) then individually assessed the 
relevancy of all abstracts corresponding with the remaining titles, and excluded abstracts 
for the following reasons: (1) not concerning gastrointestinal risk factors during NSAID 
use; (2) not written in English; and (3) no guideline or consensus agreement. From 
selected abstracts, full papers were reviewed and were only rejected if they (1) made no 
reference to gastrointestinal risk factors, or (2) were neither guidelines nor consensus 
agreements. Remaining manuscripts were independently assessed by the reviewers 
and included if they contained information regarding consideration of gastrointestinal 
risk factors in the management of NSAID users. Disagreements were adjudicated by dis-
cussion and consensus between the two primary reviewers and a third-party arbiter (MvO).
OUTCOMES
Our main interest was to identify common gastrointestinal risk factors among included 
guidelines and consensus agreements. For this purpose, we conducted a summary table 
for proper overview of all stated risk factors. Risk factors present among all included papers 
were defined as ‘definite’ risk factors. Remaining factors were discussed as ‘controversial’ 
risk factors. Classification, as indicated by the authors, of guidelines included was adopted.
OTC use was often not fully incorporated in guidelines; therefore, all statements regarding 
OTC NSAIDs were collected and presented in a separate table.
 
RESULTS
A total number of 224 studies were found, of which 215 articles were excluded in two 
selection procedures. The main reason for exclusion was no mention of a guideline or 
consensus agreement (Figure 1). Two articles were not written in English; the remaining 
nine papers were scrutinized by systematic review. Characteristics of included studies 
are shown in Table 1. 
Figure 1: Literature search
Table 1: Studies included in the review
Study Year 
published
Specialization Country
Lanza et al.16 2009 Gastroenterology USA, Hong Kong, 
Ireland
Bhatt et al.13 2008 Cardiology, Gastroenterology USA
Chan et al.14 2008 Gastroenterology Hong Kong, USA
Rostom et al.17 2008 Gastroenterology Canada
American College of 
Rheumatology12
2008 Rheumatology USA 
Targownik and  
Thomson19
2006 Gastroenterology, Family medicine Canada
Wilcox et al.20 2006 Gastroenterology, Rheumatology, 
Cardiology, Internal medicine
Canada, USA, 
Spain
Dubois et al.15 2004 Medical researcher USA
Schoenfeld et al.18 1999 Gastroenterology USA
%' &"'-
9 articles: no guideline or 
consensus
9 publications included
202 abstract excluded due to 
non-relevance
2 articles not written in English
2 excluded: 1 article published 
in three journals
Search terms PubMed:

"'".!!'#%,"'&"#"
steroidal [MeSH] OR NSAID OR 
nonsteroidal"'".!!'#%,%(&
AND guideline OR consensus with 
limits
&'%'&"'-
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DEFINITE RISK FACTORS
Risk factors for gastrointestinal complications in NSAID users present in all analyzed 
guidelines could be defined as ‘definite’ risk factors. We defined the following risk factors 
as ‘definite’: history of complicated (defined as peptic ulcer bleeding, obstruction or per-
foration) and uncomplicated peptic ulcer disease, older age, concomitant anticoagulant 
use, concomitant corticosteroid use and concomitant low-dose aspirin (acetylsalicylic 
acid) or multiple NSAID use (Figure 2, Table 2, Table 3). In this review we report on the 
most discussed variables only - older age and the use of multiple NSAIDs.
Figure 2: Presence of risk factors in analyzed guidelines and consensus agreements 
GI: gastrointestinal, NSAID: nonsteroidal anti-inflammatory drug, PUD: peptic ulcer disease, RA: rheumatoid arthritis, 
SSRI: selective serotonin reuptake inhibitor
Table 2: Overview presence of risk factors in analyzed guidelines
Risk 
factora 
Lanza 
et al.16
Bhatt 
et al.13
Chan 
et al.14
Rostom 
et al.17
Am Coll 
Rheum12
Targownik 
and 
Thomson19
Wilcox 
et al.20
Dubois 
et al.15
Schoenfeld 
et al.18
Age (years)
Age; threshold ' >65 ' t60 ' t70 ' >60-75 ' >75 ' t76 'b  t65  t60
History
Complicated PUD Ÿ Ÿ ' ' ' ' Ÿ Ÿ Ÿ
Uncomplicated PUD ' Ÿ NP ' NP ' Ÿ ' NP
GI symptoms NP ' NP ' NP NP NP NP NP
Concomitant therapy
Multiple NSAIDsc NP ' NP ' NP NP ' NP '
Low-dose aspirin 
(acetylsalicylic acid)
' ' ' ' ' ' d Ÿ d
Anticoagulants ' Ÿ ' ' ' ' ' ' Ÿ
Clopidogrel NP Ÿ ' ' NP NP NP NP NP
Risk 
factora 
Lanza 
et al.16
Bhatt 
et al.13
Chan 
et al.14
Rostom 
et al.17
Am Coll 
Rheum12
Targownik 
and 
Thomson19
Wilcox 
et al.20
Dubois 
et al.15
Schoenfeld 
et al.18
Corticosteroids ' ' ' ' ' ' ' ' '
SSRI NP NP NP ' NP ' NP NP NP
Dosage
High-dose NSAID ' NP NP ' NP NP ' NP '
Comorbidity
Cardiovascular 
disease
' NP NP ' ' NP e NP '
Severe RA disability NP NP NP ' ' NP e NP '
Additive
Helicobacter pylori ' ' NP ' ' ' ' NP '
Am Col Rheum: American College of Rheumatology, GI: gastrointestinal, NP: not present, NSAID: nonsteroidal 
anti-inflammatory drug, PUD: peptic ulcer disease, RA: rheumatoid arthritis, SSRI: selective serotonin reuptake 
inhibitor
aIf authors distinguished between moderate and high risk factors, moderate risk is indicated as ' and high risk 
as Ÿ. If no distinction is made, all risk factors are indicated as '
bRisk increases linear with 4% per advancing year
cIncluding aspirin and cyclooxygenase-2 (COX-2) inhibitors 
dLow-dose aspirin was regarded as a NSAID
eComorbidity in general was considered a risk factor
Table 3: Risk factors identified in the guidelines
Definitea 
Advanced age
History of (un)complicated PUD
Anticoagulants
Corticosteroids 
Low-dose aspirin
Multiple NSAIDs
Controversialb
High-dose NSAID
Clopidogrel
SSRI
History of gastrointestinal symptoms
Rheumatoid arthritis disability
Cardiovascular disease
Additivec
Helicobacter pylori infection
NSAID: nonsteroidal anti-inflammatory drug, PUD: peptic ulcer disease, SSRI: selective serotonin reuptake inhibitor
aDefinite risk factor is present in all analyzed guidelines and consensus agreements 
bControversial risk factor is not present in all guidelines 
cAdditive risk factor is only of importance in patients with a history of peptic ulcer disease
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Older age
All included studies regarded older age as definite risk factor, but the exact threshold 
was not uniform and ranged from 60 to 75 years. Bhatt et al., Rostom et al. and Schoenfeld 
et al. considered patients to be at high risk if they were aged > 60 years.13,17,18 Age > 65 
years was considered a risk factor by Lanza et al., and Dubois et al.15,16 Significant in-
creased risk for gastrointestinal complications in patients aged t 70 years was described 
by Chan et al.14 The threshold in the guideline of the American College of Rheumatology 
was 75 years, which is similar to the guideline by Targownik and Thomson, i.e. 76 years and 
older.12,19 Wilcox et al. did not dichotomize risk stratification according to an age threshold; 
they stated that advancing age increases gastrointestinal risk by about 4% per year.20 
Multiple NSAIDs and concomitant low-dose aspirin (acetylsalicylic acid) 
Intake of more than one type of NSAID was regarded as a risk factor in most guidelines 
and consensus articles. Some consensus groups considered low-dose aspirin (75-325 
mg daily) as a separate risk factor12-17,19, while others regarded low-dose aspirin as (sub)type 
of traditional NSAIDs.18,20 Higher gastrointestinal risk by use of multiple NSAIDs, including 
concomitant low-dose aspirin, was considered a definite risk factor among all guidelines. 
CONTROVERSIAL RISK FACTORS 
The guidelines assessed for this systematic review were not uniform for all risk factors. 
No agreement was present for a history of gastrointestinal symptoms, high-dose NSAID 
use, concomitant clopidogrel therapy, concomitant selective serotonin reuptake inhibitor 
(SSRI) use and comorbidity.
History of gastrointestinal symptoms
Only two guidelines considered the history of gastrointestinal symptoms as a risk factor 
for patients receiving NSAID therapy.13,17 Upper gastrointestinal symptoms, described 
as upper abdominal pain or discomfort or increase of symptoms of gastroesophageal 
reflux disease, should be analyzed according to the methods of Bhatt et al. and Rostom 
et al.13,17 because, according to these authors, a positive history augments the relative 
risk for gastrointestinal complications.
High-dose NSAID
In many, but not all, analyzed guidelines, a high dose of NSAIDs is a risk factor for gastroin-
testinal complications16-18,20; however, the exact definition of high dose was not stated. 
Concomitant medication
Concomitant use of several drugs was regarded as a risk factor. As stated before, corti-
costeroid, anticoagulant and low-dose aspirin use are definite risk factors. Concomitant 
clopidogrel therapy was regarded a risk factor in three of nine papers, and concomitant 
SSRI use was mentioned in two guidelines. Clopidogrel was approved in 1998 and since 
then the number of prescriptions has increased. Concomitant clopidogrel therapy has 
been recognized as a risk factor in the guidelines of Bhatt et al., Chan et al. (published 
in 2008) and Rostom et al. (published in 2009).13,14,17 However, the guideline published in 
2009 by Lanza et al. did not assess clopidogrel as a risk factor.16 Concomitant use of SSRIs 
is mentioned in two guidelines, namely in the guidelines of Rostom et al., and Targownik 
and Thomson.17,19 The latter stated that the evidence of an increased number of com-
plications is weak. 
Comorbidity
The presence of rheumatoid arthritis or cardiovascular disease was included as a risk 
factor in several guidelines and consensus agreements. Severe rheumatoid arthritis 
was assessed as a risk factor in three guidelines (Rostom et al., American College of 
Rheumatology and Schoenfeld et al.)12,17,18 According to Schoenfeld et al., rheumatoid 
arthritis patients are more prone to use multiple and higher dosages of medications.18 
Cardiovascular disease has been described by the same three groups12,17,18 as being a risk 
factor for gastrointestinal complications. Schoenfeld et al. defined cardiovascular disease 
as “a history of heart disease”.18 The two other guidelines did not define cardiovascular 
disease. The clinical consequence of rheumatoid arthritis and cardiovascular disease in 
patients requiring NSAIDs appears to be independent of the background of the authors.
ADDITIVE RISK FACTOR
Helicobacter pylori
Infection with Helicobacter pylori is a known risk factor for peptic ulcer disease23, but the 
exact role of H. pylori in NSAID-related gastrointestinal complications is not yet clear.23-25 
Guidelines agree that patients with a history of (complicated) peptic ulcer disease who 
start NSAID therapy should be tested and treated for H. pylori; however, according to 
Lanza et al., eradication of H. pylori for secondary prevention of peptic ulcer bleeding 
alone seems insufficient in long-term NSAID users.16 This is mainly based on a large, 
randomized, double-blind clinical trial in H. pylori-positive naproxen users that showed 
statistically significant more recurrent upper gastrointestinal bleeding in patients treated 
with H. pylori eradication therapy compared with patients receiving long-term omeprazole 
(hazard ratio 7.1, 95% CI 1.9 - 27.6).24 
OVER-THE-COUNTER USE
One of the purposes of this systematic review was to identify recommendations regarding 
OTC NSAID use. OTC use has been increasing last decennia and is becoming more 
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important; however, we found little information about OTC NSAID use in the studied 
guidelines and consensus agreements. In particular, no information regarding identification 
of patients at risk for gastrointestinal side effects in OTC users was mentioned. Examples 
of statements from the literature regarding OTC NSAID use are provided in Table 4.
Table 4: Quotes on over-the-counter (OTC) NSAID use 
Study Statement
Lanza et al.16 “It is important to emphasize that physicians are often unaware that pa-
tients are self-medicating with low-dose aspirin when they are pre-
scribed an NSAID for pain relief or anti-inflammatory effect.”
Bhatt et al.13 “These agents, both through prescription and over-the-counter (OTC) 
use, are the most widely used class of medications in the United 
States.”
“As the incidence of arthritis complaints increases, the use of prescrip-
tion and OTC NSAIDs is also expected to increase.”
“Recommendation: As the use of any NSAID, including COX-2-selective 
agents and OTC doses of traditional NSAIDs, in conjunction with cardi-
ac-dose aspirin, substantially increases the risk of ulcer complications, a 
gastroprotective therapy should be prescribed for at-risk patients.”
Rostom et al.17 “Nonsteroidal anti-inflammatory drugs are prescribed short term to 
about 25% of Canadians and long term (defined in this study as t 6 
months) to about 4%. However, this underestimates the magnitude of 
NSAID use as it does not include over-the-counter NSAIDs and low-
dose aspirin is extensively used for cardiovascular risk reduction.”
Wilcox et al.20 “Notably, both NSAID-associated gastrointestinal complications and 
deaths have been decreasing in recent years, after peaking in 1992. 
This decrease has been attributed to many factors including the use of 
lower-dose (particularly over-the-counter) NSAIDs, the decreasing prev-
alence ....”
Dubois et al.15 “In the year 2000, US patients received 111,400,000 prescriptions for 
nonsteroidal anti-inflammatory drugs (NSAIDs), at a cost of nearly $5 bil-
lion, with an additional $2 billion spent on over-the-counter NSAIDs.”
Schoenfeld et al.18 “In 1991, the year that naproxen and ketoprofen became available with-
out prescription, an estimated 14 million Americans ingested NSAIDs on 
a daily basis.”
DISCUSSION
We found advanced age, history of complicated as well as uncomplicated peptic ulcer 
disease, concomitant use of multiple NSAIDs (including low-dose aspirin), concomitant use 
of anticoagulant therapy and concomitant use of corticosteroids to be definite risk factors 
for a gastrointestinal event in NSAID users. Controversial risk factors were concomitant 
use of clopidogrel and concomitant SSRI use, comorbidity, a history of gastrointestinal 
symptoms and high-dose NSAID use. Infection with H. pylori was regarded as an additive 
risk factor, which was only of importance in patients with a history of (un)complicated 
peptic ulcer disease.
Although older age was an undisputed risk factor throughout all included guidelines, the 
exact threshold remains under discussion. In our review, the threshold ranged from 60 to 
75 years of age. One guideline noted a linear risk increase of 4 percent per advancing 
year.20 The choice of an adequate threshold might be influenced by the patient population 
that the guideline refers to, but we could not identify specific thresholds within medical 
specializations and therefore attempted to determine other reasons for the wide range of 
this threshold. Many articles have been published about the cut-off value for advanced 
age in NSAID users; however, not all of these were cited in the different guidelines. For 
example, only two references that determined this age cut-off, were used in more than 
one guideline.26,27 We did not have insights into the reference selection procedures of the 
included guidelines, therefore the exact reasoning behind the chosen threshold remains 
unknown. 
If medical costs are taken into account, co-prescription of a gastroprotective agent or 
prescription of a selective COX-2 inhibitor is cost-effective in patients older than 75 years 
and in patients with a history of (complicated) peptic ulcer disease, independent of their 
age.21 Logically, costs are lower when the cheapest PPI is prescribed. No therapeutic 
strategy is currently cost-effective in patients without risk factors.21 
Concomitant use of multiple NSAIDs, including low-dose aspirin, was also defined as a 
definite risk factor. Gastrointestinal adverse effects of low-dose aspirin (75 - 325 mg/day) 
are mainly attributed to systemic side effects, whereas in high dose NSAID users also 
local gastric injury is present.28 However, several authors defined low-dose aspirin to be 
a traditional NSAID and therefore categorize it as multiple NSAID use.18,20 Data are not 
uniform regarding the risks of solitary NSAID use and the combination of NSAIDs with 
low-dose aspirin. Relative risk estimations vary, from a two-fold increase for solely low-dose 
aspirin use29-31 to a six-fold increase when combining NSAIDs and low-dose aspirin.20 
Although the number needed to harm is high, the number of patients using the combination 
of NSAIDs and low-dose aspirin is extensive, subsequently resulting in a large number 
of gastrointestinal events.13,32
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Following the report by Lanza et al., infection with H. pylori was regarded as on additive 
risk factor for gastrointestinal events in NSAID users.16 Secondary prevention, by testing and 
subsequently treating H. pylori infection in patients with a known history of (complicated) 
peptic ulcer disease, has proven to be beneficial in NSAID users at high risk for gastroin-
testinal complications.13 Eradication of H. pylori in high-risk patients before the start of 
NSAID therapy has shown to reduce the incidence of ulceration33; however, eradication 
therapy of H. pylori in long-term NSAID users is inferior to using adequate gastroprotec-
tion.24 When both H. pylori and NSAID use are present, the relative risk for gastrointestinal 
complications of NSAID use is greater than that of infection with H. pylori alone, suggesting 
that NSAIDs play a more dominant role.34 A study regarding cost-effectiveness demon-
strated that H. pylori eradication in patients above the age of 50 years was the most 
effective cost-saving strategy in preventing gastrointestinal complications in NSAID 
users.35 In summary, data about the exact role of H. pylori in peptic ulcer disease in 
NSAID users are conflicting and the importance of H. pylori in ulcer development in 
NSAID users is still under debate. 
Concomitant use of clopidogrel is a controversial risk factor. Only three included papers 
mentioned an increased gastrointestinal risk. Although clopidogrel was only approved in 
1998, its gastrointestinal adverse effects are well known.29,36 Combination of different 
antithrombotics act in a synergistic manner, suggesting that the combination of a traditional 
NSAID with clopidogrel will also lead to an increased risk of gastrointestinal complications.37 
Recently, studies regarding the interaction between clopidogrel and PPIs were published.38,39 
Concomitant PPI use seems to abolish the cardiovascular protecting effects of clopidogrel. 
With this knowledge, the European Medicines Agency made a public statement about 
this interaction in May 2009 and discourages concomitant use of a PPI and clopidogrel-
containing medicines unless absolutely necessary. This further complicates the preventive 
strategies as PPIs are the primary choice for gastroprotection in this population.13,40
Concomitant use of SSRIs is also a controversial risk factor. A recently published meta-
analysis by Loke et al. demonstrated that the odds ratio for upper gastrointestinal 
hemorrhage in patients using SSRIs alone was 2.36 (95% CI 1.44 - 3.85) compared 
with 6.33 (95% CI 3.40 - 11.8) in patients using NSAIDs and concomitant SSRIs.41 The 
increased risk of concomitant SSRI therapy on gastrointestinal events in patients using 
NSAIDs should be taken into account by any physician as both drugs are often prescribed 
together. At present, SSRIs as risk factor might be controversial as it only has been recently 
identified and will need further exploration. 
Individual NSAIDs have different gastrointestinal toxicity profiles and, therefore, do not 
lead to comparable amounts of gastrointestinal complications. Ibuprofen is a traditional 
NSAID with the lowest gastrointestinal risk, whereas piroxicam has an almost four-fold 
higher risk of gastrointestinal complications compared with ibuprofen.42 Also, the dosage 
of NSAIDs is of importance in gastrointestinal complications. For example, it is possible 
that the low risk associated with ibuprofen found in the majority of studies where it is 
included may be because a low dose is usually used. A study by Gutthann et al. indicated 
that the risk of upper gastrointestinal bleeding and perforation with ibuprofen at a daily 
dose of 1500 mg or less was 1.2 compared with 5.8 at daily doses above 1500 mg.43 
The definition of high dose was not stated in the included guidelines and consensus 
agreements. 
Comorbidity was recognized as a risk factor. Depending on specialization, authors found 
severe rheumatoid arthritis, a history of any cardiovascular event, heart failure and diabetes 
mellitus to be risk factors;14,16-18 however, patients experiencing any of the mentioned 
diseases may use more, and higher, doses of medication. Association of comorbidity 
with an increased risk of a gastrointestinal event in patients using NSAIDs could therefore 
well be secondary to concomitant multiple drug use. Cardiovascular risks of NSAID use, 
with emphasis on selective COX-2 inhibitors, are widespread. 
OTC availability contributes to the growing consumption of NSAIDs.13,22,44,45 Guidelines 
and consensus agreements on the role of OTC NSAIDs were therefore reviewed in order 
to examine risk factors in this specific but large group of NSAID users. We hypothesize 
that gastrointestinal risk in individuals using OTC NSAIDs may well be similar to patients 
using prescribed NSAIDs. Both lower dosing and less frequent use could contribute to 
a lower gastrointestinal risk than that of prescribed NSAIDs. On the contrary, gastrointes-
tinal risk could be higher because of multiple NSAID use if a NSAID is prescribed by a 
physician in addition to OTC use or individuals might not adhere to recommended dos-
ages or cautions. However, although the risk is difficult to assess, it may not be dis-
carded because of the large numbers of NSAIDs used.13,24,44,45 OTC NSAID use is diffi-
cult to control by physicians; therefore, perhaps guidelines with directive focus on OTC 
use should primarily be aimed at pharmacists in order to identify patients at risk. This 
may explain why reviewed guidelines did not address OTC use. 
We advise physicians to carefully interrogate for possible OTC NSAID use if a patient is 
at increased risk for gastrointestinal complications. Moreover, if physicians recommend 
(OTC) NSAID use, they should always consider gastrointestinal risk factors and take 
these into account prior to their recommendation. Other options include switching to 
paracetamol (acetaminophen) or co-prescription of a gastroprotective agent. No studies 
are currently available that have examined gastrointestinal risks in naive OTC NSAID users. 
To elucidate this issue, a large clinical trial should be performed wherein OTC NSAID 
users with definite gastrointestinal risk factors would randomly be assigned to either of 
the following options: 1) switching to (OTC) paracetamol; 2) co-prescription of a PPI; 
and 3) no intervention. However, this is not feasible because of ethical concerns with an 
increased mortality due to gastrointestinal complications in older patients.46 Without the 
results of a prospective study, recommendations regarding OTC NSAID use in patients 
at risk for gastrointestinal complications are not evidence-based.
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In this systematic review, we only included guidelines and consensus agreements published 
in English, which could possibly account for selection bias as the reviewed guidelines 
are all derived from Western countries, which are accountable for the vast majority of 
NSAID use; therefore, guidelines and consensus agreements mostly originate from 
these countries. Another limitation of this study might be our interpretation of the authors’ 
interpretation of analyzed guidelines and consensus agreements. A systematic review is 
as strong as its individual components; however, interpretation of numerous studies is 
the limitation of all (systematic) reviews. In contrast, although scientific sources of most 
guidelines and consensus agreements concur, authors’ interpretations lead to different 
recommendations, as shown in this article. This systematic review puts these interpre-
tations into perspective. We included articles that used differing methodology, such as 
panel discussions and opinion articles, with the terms ‘guideline’ or ‘consensus’ present 
in the title. Although methodology is not consistent, the management of patients using 
NSAIDs in many countries worldwide is largely dependent on discussed guidelines and 
consensus agreements. 
In conclusion, we reviewed guidelines and consensus agreements on risk factors for 
gastrointestinal events in patients using NSAIDs and identified a history of (complicated) 
peptic ulcer disease, older age (cut-off age ranging from 60 to 76 years), concomitant 
anticoagulant use, concomitant corticosteroid use, and multiple NSAID use, including 
low-dose aspirin, as undisputed definite gastrointestinal risk factors in NSAID users. 
Several controversial risk factors, including concomitant clopidogrel and SSRI use, require 
further research. Finally, we found an absence of recommendations regarding OTC NSAIDs 
in studied guidelines and consensus agreements. OTC NSAID use should be addressed 
and considered by physicians in the identification of patients at risk for a gastrointestinal 
event.
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Aims Nonsteroidal anti-inflammatory drug (NSAID) use is widespread and associated 
with gastrointestinal symptoms and complications. The aims of this study are to assess: 
1) gastrointestinal symptoms in users of prescribed and over-the-counter (OTC) NSAIDs, 
and 2) proton pump inhibitor (PPI) co-prescription rates in NSAID users at increased risk 
for gastrointestinal complications.
Methods Surveys were sent to a randomly selected sample of the adult Dutch general 
population in December 2008. Questions included demographics, gastrointestinal 
symptoms, medication use and comorbidity. Main outcome measure was presence of 
gastrointestinal symptoms. 
Results A total of 18,317 surveys returned (response rate 35%), of which 16,758 
surveys were eligible for analysis. Of these, 3,233 participants (19%) reported NSAID 
use. NSAID users more frequently reported gastrointestinal symptoms than persons not 
using NSAIDs (33% vs. 24%, p < 0.01). Respondents that specified on prescription 
NSAID use (n = 683) were older, reported more comorbidity, and experienced more 
gastrointestinal symptoms (41%) compared to OTC users (n = 894, 33%, p < 0.01). This 
difference was not statistically significant after adjustment for confounders (aOR 0.99, 
95% CI 0.71 - 1.37). In respondents with an increased gastrointestinal risk profile PPI 
co-prescription rates were 51% for on prescription users and 25% for OTC users.
Conclusions Prevalence of gastrointestinal symptoms was high in both prescribed 
and OTC NSAID users, emphasizing the side effects of both types of NSAIDs. PPI 
co-prescription rates in NSAID users at risk for gastrointestinal complications were low.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed 
drugs worldwide. In the Netherlands, NSAIDs were prescribed to 3 million users in 2009 
(Data from the Dutch Foundation for Pharmaceutical Statistics (SFK)) and in the United 
States, prescriptions for generic ibuprofen and naproxen almost reached 40 million in 2009.1 
Over-the-counter (OTC) NSAID use is also widespread, as an Italian survey suggested that 
approximately 15% of the general population had used OTC NSAIDs in the previous 
week.2
The prevalence of upper gastrointestinal symptoms in users of prescribed NSAIDs varies 
widely from 5% to 50%.3,4 Studies regarding these adverse events have frequently been 
performed in selected populations, such as in patients with rheumatoid arthritis. Data 
about gastrointestinal symptoms in OTC NSAID users are scarce. Some studies conclude 
that side effects of OTC NSAIDs are comparable to paracetamol and placebo5-7, while 
others report that prevalence of gastrointestinal symptoms in OTC NSAID users is twice 
as high compared to non-NSAID users.8
In addition to gastrointestinal symptoms, NSAID use is associated with gastrointestinal 
bleeding.3,9-11 In order to prevent gastrointestinal complications in NSAID users at risk for 
gastrointestinal complications (e.g. those at advanced age), guidelines advise to apply a 
gastroprotective strategy.12 However, purchase of OTC NSAIDs occurs outside the scope 
of pharmacies and healthcare practitioners and careful consideration for the need of 
gastroprotection may not be present. 
Therefore, the aims of this study are to assess 1) gastrointestinal symptoms in prescribed 
and OTC NSAID users, and 2) PPI co-prescription rates in NSAID users at increased risk 
for gastrointestinal complications via a cross-sectional study in the general population.
 
METHODS
STUDY POPULATION
We sent 51,869 questionnaires by mail to a sample of the Dutch population in December 
2008. We included returned questionnaires from December until the end of March 2009. 
Invited subjects were 18 years or older and randomly selected from municipal databases 
of five different municipalities selected on their geographical location in The Netherlands, 
in order to gather a representative sample of the Dutch population. We excluded returned 
questionnaires with missing elements that were part of (1) the primary outcome measure, 
(2) all individual gastrointestinal symptoms, (3) missing of all baseline characteristics, or 
(4) questionnaires with unreadable medication.
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The Medical Ethical Committee of the Radboud University Nijmegen assessed the proposal 
of this study and concluded that it could be waived for ethical review, as questionnaires 
were returned and stored anonymously, and (non-)responders would not be contacted 
again. For this reason, we did not obtain written informed consent of all participants. 
QUESTIONNAIRE
The questionnaire was specifically designed for collection of demographic information, 
gastrointestinal symptoms, medication use, and health-related quality of life and has been 
used before.13-15 Participants were asked whether they suffer from gastrointestinal 
symptoms in general, and if so, they were asked about the presence of 26 specific 
gastrointestinal symptoms such as nausea, early satiety, bloating, constipation and 
diarrhoea. Severity of these gastrointestinal symptoms was assessed on a seven-point 
Likert scale (0 = absent, 1 = almost absent, 2 = mild, 3 = moderate, 4 = moderately se-
vere, 5 = severe, 6 = very severe) over the four preceding weeks.16 A symptom was con-
sidered to be present if participants scored t 2 on the Likert scale.
Our primary outcome was the presence of gastrointestinal symptoms in general assessed 
by: “Do you experience gastrointestinal complaints?” and had to be answered with either 
“yes” or “no”. Secondary outcome was type of gastrointestinal symptoms experienced 
in the preceding four weeks. 
Participants were asked to report currently used medication and to specify whether it was 
prescribed or bought OTC. When NSAID users reported a history of (complicated) peptic 
ulcer disease, concomitant use of systemic corticosteroids, anticoagulants or antiplatelet 
therapy, or were aged t 65 years, we defined them as participants with high risk for gas-
trointestinal complications in accordance with current guidelines.12
We defined excessive alcohol consumption as 14 units or more a week for women and 
21 units or more a week for men.17 Body mass index (BMI in kg/m2) was categorized in 
< 25 (normal weight) and t 25 (overweight or obese).18 Participants were asked to report 
their current smoking habits without specification of the amount of tobacco used. 
STATISTICAL ANALYSIS
Data were analyzed using Statistical Package for the Social Sciences (SPSS), version 
16.0 (IBM Corporation, New York, United States). Frequency tables with characteristics 
of the participants were presented according to NSAID use. Pearson’s chi-square (Ȥ2) 
analysis was used to compare categorical variables between users of prescribed and 
OTC NSAIDs, and to assess symptoms according to PPI use. Concomitant medication use 
in users of prescribed and OTC NSAIDs was also assessed using Pearson’s chi-square 
(Ȥ2) test. Continuous variables were compared with Student’s t-test or the Mann-Whitney 
U method whenever appropriate. In respondents with gastrointestinal symptoms, specific 
symptoms were provided using frequency tables. Individual symptoms between prescribed 
and OTC NSAID users were compared with Pearson’s chi-square (Ȥ2) test. We performed 
univariable logistic regression and subsequent multivariable logistic regression analysis 
to correct for confounders. Covariates were included if baseline characteristics differed 
significantly between on prescription and OTC NSAID users, or if factors were known to 
be associated with gastrointestinal symptoms in NSAID users from the literature. Odds 
ratios and 95% confidence intervals were stated. A p-value < 0.05 was assumed to be 
statistically significant. 
 
RESULTS
Of the 51,869 surveys sent, a total of 18,317 were returned (response rate 35%). Seven 
hundred forty-two surveys returned unopened to sender for various reasons and after 
exclusion for previously described reasons (n = 817), a total of 16,758 questionnaires could 
be included in the analysis (Figure 1). Nineteen percent of all participants (n = 3,233) report-
ed NSAID use. NSAID users reported more frequently gastrointestinal symptoms (n = 1,076 
of 3,233; 33%) compared with non-NSAID users (n = 3,239 of 13,525; 24%, p < 0.01).
Figure 1: Flowchart 
*Some respondents met more than one exclusion criterion
NSAID: nonsteroidal anti-inflammatory drug, OTC: over-the-counter
51,869 questionnaires sent
17,575 completed questionnaires 
received
817 questionnaires excluded* 
     284 all baseline variables missing
     308 primary outcome missing
     413 gastrointestinal symptoms missing
     111 medication unreadable     
742 questionnaires returned to sender
     360 no reason
     298 moved
       47 deceased
       37 not interested 
16,758 questionnaires eligible for 
analysis
OTC NSAID use
N = 894
On prescription NSAID use 
N = 683
3,233 reported NSAID use
13,525 reported no NSAID use

	
(&!"'&#,
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A total of 1,656 NSAID using respondents did not specify whether their NSAID use was 
on prescription or OTC. Of the remainder; six hundred eighty-three (43%) respondents 
reported on prescription NSAID use and 894 participants (57%) use of OTC NSAIDs. 
Users of prescribed NSAIDs were older (mean 51 years, SD 15) compared with OTC users 
(mean 40 years, SD 14, p < 0.01), more often overweight (58% vs. 39%, p < 0.01) and 
more frequently reported comorbidity (33% vs.10%, p < 0.01; Table 1). 
Prevalence of gastrointestinal symptoms was 41% in users of prescribed NSAIDs and 
33% in OTC users (OR 1.41, 95% CI 1.15 - 1.74; Table 2). Reported symptom frequencies 
are depicted in Figures 2a and 2b. On prescription NSAID users significantly more often 
reported nocturnal epigastric pain (36% vs. 23%, p < 0.01), nocturnal heartburn (33% 
vs. 24%, p = 0.03), vomiting (15% vs. 9%, p = 0.03) and pre-prandial lower abdominal pain 
(29% vs. 21%, p = 0.03) compared to OTC NSAID users. All other reported symptoms 
were comparable between groups. After adjustment with multivariable analysis, the odds 
ratio was not statistically significant (adjusted OR 0.99, 95% CI 0.71 – 1.38; Table 2). 
Table 1: Population characteristics
Respondents 
without 
NSAID use
Respondents 
that did not 
specify type 
of NSAID use
On 
prescription 
NSAID users
OTC 
NSAID 
users
n = 13,525 n = 1,656 n = 683 n = 894 p-value*
Mean age (±SD) 50 (16) 50 (16) 51 (15) 40 (14) < 0.01
Age t 65 years (%) 2,706 (20) 332 (20) 123 (18) 37 (4) < 0.01
Female (%) 7,188 (55) 971 (60) 452 (68) 621 (71) 0.31
Body mass index 
t 25 kg/m2 (%)
6,064 (46) 824 (51) 381 (58) 347 (39) < 0.01
Smoking (%) 2,302 (17) 341 (21) 124 (19) 162 (18) 0.95
Excessive alcohol usea (%) 1,312 (13) 174 (15) 71 (17) 66 (10) 0.01
History
Peptic ulcer disease (%) 677 (5) 123 (8) 55 (8) 31 (4) < 0.01
Peptic ulcer bleeding (%) 217 (2) 39 (2) 17 (3) 9 (1) 0.02
Comorbidity
Diabetes mellitus (%) 695 (5) 113 (7) 46 (7) 23 (3) < 0.01
Rheumatoid arthritis (%) 458 (3) 120 (7) 168 (25) 27 (3) < 0.01
Asthma / COPD (%) 811 (6) 128 (8) 53 (8) 52 (6) 0.13
COPD: chronic obstructive pulmonary disease, NSAID: nonsteroidal anti-inflammatory drug, OTC: over-the-counter
*comparison between on prescription and OTC NSAID users
aExcessive alcohol use is defined as 14 units or more a week for women and 21 units or more a week for men
Table 2: Unadjusted and adjusted odds ratios for presence of gastrointestinal symptoms in NSAID users 
Unadjusted OR (95% CI) Adjusted OR (95% CI)a
On prescription vs. OTC 1.41 (1.15 - 1.74) 0.99 (0.71 - 1.38)
Ageb 1.00 (0.99 - 1.01) 0.98 (0.97 - 0.99)
Female 2.01 (1.58 - 2.55) 2.69 (1.92 - 3.77)
Body mass index t 25 kg/m2 1.27 (1.03 - 1.56) 1.38 (1.01 - 1.87)
History of peptic ulcer disease 4.99 (3.20 - 7.77) 3.07 (1.66 - 5.66)
Smoking 1.82 (1.40 - 2.35) 2.34 (1.63 - 3.36)
Excessive alcohol usec 1.12 (0.77 - 1.63) 0.74 (0.47 - 1.18)
Rheumatoid arthritis 1.83 (1.35 - 2.47) 0.94 (0.54 - 1.66)
Asthma/COPD 1.61 (1.08 - 2.39) 1.30 (0.70 - 2.41)
PPIs 4.07 (3.14 - 5.29) 7.16 (4.59 - 11.17)
H2RAs 6.14 (3.10 - 12.16) 6.44 (2.64 - 15.68)
Antacids 2.46 (1.79 - 3.38) 2.59 (1.66 - 4.02)
Systemic corticosteroids 2.05 (0.74 - 1.39) 0.66 (0.12 - 3.48)
Low-dose aspirind 0.99 (0.67 - 1.44) 0.81 (0.46 - 1.41)
COPD: chronic obstructive pulmonary disease, H2RA: H2-receptor antagonist, NSAID: nonsteroidal anti- 
inflammatory drug, OTC: over-the-counter, PPI: proton pump inhibitor 
aAdjusted for all variables depicted in this table
bPer advancing year
cExcessive alcohol use is defined as 14 units or more a week for women and 21 units or more a week for men
dLow-dose aspirin: acetylsalicylic acid and calcium carbasalate are taken together 
USE OF ACID-SUPPRESSIVE MEDICATION IN NSAID USERS 
For our analyses regarding gastroprotection, we found that concomitant PPI use was 
reported by 227 on prescription NSAID users (33%), compared with 81 OTC NSAID 
users (9%; Table 3). These numbers were 114 (51%) and 28 (25%) respectively in the 
subgroup of participants with an increased risk for gastrointestinal complications based 
on international guidelines for gastroprotection (p < 0.01). 
We performed subgroup analyses in NSAID users that used any form of acid suppression 
(PPI, H2RA or antacid) in addition to their NSAID use. In this analysis, we did not find any 
statistically significantly differences (adjusted OR 0.76, 95%CI 0.41 - 1.39). We also 
performed a subgroup analysis in NSAID users that did not use PPIs, H2RAs or antacids. 
We did not find any differences in gastrointestinal symptom prevalence between on 
prescription NSAID users (n = 384) and OTC NSAID users (n = 713) (adjusted OR 1.01, 
95% CI 0.67 - 1.52).  
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Figure 2b: Lower gastrointestinal symptoms in respondents reporting gastrointestinal symptoms
Respondents without NSAID use
On prescription NSAID users 
Over-the-counter NSAID users
*p < 0.05
NSAID: nonsteroidal anti-inflammatory drug
Figure 2a: Upper gastrointestinal symptoms in respondents reporting gastrointestinal symptoms
Respondents without NSAID use
On prescription NSAID users 
Over-the-counter NSAID users
*p < 0.05
NSAID: nonsteroidal anti-inflammatory drug
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Table 3: Concomitant drug use in NSAID users
Concomitant drugs On prescription NSAID users OTC NSAID users p-value*
All
n = 683
High-riska
n = 223
All
n = 894
High-riska
n = 114
Paracetamol (%) 488 (71) 160 (72) 642 (72) 89 (78) 0.21
PPIs (%) 227 (33) 114 (51) 81 (9) 28 (25) < 0.01
H2RAs (%) 25 (4) 8 (4) 22 (3) 3 (13) 0.64
Antacids (%) 75 (11) 25 (11) 100 (11) 18 (16) 0.26
Low-dose aspirinb (%) 78 (11) 77 (35) 48 (5) 47 (41) 0.23
Other platelet inhibitorsc (%) 11 (2) 9 (4) 1 (0) 1 (1) 0.11
Systemic corticosteroids (%) 12 (2) 12 (5) 3 (0) 3 (3) 0.40
Anticoagulants (%) 3 (0) 3 (1) 3 (0) 3 (3) 0.25
 
H2RA: H2-receptor antagonist, NSAID: nonsteroidal anti-inflammatory drug, OTC: over-the-counter, PPI: proton 
pump inhibitor
*P-value: comparison between high-risk categories
aHigh-risk is defined as presence of a history of (complicated) peptic ulcer disease, age t 65 years, concomitant 
use of systemic corticosteroids, anticoagulants or antiplatelet therapy 
bLow-dose aspirin: acetylsalicylic acid and calcium carbasalate are combined 
cOther platelet inhibitors: dipyridamol or clopidogrel use 
 
We compared type of gastrointestinal symptoms in respondents with gastrointestinal 
symptom presence, according to PPI and type of NSAID use. Epigastric pain during day-
time (58% vs. 42%, p = 0.02), heartburn in general (51% vs. 34%, p < 0.01), heartburn 
during daytime (52% vs. 35%, p < 0.01), and regurgitation (54% vs. 36%, p < 0.01) 
were more frequently reported in prescribed NSAID users with concomitant PPI use 
than prescribed NSAID users without PPI use.
Epigastric pain during daytime (60% vs. 41%, p = 0.02), nocturnal epigastric pain (39% 
vs. 19%, p < 0.01), heartburn in general (52% vs. 30%, p < 0.01), heartburn during daytime 
(48% vs. 31%, p = 0.03) and regurgitation (53% vs. 38%, p = 0.04) were more frequently 
reported in OTC NSAID users with PPI use compared with OTC NSAID users without 
PPI use. 
DISCUSSION
Nineteen percent of our random sample of the Dutch general population reported NSAID 
use. This was associated with a higher prevalence of gastrointestinal symptoms com-
pared to participants not using NSAIDs. After adjustment for confounders, prevalence of 
gastrointestinal symptoms did not differ between participants reporting NSAID use on 
prescription compared to OTC. This indicates that NSAID use was an independent risk 
factor for occurrence of gastrointestinal symptoms, irrespective of on prescription or 
OTC use. PPI co-prescription was frequently absent in NSAID users at increased risk for 
gastrointestinal complications.
Previously conducted randomized controlled trials about NSAIDs in OTC dosages 
concluded that maximum OTC doses naproxen and ibuprofen were not associated with 
increased side effects.5,19 However, included participants were healthy volunteers, and 
the duration of exposure was short. A recent review article supported the safety of OTC 
NSAIDs.20 We found a higher prevalence of gastrointestinal symptoms in NSAID users, but 
our study included a wide variety of individuals, while most previous studies in OTC 
NSAID users included a more homogenous – relatively low risk – population, leading to less 
gastrointestinal symptoms. Therefore, extrapolation of the former results to the general 
population needs to be done with caution. 
We studied PPI co-prescription in NSAID users at increased risk for gastrointestinal 
complications. Gastroprotection rates in users of prescribed NSAIDs range between 
44-70% and are mainly based on either prescription numbers generated from medical 
records or reimbursement schemes by health insurance databases.21-25 The PPI co-
prescription rate in NSAID users at risk in our study was at the lower end of this range, 
but we used self-reported, and probably more reliable, data. We also analyzed gastro-
protection rates in OTC NSAID users, as the risk on gastrointestinal complications is up 
to 3-4 times increased compared to placebo26,27, and found that only 25% of those at 
risk concomitantly used PPIs. 
It is a challenge to improve the current low gastroprotection rates in OTC NSAID users at 
risk. If NSAIDs are prescribed it is clear that the responsibility – to identify patients at risk 
and co-prescribe gastroprotection – lies with the attending physician, but with OTC NSAID 
use this is less clear. NSAID OTC packages could be marked with warning signs and 
depict risk factors for gastrointestinal complications, but consumers of OTC medication 
frequently do not read the package inserts.28 We also could instruct sellers of OTC NSAIDs 
to systematically ask presence of gastrointestinal risk factors and subsequently advice 
to concomitantly use a PPI. In practice this will be difficult to implement. The alternative, 
a NSAID-PPI combination pill, is not yet available OTC. 
Based on the results of our cross-sectional study, we are unable to confirm the role of PPIs 
in reducing NSAID-associated gastrointestinal symptoms, which has been demonstrated 
before.29-32 PPI use is independently associated with gastrointestinal symptom presence 
in our survey due to confounding by indication. 
The major strength of our study is that we performed a direct comparison between users 
of prescribed and OTC NSAIDs in the general population, which is a mixture of different 
gastrointestinal risk categories. Secondly, our data regarding NSAID use and subsequent 
gastroprotection are not based on prescription or sales rates, but on self-reported use. 
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Our population survey also has limitations. Approximately half of respondents that reported 
NSAID use did not specify whether used NSAIDs were on prescription or OTC. Respon-
dents that did not specify their NSAID use reported a lower frequency of gastrointestinal 
symptoms, which may have led to an overestimation of gastrointestinal symptom prevalence 
in our cohort of NSAID users, because NSAID users that developed side effects could have 
been more likely to remember this previous NSAID use and additional details. Second, 
the response rate of our study was 35% and respondents experiencing gastrointestinal 
symptoms may have been more susceptible to return the questionnaire. To minimize this 
bias, all participants were invited with a personalized cover letter, asked explicitly to return 
the questionnaire, indifferent of gastrointestinal symptoms. The two types of bias described 
above, recall bias and selection bias, both may have influenced our primary outcome. 
Due to our study design we were not able to test this in non-responders or respondents 
who returned an incomplete questionnaire.
Another limitation is that we are uninformed whether PPIs were primarily prescribed for 
gastroprotection, or for another indication as gastroesophageal reflux disease (GERD) or 
dyspepsia. Another study found that a history of NSAID intolerance, GERD and dyspepsia 
were all significantly associated with use of gastroprotective agents in NSAID users.23 As 
we were unaware of the reason for PPI co-prescription, we also did not question our 
population for the indication, dose and duration of NSAID use. 
Adequate gastroprotection in NSAID users at risk for gastrointestinal complications can 
be achieved by PPI co-prescription or by prescription of a COX-2 selective NSAID. Due to 
the nature of our questionnaire we were not able to separately assess COX-2 selective 
NSAID users and nonselective NSAID users. This may have led to some underestima-
tion of adequate gastroprotection rates in users of prescribed NSAIDs. However, 
PPI co-prescription is the most frequently adapted strategy in NSAID users at risk for 
gastrointestinal complications in daily practice.
In all questionnaire-based studies the results rely on fairness and adequacy of the answers 
reported by participants. We assume our questionnaire has been completed properly, 
but we cannot rule out that some misclassification has occurred. At last, we cannot rule 
out that NSAID users are unaware of the gastrotoxic nature of this medication28,33,34 and 
used these analgesics for dyspeptic symptoms. 
Use of prescribed NSAIDs will probably increase in future with prolonged life expectancy 
and concomitant rheumatic complaints. Continuing increase of self-medication and 
promotion of OTC NSAID use by general practitioners and specialists will also contribute 
to increased NSAID use. Our study documents that OTC NSAID use is associated with 
gastrointestinal symptoms. A study, published in 2001, found that physicians do no 
question patients on a regular basis OTC medication use.35 We suppose that awareness 
regarding OTC use has improved since due to incorporation of questions about OTC 
use in guidelines regarding gastrointestinal symptoms.36,37
The major medical implication of our study is that awareness of physicians about the 
risks of OTC NSAID medication use should be further improved. Second, we would 
recommend policy makers to either stimulate adequate gastroprotection in OTC NSAID 
users at risk or to limit free availability of OTC NSAIDs or preferably both.  
In conclusion, nineteen percent of participants reported NSAID use. Prevalence of 
gastrointestinal symptoms was increased in both prescribed and OTC NSAID users. 
Physicians should be aware of the extensive use of OTC NSAIDs in the general population 
and ask patients presenting with gastrointestinal symptoms about OTC drug use. An 
advice to stop any avoidable use of OTC NSAID should be considered prior to or at least 
in addition to prescribing gastroprotective medication.
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 ABSTRACT
Objective To investigate whether esomeprazole can provide relief for nonsteroidal 
anti-inflammatory drug (NSAID)-associated upper gastrointestinal symptoms in patients 
at different gastrointestinal risk. 
Methods A multicentre, prospective, open-label study was conducted, wherein NSAID 
users visiting their general practitioner for upper gastrointestinal symptoms were asked 
to participate. Patients were treated with 20 mg esomeprazole and treatment effect was 
evaluated within 8 weeks. Response was defined as a maximum of one day per week 
with gastrointestinal symptoms during the last week of treatment. Partial response was 
defined as more than 50% improvement in the number of days per week with symptoms 
compared with baseline. Patients not meeting the above-mentioned criteria were classified 
as nonresponders. Patients who completely responded were compared with partial 
responders and nonresponders and were analyzed according to their baseline gastroin-
testinal risk.
Results A total of 1,042 patients (mean age 57 years, SD 15, 43% male) were analyzed. 
Complete response, partial response and nonresponse were achieved in 57%, 24% and 
19% of the patients, respectively. Similar response was seen in average-risk and high-risk 
patients (58% and 56%, p = 0.46) and in nonselective NSAID and selective cyclooxygen-
ase-2 users (57% and 53%, p = 0.32).
Conclusion Esomeprazole (20mg) improved NSAID-associated upper gastrointestinal 
symptoms. Baseline gastrointestinal risk did not influence esomeprazole effectiveness. 
INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are often prescribed for treatment of pain 
and inflammation but are associated with gastrointestinal side-effects ranging from 
life-threatening peptic ulcer bleeding to minor dyspeptic symptoms.1-4 Side effects are the 
most common reason for NSAID discontinuation and have a considerable negative impact 
on quality of life.5,6 Compared with nonselective NSAIDs, selective cyclooxygenase-2 
(COX-2) inhibitors induce fewer ulcers and complications, although the prevalence of 
gastrointestinal symptoms in patients using selective COX-2 inhibitors is still 5-50%. 2,3,7,8
In treatment guidelines9,10, acid-suppressive drugs are recommended as a first-line 
treatment option for acid-related upper gastrointestinal symptoms. Proton pump inhibitors 
(PPIs) are the most potent agents for suppressing intragastric acidity, but remarkably, 
only few studies have examined upper gastrointestinal symptoms as a primary endpoint 
in NSAID users.11-13 Studies by Hawkey et al.11-12 and Scheiman et al.13 have already 
shown the ability of esomeprazole (20 and 40 mg) to reduce gastrointestinal symptoms 
in NSAID users in large randomized clinical trials with stringent in- and exclusion criteria 
(NASA1 and SPACE1, VENUS, PLUTO). However, the actual effectiveness of PPIs on 
gastrointestinal symptoms in daily practice has not been thoroughly investigated. In most 
clinical trials, patients with risk factors for gastrointestinal complications, for example, 
concomitant low-dose aspirin or systemic corticosteroid use, are frequently excluded, 
but such patients are encountered in clinical care.14 
In NSAID users, treatment of upper gastrointestinal symptoms using a PPI may prevent 
complications such as peptic ulcer disease.13,15-17 If gastrointestinal symptoms are reduced 
by PPI therapy, then patients might also be more adherent to treatment after gastroprotec-
tion guidelines. This hypothesis is untested to date, but, if true, it may contribute to closing 
of the gastroprotective gap.
We hypothesize that PPI therapy will relieve upper gastrointestinal symptoms in NSAID 
users in daily clinical practice. Second, we want to assess symptom relief in both average-
risk and high-risk patients, as NSAID users at risk might experience less symptom relief. 
Therefore, the aim of this study was to investigate whether PPI therapy can reduce upper 
gastrointestinal symptoms in NSAID users in daily clinical practice and to assess response 
to PPI therapy in several subgroups according to risk for gastrointestinal complications. 
 
METHODS
STUDY DESIGN AND PATIENTS
In this multicentre prospective open-label study, patients were included between October 
2006 and June 2007. Follow-up visits were performed until August 2007. A total of 162 
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general practitioner centres in the Netherlands participated. NSAID users who visited 
their general practitioner with heartburn, regurgitation, nausea and/or bloating were 
asked to participate. Patients were included if they used NSAIDs for more than 2 days a 
week for at least one week and if NSAID treatment was expected to continue during 
study follow-up. Because patients presented to a general practitioner with varying dura-
tions of symptoms, no minimal symptom period was defined. The effect of PPI treatment 
was evaluated once within 8 weeks. Exclusion criteria included: age less than 18 years, 
a history of gastrooesophageal reflux disease (GERD), and use of PPI and/or H2-receptor 
antagonist in the month preceding the study. Eligible patients were prescribed 20mg 
esomeprazole once daily. 
OUTCOMES
Patients were questioned at baseline visit and at follow-up visit within 8 weeks. Demo-
graphic factors, type and dosage of NSAID, indication, risk factors for gastrointestinal 
complications and the severity of upper gastrointestinal symptoms were recorded. More 
than one indication could be reported per NSAID prescription. Symptoms assessed 
were heartburn, regurgitation, bloating and nausea. The number of days that patients 
experienced one or more of these symptoms during the last week was assessed. Severity 
of gastrointestinal symptoms was measured on a four-point Likert scale (0 = absent, 1 
= mild, 2 = moderate, 3 = severe), and a mean symptom score was calculated.11 
Primary outcome was treatment response, which was defined as a maximum of 1 day 
per week with gastrointestinal symptoms during the last week of treatment. A patient not 
meeting this definition would be a partial or non-responder. Partial response was defined as 
more than 50% improvement in the number of days per week with symptoms compared 
with baseline. Patients not meeting the above-described criteria were classified as non-
responders. 
The general practitioner was also asked to score the patient as “high-risk” or “average-risk” 
for gastrointestinal events on the basis of global physician assessment. Thereafter, the 
gastrointestinal risk profile of a patient was assessed more structurally using the following 
individual risk factors: aged 65 years or above, a history of (complicated) peptic ulcer 
disease, and co-prescription of low-dose aspirin, anticoagulants or systemic corticosteroids.
SAFETY
During the study general physicians recorded all serious adverse events and adverse 
events resulting in discontinuation of esomeprazole treatment. A serious adverse event was 
defined as an adverse event leading to death, life-threatening situation, unscheduled 
hospital admission or extension of a hospital stay, a permanent or severe disability, or a 
necessity for an intervention to prevent permanent loss of function or permanent damage 
to any part of the body. 
SAMPLE SIZE
Sample size calculation was based on the assumption that mean improvement in gas-
trointestinal symptom score would be different between patients at high gastrointestinal 
risk and those with average risk, favouring patients at average gastrointestinal risk. The 
expected difference was estimated to be 0.25 with a standard deviation of 1.45 and was 
derived from a former study.11 To detect this difference with 80% power and 5% signifi-
cance level, 530 patients were needed in each group. With an expected dropout of 
15%, a total of 1,220 had to be included. We assumed that high and average risks were 
equally divided in the patients visiting the general practitioner for gastrointestinal symptoms 
who were taking NSAIDs.18,19
STATISTICAL ANALYSIS 
Analyses were carried out using Statistical Package for the Social Sciences, version 
16.0 (IBM Corp., Somers, New York, USA). Baseline characteristics were analyzed using 
standard descriptive statistics. Response of upper gastrointestinal symptoms (primary 
endpoint) was analyzed as follows: mean symptom scores at baseline were compared 
with scores after treatment using paired t-tests for all individual symptoms. Baseline 
characteristics were then compared between responders and all others using chi-square 
(Ȥ2) tests for intergroup comparisons of dichotomous data and analysis of variance for 
continuous data. The correlation between the number of days between two general 
practitioner visits and the likelihood of response was compared using Spearman’s cor-
relation coefficient.
We carried out multivariable analysis to assess the factors that were associated with 
response to PPI therapy. Logistic regression analysis was also carried out to assess the 
adjusted impact of several risk factors (older age, history of peptic ulcer disease and 
concomitant low-dose aspirin, corticosteroid, selective serotonin reuptake inhibitor and 
anticoagulant use) on the general practitioners’ estimation of patients’ gastrointestinal 
risk. Odds ratios and 95% confidence intervals (CIs) were stated. A p value < 0.05 was 
assumed to be statistically significant. 
ETHICAL ISSUES
This study was conducted according to the Declaration of Helsinki and international 
standards of good clinical practice. The trial had been registered at Clinicaltrials.gov 
(NCT00524329). 
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RESULTS
A total of 1,233 patients were included in this study. In all, 191 patients were excluded 
from the study: 29 patients did not meet the inclusion criteria; 1 did not return for the 
second visit; and 161 patients did not visit the general practitioner within the defined 
period for analysis following the first visit. In comparison with patients included in the 
study, excluded patients were younger (mean age 54 years, SD 16 years). No differences 
were found in comorbidities or in the use of concomitant medications. 
Treatment outcome was analyzed in the remaining 1,042 patients (mean age 57 years, 
SD 15 years, 43% male). Almost one-third of the patients were aged above the age of 65 
years (Table 1). 
Table 1: Population characteristics 
n = 1,042
Mean age in years (±SD) 57.2 (15.4)
t 65 years (%) 335 (32)
Male (%) 447 (43)
History of peptic ulcer disease (%) 104 (10)
Concomitant medication (%)
Anticoagulants 162 (16)
Low-dose aspirin 121 (12)
SSRI 120 (12)
Corticosteroids 69 (7)
Comorbidity (%)
Diabetes mellitus 156 (15)
Heart failure 72 (7)
Indicationa (%)
Nonspecific musculoskeletal pain 521 (50)
Osteoarthritis 356 (34)
Rheumatoid arthritis 56 (5)
Gout 50 (5)
Other 210 (20)
NSAID switch (%) 104 (10)
Selective COX-2 inhibitor (%) 146 (14)
High risk according to GPb (%) 604 (58)
 
COX-2: cyclooxygenase-2, GP: general practitioner, NSAID: nonsteroidal anti-inflammatory drug, SSRI: selective 
serotonin reuptake inhibitor 
aSome patients reported more than one indication
bPatients at high risk for gastrointestinal complications according to the general practitioner
The most frequently reported indication for NSAID use was nonspecific musculoskeletal 
pain (50%), followed by osteoarthritis (34%). The most often prescribed NSAID was 
diclofenac (46%), followed by ibuprofen (30%) and naproxen (15%) (Table 2). More than 
10% of used NSAIDs were purchased over-the-counter. A total of 104 patients changed 
their NSAIDs during the study period, of which 87 patients reported the names of both 
NSAIDs; most patients (73 of 87) changed NSAIDs within the non selective NSAID group. 
Seven patients changed within the COX-2 selective group and 7 patients switched from 
a nonselective NSAID to COX-2 selective or vice versa. A total of 604 patients (58%) 
were assessed to be at high risk for gastrointestinal complications by the general prac-
titioner. 
Table 2: Number of patients (%) using NSAIDs at the time of inclusion
Type of NSAID Total
n = 1,042
OTC (%)
Nonselective  n = 896 (%) n = 122 (12%)
Diclofenac 413 (46) 5 (1)
Ibuprofen 266 (30) 96 (36)
Naproxen 137 (15) 19 (14)
Diclofenac/misoprostol 45 (5) -
Indomethacin 12 (1) -
Piroxicam  11 (1) -
Othera 12 (1) 2 (17)
Selective COX-2 inhibitor n = 146 (%) n = 0
Etoricoxib 63 (43) -
Meloxicam 45 (31) -
Celecoxib 37 (25) -
Valdecoxib 1 (0) -
COX-2: cyclooxygenase-2, NSAID: nonsteroidal anti-inflammatory drug, OTC: over-the-counter
aAceclofenac (n = 1), aspirin: 100-300 mg (n = 1), aspirin/paracetamol (n = 1), carbasalate calcium: 100-300 
mg (n = 2), dexibuprofen (n = 2), ketoprofen (n = 2), sulindac (n = 2), tiaprofenic acid (n = 1)
Figure 1 presents the effects of esomeprazole on NSAID-associated gastrointestinal 
symptoms. Overall, 81% of patients responded positively to PPI therapy, of which 24% 
responded partially. Nineteen percent of patients were nonresponders. 
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Figure 1: Percentage of patients with response, partial response and no response to esomeprazole
*Risk of gastrointestinal complications according to the general practitioner
COX-2: cyclooxygenase-2, GP: general practitioner, NSAID: nonsteroidal anti-inflammatory drug
Characteristics of patients, such as completely responding, partially responding and 
non-responders on esomeprazole therapy, are shown in Table 3. Patients at higher risk 
for gastrointestinal complications (according to the general practitioner) were older 
(mean age 61 years, SD 15) compared with patients with average risk (mean age 52 
years, SD 14). Sex distribution was similar between the two subgroups. The outcome in 
patients at higher risk for gastrointestinal complications was comparable with the other 
groups: in the high-risk group, response and non-response was 56% and 18%, respec-
tively, compared with 58% and 20% in the average-risk group. In addition, response in 
nonselective NSAID and COX-2 selective NSAID users was similar: response 57%, par-
tial response 24%, and nonresponse 19% in nonselective NSAID users compared to 
53%, 30%, and 17% in COX-2 selective NSAID users, respectively. No relationship was 
found between the number of days between two general practitioner visits and the like-
lihood of response (r = -0.001, p = 0.964). The most frequently reported symptom at in-
clusion was heartburn (93%) with a mean symptom score of 1.77 (Table 4). After treat-
ment, upper gastrointestinal symptom scores improved significantly for all studied 
domains: heartburn, regurgitation, bloating and nausea (p < 0.01 for all comparisons). 
Multivariable regression analysis demonstrated that selective serotonin reuptake inhibi-
tor use (adjusted odds ratio (aOR) 0.49, 95% CI 0.33 - 0.74), anticoagulant use (aOR 
0.56, 95% CI 0.32 - 0.98), heartburn (aOR 0.83, 95% CI 0.70 - 0.99) and regurgitation 
(aOR 0.84, 95% CI 0.72 - 0.99) at baseline were associated with a higher response rate 
to PPI therapy (Table 5).
Response
Partial response
No response
Table 3: Response after treatment with esomeprazole
Total
n = 1,042
Responsea
n = 592
Partial responseb
n = 252
No responsec
n = 198
Age (±SD) 57.2 (15) 56.6 (15.6) 58.3 (15.1) 57.6 (15.4)
<65 years (%) 707 407 (58) 164 (23) 136 (19)
t 65 years (%) 335 185 (55) 88 (26) 62 (19)
Male (%) 447 267 (60) 95 (21) 85 (19)
Female (%) 595 325 (55) 157 (26) 113 (19)
History of peptic ulcer disease (%) 104 61 (59) 25 (24) 18 (17)
No history of peptic ulcer disease (%) 938 531 (57) 227 (24) 180 (19)
Concomitant medication
Anticoagulants 162 83 (51) 47 (29) 32 (20)
Low-dose aspirin 141 73 (52) 40 (28) 28 (20)
SSRI 120 49 (41)** 37 (31) 34 (28)
Corticosteroids 69 39 (57) 14 (20) 16 (23)
Comorbidity
Diabetes mellitus 156 89 (57) 40 (26) 27 (17)
Heart failure 72 35 (49) 19 (26) 18 (25)
Indicationd
Nonspecific musculoskeletal pain 521 313 (60)* 108 (21) 100 (19)
Osteoarthritis 356 194 (54) 98 (28) 64 (18)
Rheumatoid arthritis 56 33 (59) 14 (25) 9 (16)
Gout 50 34 (68) 8 (16) 8 (16)
Other 209 94 (45)* 60 (29) 55 (26)
No NSAID switch (%) 938 531 (57) 230 (25) 177 (19)
NSAID switch (%) 104 61 (59) 22 (21) 21 (20)
Nonselective NSAID (%) 896 514 (57) 209 (23) 173 (19)
Selective COX-2 inhibitor (%) 146 78 (53) 43 (29) 25 (17)
High risk according to GP (%) 604 337 (56) 157 (26) 110 (18)
Average risk according to GP (%) 437 255 (58) 95 (22) 88 (20)
Mean symptom score baseline
Bloating (±SD) 1.37 (0.89)* 1.51 (0.89) 1.46 (0.97)
Heartburn (±SD) 1.69 (0.85)** 1.92 (0.69) 1.84 (0.88)
Nausea (±SD) 0.98 (0.91)** 1.10 (0.88) 1.23 (0.94)
Regurgitation (±SD) 1.09 (0.87)** 1.33 (0.84) 1.31 (0.96)
COX-2: cyclooxygenase-2, GP: general practioner, NSAID: nonsteroidal anti-inflammatory drug
aResponse was defined as gastrointestinal symptoms occurring less than 2 days a week
bPartial response was defined as more than 50% improvement in the number of days per week with symptoms 
compared with baseline
cNo response was defined as not meeting the definition for response or partial response 
dSome patients reported more than one indication
*p < 0.05, **p < 0.01, p-values between response and all others
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Table 4: Overall symptom improvement in terms of mean symptom score 
Symptom score Before esomeprazole treatment After esomeprazole treatment
Heartburn, mean (SEM) 1.77 (0.026) 0.35 (0.017)*
Regurgitation, mean (SEM) 1.19 (0.028) 0.23 (0.015)*
Bloating, mean (SEM) 1.42 (0.028) 0.31 (0.016)*
Nausea, mean (SEM) 1.06 (0.028) 0.16 (0.013)*
SEM: standard error of mean
*p < 0.01
Table 5: Multivariable analysis of factors associated with response vs. partial and no response combined
Unadjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
Age t 65 years 0.91 (0.70 - 1.18) 0.93 (0.70 – 1.24)
Female 0.81 (0.63 – 1.04) 0.81 (0.62 – 1.05)
Concomitant medication use
Corticosteroids 0.97 (0.59 – 1.58) 1.19 (0.71 – 2.00)
SSRIs 0.47 (0.32 – 0.70) 0.49 (0.33 – 0.74)
Low-dose aspirin 0.93 (0.64 – 1.36) 1.73 (0.91 – 3.29)
Anticoagulants 0.75 (0.54 – 1.06) 0.56 (0.32 – 0.98)
Comorbidity
Diabetes mellitus 0.99 (0.70 – 1.40) 1.07 (0.73 – 1.56)
Heart failure 0.69 (0.43 – 1.11) 0.79 (0.45 – 1.36)
History of PUD 1.07 (0.71 – 1.62) 1.34 (0.86 – 2.10)
Use of COX-2 selective NSAID 0.85 (0.60 – 1.21) 0.86 (0.59 – 1.25)
Symptom severity baseline
Bloating 0.87 (0.76 – 0.99) 0.99 (0.84 – 1.17)
Heartburn 0.74 (0.64 – 0.86) 0.83 (0.70 – 0.99)
Nausea 0.81 (0.71 – 0.93) 0.89 (0.75 – 1.05)
Regurgitation 0.75 (0.65 – 0.86) 0.84 (0.72 – 0.99)
 
COX-2: cyclooxygenase-2, NSAID: nonsteroidal anti-inflammatory drug, PUD: (complicated) peptic ulcer dis-
ease, SSRI: selective serotonin reuptake inhibitor 
General practitioners were asked to estimate whether patients were at high risk for 
gastrointestinal complications. A patient reporting a history of (complicated) peptic ulcer 
disease had a 12 times higher chance of being classified as “high-risk” by the general 
practitioner compared with patients without a history of (complicated) peptic ulcer disease 
(OR 12.0, 95% CI 5.51 - 26.1). After adjustment for all variables listed in Table 6, all tested 
variables were independently associated with risk classification by the general practitioner. 
In addition, the number of risk factors was found to be independently associated with the 
general practitioners’ classification as high risk; general practitioners more frequently 
classified patients adequately if several risk factors were present. 
Table 6: Risk factors associated with general practitioner assessment for patients to be at high risk for 
gastrointestinal complications (average risk served as a reference)
Risk factor Adjusted OR (95% CI)
Age t 65 years 3.82 (2.74 – 5.34)
Corticosteroids 5.29 (2.54 – 11.0)
SSRIs 7.39 (4.15 – 13.1)
Anticoagulantsa 10.3 (5.50 – 19.3)
History of PUD 16.0 (7.17 – 35.7)
Number of risk factors Unadjusted OR (95% CI)
0 (n = 546) Reference
1 (n = 303) 5.07 (3.71 – 6.93)
2 (n = 103) 9.23 (5.27 – 16.2)
3 or more (n = 90) 74.4 (18.2 – 307)
PUD: (complicated) peptic ulcer disease, SSRI: selective serotonin reuptake inhibitor
aAnticoagulants and low-dose aspirin are taken together
SAFETY
All patients were included in safety analysis. One patient stopped esomeprazole preliminary 
because of diarrhoea. This patient used meloxicam at inclusion. No serious side-effects 
were reported. 
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DISCUSSION
In our study, reflecting current daily practice, we assessed the effect of esomeprazole on 
NSAID-associated gastrointestinal symptoms in 1042 patients. Response was seen in 
81% of patients, and 57% of patients reported a maximum of 1 day per week of upper 
gastrointestinal symptoms. An additional 24% had a partial response. We found that 
esomeprazole consistently and significantly decreased the symptom scores for all four 
studied gastrointestinal symptoms, that is, heartburn, regurgitation, bloating and nausea. 
The beneficial response was present irrespective of risk for upper gastrointestinal compli-
cations. Patients with comorbidity or comedication, or patients on nonselective or COX-2 
selective NSAID fared equally well. History of peptic ulcer disease and presence of more 
than one established risk factor were the strongest predictors for patients to be classified 
as high risk by the general practitioner. Earlier randomized clinical trials have shown that 
20 mg or 40 mg esomeprazole provides relief of upper gastrointestinal symptoms in 
approximately 70% of patients using nonselective NSAIDs or COX-2 inhibitors.12 
We confirmed these results, but our response rates were slightly lower. This reflects the 
difference between a randomized clinical trial and daily practice. Patients participating in 
randomized trials are highly selected, and patients who are commonly seen in primary 
care (with comorbidities and multiple drug use) are excluded from randomized clinical 
trials.14 Other reasons for decreased efficacy are noncompliance, a higher or lower dose 
than tested, greater disease severity, and drug interactions.14 As a consequence, treatment 
effect of a drug may decrease if it is used in daily practice. 
The definition of response, “ a maximum of 1 day per week with persistent symptoms”, 
was in line with relief definitions used in a previous randomized trial in NSAID users and 
in patients with GERD, in which this is a commonly used method to assess treatment 
response.11,20-22
Our study showed that more than 10% of patients were taking over-the-counter (OTC) 
NSAIDs. Generally, OTC NSAIDs are sold in lower dosages and carry less gastrointesti-
nal risk compared with prescribed NSAIDs. However, when a patient is taking both pre-
scribed and OTC NSAIDs the risk of gastrointestinal complications increases, and 
both patients and physicians are often unaware of this risk. We also registered switch-
es among NSAID use. Interestingly, most patients switched within either nonselective 
NSAIDs or COX-2 selective inhibitors, whereas we expected more switchers to COX-2 
selective inhibitors in high-risk patients. A minority of 14% of all NSAID users used COX-
2 selective inhibitors. This reflects the Dutch gastroprotection guideline, which recom-
mends co-prescription of a PPI or misoprostol for NSAID users at risk for complications. 
Prescription of a COX-2 selective inhibitor should be considered only when there are ma-
jor concerns about multiple drug use.23 
The most frequently reported symptom at inclusion was heartburn (93%), despite exclusion 
of patients with (a history of) GERD. This seems contradictory but is in line with two multi-
center studies that also assessed gastrointestinal symptom relief on PPI therapy in 
NSAID users in a randomized controlled manner.11,12
The strengths of our study are the large number of included patients and the daily practice 
setting. Patients were included without stringent inclusion and exclusion criteria, reflecting 
daily practice as much as possible. On the basis of its pragmatic design, our study also 
has some limitations. We did not perform endoscopy before inclusion or at treatment 
evaluation. In Dutch daily practice, the majority of patients visiting a general practitioner with 
upper gastrointestinal symptoms are at first pragmatically treated with acid-suppressive 
drugs without prior endoscopic procedures.24 This is based on the high rates of ‘functional’ 
dyspepsia - that is, no organic cause for upper gastrointestinal complaints can be found.25 
Referral for endoscopy is only warranted if alarming symptoms are present or if symptoms 
persist after adequate treatment with acid suppressants. This fell outside the scope of 
this study. We did not perform any diagnostic test for Helicobacter pylori infection either. 
Although many studies have been conducted regarding the association between H. pylo-
ri infection and upper gastrointestinal symptoms, the actual contribution of H. pylori in pa-
tients with upper gastrointestinal symptoms is still under debate.26-28 
Second, we did not include a placebo group. The efficacy of esomeprazole has already 
been proven11; withholding effective treatment from patients is unethical. By using this 
pragmatic design, we were able to estimate how patients responded to esomeprazole 
in daily primary care. Third, we cannot rule out selection bias in our cohort of Dutch patients 
visiting their general practitioner for upper gastrointestinal symptoms while on NSAID 
therapy. Not all patients with NSAID-associated upper gastrointestinal symptoms will 
decide to visit a general practitioner for their upper gastrointestinal symptoms; moreover, 
we were dependent on general practitioners who selected NSAID users for participation 
in the study. We believe that the resemblance of daily practice and the large number of 
patients included in our study outweigh these shortcomings. 
In conclusion, PPIs are effective in diminishing upper gastrointestinal symptoms in 
NSAID users in daily general practice. The type of NSAID and patients’ gastrointestinal risk 
according to the general practitioner did not seem to affect esomeprazole’s effectiveness.
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 ABSTRACT
Background Aspirin (acetylsalicylic acid) is associated with gastrointestinal side-effects 
like gastric ulcers, gastric bleeding and dyspepsia. High dose effervescent calcium 
carbasalate (ECC), a buffered formulation of aspirin, is associated with reduced gastric 
toxicity compared to plain aspirin in healthy volunteers, but at lower cardiovascular doses 
no beneficial effects were observed.
Aim To compare the prevalence of self-reported gastrointestinal symptoms between 
low-dose plain aspirin and ECC. 
Methods A total of 51,869 questionnaires were sent to a representative sample of the 
Dutch adult general population in December 2008. Questions about demographics, 
gastrointestinal symptoms in general and specific symptoms, comorbidity, and medication 
use including bioequivalent doses of ECC (100mg) and plain aspirin (80mg) were stated. 
We investigated the prevalence of self-reported gastrointestinal symptoms on ECC 
compared to plain aspirin using univariate and multivariate logistic regression analyses. 
Results A total of 16,715 questionnaires (32%) were returned and eligible for analysis. 
Of these, 911 respondents (5%) reported the use of plain aspirin, 633 ECC (4%) and 
15,171 reported to use neither form of aspirin (no aspirin). The prevalence of self-reported 
gastrointestinal symptoms in general was higher in respondents using ECC (27.5%) 
compared to plain aspirin (26.3%), but did not significantly differ with both univariate (OR 
1.06, 95% CI 0.84 - 1.33), nor with multivariate analysis (aOR 1.08, 95% CI 0.83 - 1.41). 
Also, none of the specific types of symptoms differed between both aspirin formulations.
Conclusions In this large cohort representative of the general Dutch population, low-dose 
ECC is not associated with a reduction in self-reported gastrointestinal symptoms compared 
to plain aspirin. 
INTRODUCTION
Optimal antithrombotic therapy has proven to be essential in secondary prevention in 
cardiovascular disease. In this, aspirin (acetylsalicylic acid) has a pivotal role and is 
associated with a relative reduction of approximately 25% on recurrent cardiovascular 
events1. However, gastric toxicity is a well-known side effect of aspirin presenting as 
gastric or duodenal ulcers, bleeding and dyspepsia.1-7 Of these, dyspepsia is mostly 
reported which is present in 20-40% of chronic aspirin users4,7,8 and is associated with 
reduced compliance 9,10,increased healthcare costs11 and reduced health-related quality 
of life.12  
To reduce gastrointestinal damage different formulations of aspirin have been developed. 
These formulations either inhibit the release of aspirin in the stomach (enteric-coated 
aspirin), facilitate the transit of aspirin across the gastric mucous layer (the newly developed 
PL2200), or increase solubility of aspirin supposedly resulting in lower local concentrations 
(effervescent calcium carbasalate (ECC)). All these forms were mainly studied in high 
dosages and showed clear benefit with respect to gastric ulcer formation when studied 
in healthy volunteers.13-18 However, when investigating its clinical effect in patients on 
(low-dose) chronic antiplatelet therapy, no clear beneficial effect on gastrointestinal side 
effects was noticeable.19-21 
Data on the effects of the various aspirin formulations on gastrointestinal symptoms are 
scarce. With respect to enteric-coated aspirin, the currently available literature does not 
indicate that this would reduce gastrointestinal complaints when compared to plain aspirin.22 
In the Netherlands, a total of 1,290,000 patients were using low-dose aspirin of which 
41% used ECC.23 In contrast to enteric-coated aspirin, no data are published comparing 
the effects of ECC and plain aspirin on gastrointestinal symptoms. We hypothesize that 
in our population-based cohort of respondents using low-dose aspirin, the prevalence 
of gastrointestinal symptoms is lower in those using effervescent calcium carbasalate 
compared to plain aspirin. We also anticipate that respondents using different formulations 
may present with different type of gastrointestinal symptoms. 
METHODS
STUDY POPULATION
We sent 51,869 questionnaires by surface mail to a representative sample of the Dutch 
population in December 2008. Invited subjects were aged 18 years and above, and 
randomly selected from municipal databases of five different municipalities selected on 
their geographical location in the Netherlands, in order to gather a representative sample 
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of the Dutch population. We included returned questionnaires until March 31st 2009. 
We excluded returned questionnaires with missing elements that were part of the primary 
outcome measure. We also excluded returned questionnaires in which all baseline char-
acteristics were missing or when the medication was unreadable or if the used aspirin 
formulation was not reported. The complete cohort was described previously.24 The cur-
rent sample size consisted of those respondents reporting the use of either low dose 
plain aspirin or effervescent calcium carbasalate.
The Medical Ethical Committee of the Radboud University Nijmegen assessed the research 
proposal of this study and concluded that it could be waived for ethical review, as ques-
tionnaires were returned and stored anonymously, and (non-)responders would not be 
contacted again. For this reason, we did not obtain written informed consent.
QUESTIONNAIRE
The questionnaire has been used before and was specifically designed for collection of 
demographic information, gastrointestinal symptoms, and medication use.25,26 Participants 
were asked whether they suffer from gastrointestinal symptoms in general and about the 
presence of 26 gastrointestinal symptoms such as nausea, early satiety and bloating. 
Severity of gastrointestinal symptoms was assessed on a seven-point Likert scale (0 = 
absent, 1 = almost absent, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe, 
6 = very severe) over the preceding four weeks.27 A symptom was considered to be 
present if the participants scored t 2 on the Likert scale.
OUTCOMES
Our primary outcome was the presence of gastrointestinal symptoms, which was 
assessed with the question: “Do you experience gastrointestinal complaints?” and had 
to be answered with either “yes” or “no”. Secondary outcomes were duration of the 
primary endpoint and the individual gastrointestinal symptoms among responders who 
reported the presence of gastrointestinal complaints. The primary and secondary out-
comes were compared between respondents reporting the use of low-dose plain aspirin 
(80mg) and those using effervescent calcium carbasalate (100mg).
STATISTICAL ANALYSIS
Statistical analyses were performed with SPSS statistical software, version 16.0 (SPSS, 
Inc., Chicago, Illinois, USA). Frequency tables were provided describing respondents’ 
baseline characteristics. Pearson’s chi-square (Ȥ2) test was used to compare categorical 
variables. Continuous variables were compared with the Student’s t-test or the Mann-
Whitney U method whenever appropriate. Univariate and multivariate associations for 
gastrointestinal endpoints in respondents using plain aspirin or ECC were analyzed 
using logistic regression. A p-value of < 0.05 was considered statistically significant. 
Covariates were included in multivariate analysis if they significantly differed between 
respondents using effervescent calcium carbasalate versus plain aspirin. In addition 
were those covariates associated with gastrointestinal symptoms at a level of p < 0.1 in 
the univariate analysis included in the multivariate analysis. Using forward selection, a 
covariate was allowed into the multivariate model if it influenced the model with a likelihood 
ratio significance level of p < 0.05, and was removed again if its significance level exceeded 
p = 0.1 during any of the following steps. The type of formulation used (effervescent calcium 
carbasalate versus plain aspirin) was forced into the model.
 
RESULTS
A total of 18,317 (35%) questionnaires were returned, of which 742 unopened for various 
reasons (Figure 1). 
Figure 1: Flowchart
* Some respondents fulfilled more than 1 exclusion criterion
ECC: effervescent calcium carbasalate
After applying our predetermined exclusion criteria a total of 16,715 questionnaires were 
included in our analyses. In total, 911 persons (5.4%) reported plain aspirin use, 633 
ECC (3.8%) and 15,171 reported not using any form of aspirin (90.8%). Compared to 
51,869 questionnaires sent
17,575 completed questionnaires 
received
860 questionnaires excluded* 
     284 all baseline variables missing
     308 primary outcome missing
     413 gastrointestinal symptoms missing
     111 medication unreadable  
 $ %
742 questionnaires returned to sender
     360 no reason
     298 moved
       47 deceased
       37 not interested 
16,715 questionnaires analysed
15,171 no aspirin 911 plain aspirin 633 ECC
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participants using plain aspirin, those with ECC were older, reported more comorbidity 
and were using more co-medication (Table 1).
Table 1: Baseline characteristics
Plain aspirin
n = 911
Effervescent calcium 
carbasalate
n = 633
p-value
Mean age (±SD) (years) 59.7 (15.2) 64.7 (11.3) < 0.01
Male (%) 494 (56) 377 (61) 0.09
Smoking (%) 160 (18) 116 (19) 0.74
Body mass index (±SD) (kg/m2) 26.3 (4.6) 27.0 (4.9) < 0.01
Comorbidity (%)
Diabetes mellitus 108 (12) 106 (17) < 0.01
Rheumatoid arthritis 53 (6) 54 (9) 0.04
Asthma/COPD 62 (7) 69 (11) < 0.01
Celiac disease 16 (2) 9 (1) 0.61
IBD 27 (3) 18 (3) 0.89
Medication use (%)
PPI 191 (21) 188 (30) < 0.01
H2RA 24 (3) 14 (2) 0.60
Antacids 79 (9) 50 (8) 0.59
Paracetamol 474 (52) 276 (44) < 0.01
NSAIDs 274 (30) 186 (29) 0.77
Clopidogrel 17 (2) 36 (6) < 0.01
Dipyridamol 43 (5) 69 (11) < 0.01
Beta blockers 351 (39) 301 (48) < 0.01
ACE inhibitors 175 (19) 189 (30) < 0.01
Angiotensin-receptor  
antagonist
103 (11) 83 (13) 0.28
Calcium antagonist 128 (14) 105 (17) 0.17
Diuretics 185 (20) 155 (25) 0.051
Statins 396 (44) 373 (59) < 0.01
Systemic corticosteroids 15 (2) 11 (2) 0.89
Oral glucose lowering agents 85 (9) 70 (11) 0.27
Antidepressants 47 (5) 40 (6) 0.33
History (%)
Peptic ulcer disease 69 (8) 76 (12) < 0.01
Peptic ulcer bleeding 26 (3) 15 (2) 0.56
ACE: angiotensin converting enzyme, COPD: chronic obstructive pulmonary disease, H2RA: H2-receptor antagonist, 
IBD: inflammatory bowel disease, NSAID: nonsteroidal anti-inflammatory drug, PPI: proton pump inhibitor
The self-reported prevalence of gastrointestinal symptoms of plain aspirin and ECC were 
26.3%, and 27.5%, respectively. When comparing self-reported gastrointestinal symptoms 
between plain aspirin and ECC we observed no difference (ECC: OR 1.06, 95% CI 0.84 - 
1.33). Also after adjustment with multivariate regression for multiple possible confounders 
there was no significant difference between plain aspirin and ECC for the presence of 
gastrointestinal symptoms (ECC: aOR 1.08, 95% CI 0.83 - 1.41, Table 2). Among those 
reporting gastrointestinal symptoms, respondents using ECC had a significantly longer 
history of symptoms (10 years, IQR 4 - 20) compared to participants using plain aspirin 
(7 years, IQR 3 - 16, p = 0.04).
Table 2: Multivariate logistic regression model for reporting gastrointestinal symptoms with effervescent 
calcium carbasalate entered into the model
Adjusted OR 95% CI p-value
Age (per year increase) 0.98 0.97 - 0.99 < 0.01
Male gender 0.71 0.55 - 0.92 0.01
Comorbidity
Asthma/COPD 1.54 1.01 - 2.36 0.046
IBD 2.01 1.00 - 4.04 0.050
Medication use
PPI 3.96 2.96 - 5.30 < 0.01
H2RA 4.39 2.01 - 9.57 < 0.01
Antacids 2.90 1.90 - 4.44 < 0.01
Paracetamol 1.42 1.09 - 1.86 < 0.01
Effervescent calcium carbasalate 1.08 0.83 - 1.41 0.57
History
Peptic ulcer disease 2.39 1.60 - 3.58 < 0.01
COPD: chronic obstructive pulmonary disease, H2RA: H2-receptor antagonist, IBD: inflammatory bowel disease, 
PPI: proton pump inhibitor
In respondents reporting the presence of gastrointestinal symptoms and using either 
plain aspirin or ECC, the most frequently reported upper gastrointestinal symptoms 
were bloating (61%), belching (47%) and regurgitation (42%; Figure 2a). Flatulence (70%) 
and borborygmi (56%) were the most frequently reported lower gastrointestinal symp-
toms (Figure 2b). No significant differences between plain aspirin and ECC were present 
for any of the gastrointestinal symptoms. 
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Figure 2: Type and prevalence of specific upper (a) and lower (b) gastrointestinal symptoms in respondents 
experiencing gastrointestinal symptoms categorized by aspirin formulation 
ECC: effervescent calcium carbasalate
a
b
DISCUSSION
We aimed to compare the prevalence of self-reported gastrointestinal symptoms between 
respondents using plain aspirin and those who were prescribed ECC. We observed that 
in respondents using any form of low-dose aspirin the prevalence of gastrointestinal 
symptoms was 27%. The use of ECC is not associated with less gastrointestinal symptoms 
compared to plain aspirin. Most reported upper gastrointestinal symptoms were bloating, 
belching, and regurgitation, whereas flatulence and borborygmi were reported most for 
lower gastrointestinal symptoms. No differences in type of symptoms between users of 
ECC and plain aspirin were observed.
The prevalence of gastrointestinal symptoms in our study cohort is in line with previously 
reported data of aspirin users.4,7,8 Interestingly, the prevalence is also comparable with 
the general (mostly non-aspirin using) population.24 The selection of our study population 
could have contributed to this finding. Low-dose aspirin is generally a long-term treatment, 
i.e. for the remainder of the patients’ life span. For our study we selected all low-dose 
aspirin users from a large cohort of participants returning the questionnaire. As a result 
of our design the odds that aspirin treatment was recently initiated for our participants 
are minimal. Those patients who suffered from gastrointestinal symptoms during (the 
initiation of) aspirin treatment were likely to receive co-treatment with a PPI, H2 receptor 
antagonist or antacid or were even switched to other antiplatelet agents. Consequently, 
our cohort consists of a selected population of respondents in whom aspirin is relatively 
well tolerated. This hypothesis is supported by more frequently use of gastroprotective 
agents in low-dose aspirin users compared to the general population (e.g. PPI use: 
24.5% vs 10.6%).24 Irrespectively, our data indicates that ECC is of no beneficial value 
for gastrointestinal symptoms among our population of long-term aspirin users. 
So far, only two studies have been conducted to investigate endoscopically proven 
gastric mucosal damage in users of ECC and plain aspirin. In a randomized cross-over 
trial, ECC significantly reduced endoscopically observed gastric erosions and ulcers 
compared to the bioequivalent dose of plain aspirin.13 However, this study assessed 
healthy volunteers, investigated very high doses of aspirin (650mg t.i.d.) and only studied 
the short-term effects. More recently, the effects of low-dose ECC and plain aspirin were 
compared in patients using long-term aspirin for cardiovascular prevention.19 In this 
large retrospective cohort study, the authors concluded that the incidence rates of 
endoscopically proven peptic ulcers were not significantly different between both groups.
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This is the first study comparing the effects of ECC with plain aspirin for gastrointestinal 
symptoms. Moreover, in order to obtain a representative sample, persons were randomly 
selected through databases of local authorities without stringent in- and exclusion criteria. 
We do acknowledge some limitations in our study. First, because of our study design, 
response bias could be a potential limitation. Due to concealment we were unable to 
contact non-responders and compare their characteristics with responders. To minimize 
the effect of response bias all participants were invited with a personalized invitational 
letter and were asked explicitly to participate irrespective of experiencing gastrointestinal 
symptoms. Seventy-five percent of all respondents indeed did not report the presence 
of gastrointestinal symptoms. Second, we did not study the duration of low-dose 
aspirin use or the effect of gastrointestinal symptoms on aspirin compliance.
In view of our finding that ECC is not associated with a reduction in gastrointestinal 
symptoms and taken into account the higher costs of ECC compared to plain aspirin, 
we feel that plain aspirin is the first drug of choice. If gastrointestinal symptoms occur, we 
advise to prescribe a relatively cheap PPI or another gastroprotective agent, albeit that 
this is only of limited value.28-30 Only if this does not reduce the symptoms, one might con-
sider ECC as an alternative to plain aspirin.
In conclusion, the prevalence of gastrointestinal symptoms among aspirin users in the 
Dutch community is 27% with no difference between effervescent calcium carbasalate 
and plain aspirin in overall prevalence and type of symptoms reported.
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ABSTRACT
Background Gastrointestinal symptoms are frequently reported side effects of anti-
depressants, but antidepressants are also a treatment modality in functional gastroin-
testinal disorders. We aimed to assess the association between antidepressant use and 
gastrointestinal symptoms in the general adult population.
Materials and methods We assessed gastrointestinal symptoms, medication use, 
and comorbidity through structured questionnaires in randomly selected individuals. 
We compared presence of gastrointestinal symptoms in respondents whom reported 
antidepressant use to those that did not. We used multivariable regression analysis to 
verify the association between antidepressant use and gastrointestinal symptoms. 
Results In total, 16,758 questionnaires were returned and eligible for analysis. Anti-
depressant use was reported by 701 respondents (4.2%). Gastrointestinal symptoms 
were more frequently reported by antidepressant users compared to non-users (40% vs. 
25%, p < 0.01). This apparent association between antidepressant use and gastrointestinal 
symptoms did not remain after adjusting for demographic factors, comorbidity, and use 
of other medications (adjusted OR 0.94, 95% CI 0.74 - 1.18). 
Conclusions In our cross-sectional population-based study, we did not find an association 
between antidepressant use and gastrointestinal symptoms. 
INTRODUCTION
Antidepressants are frequently prescribed medications. Its use has risen tremendously 
over the last decades, which is associated with high healthcare expenditures.1-3 In 2011, 
264 million prescriptions for antidepressants were made in the United States, with asso-
ciated costs of 11 billion dollar, which is equivalent to approximately 8 billion Euros.4 In 
the Netherlands, antidepressant use accounted for 47 million Euros in 2011.5  
In well-designed clinical trials that assessed the effectiveness of antidepressants for psy-
chiatric disorders, gastrointestinal symptoms were frequently reported adverse effects.6-10 
A meta-analysis that assessed side effects of selective serotonin reuptake inhibitors (SSRIs) 
and tricyclic antidepressants (TCAs) confirmed these findings.11 
Years later, the effect of antidepressants was studied in patients with functional digestive 
disorders.12-14 A number of randomized clinical trials investigated the efficacy of anti-
depressant treatment in improving gastrointestinal symptoms in patients with irritable 
bowel syndrome (IBS) and functional dyspepsia.13,15,16 Subsequent systematic reviews 
concluded that antidepressants have beneficial effects in these patients.17-19 Although 
one review signalled possible publication bias17, clinical guidelines incorporated anti-
depressants as second line treatment option for functional gastrointestinal disorders.20 
Given the ambiguous effect of antidepressants on the gastrointestinal system we set out to 
assess the association between use of antidepressants and gastrointestinal symptoms 
in the general population.
 
MATERIALS AND METHODS
STUDY POPULATION
We sent 51,869 questionnaires to a random sample of the adult Dutch population in 
December 2008. Invited subjects were eighteen years and older, and were randomly 
selected from municipal databases of five different Dutch municipalities. The municipalities 
were selected to achieve a representative sample of the population. Questionnaires that 
returned until the end of March 2009 were included in the study. Questionnaires were 
excluded if 1) baseline variables were missing, 2) the primary outcome was missing, 3) 
type of symptoms was missing, and/or 4) illegible input of medication. 
ASSESSMENT INSTRUMENT
We used a questionnaire that was used previously and that was specifically designed to 
collect information on gastrointestinal symptoms, medication use, comorbidity, and 
health-related quality of life.21-23
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Respondents were asked about the general presence of gastrointestinal symptoms. We 
also questioned the following 16 different symptoms: epigastric pain (in general, during 
daytime, nocturnal), heartburn (in general, during daytime, nocturnal), regurgitation, 
borborygmi, bloating, empty feeling, nausea, vomiting, loss of appetite, early satiety, 
belching, haematemesis, dysphagia (for liquids, for solid food), lower abdominal pain (in 
general, postprandial, pre-prandial, persistent after defecation), flatulence, and abnormal 
stools (black, bloody, mucous, frequently hard, diarrhoea, alternately solid or loose, consti-
pation, painful defecation, strong urgency, incomplete, fatty stools). Respondents could 
indicate severity of symptoms over the preceding four weeks on a seven-point Likert 
scale (0 = absent, 1 = almost absent, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = 
severe, 6 = very severe). A symptom was considered present if respondents rated it t 2 
on the Likert scale.
We asked for medication use and categorized antidepressants into: tricyclic antidepres-
sants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine 
reuptake inhibitors (SNRIs), and a group of “other antidepressants” (tetracyclic anti-
depressants, monoamine oxidase (MAO) inhibitors, and type of antidepressants not 
specified). Respondents were categorised as antidepressant users and non-antidepressant 
users (‘non-users’). 
Consumption of t 42 units coffee per week was defined as excessive coffee consump-
tion.23,24 Body mass index (BMI) was calculated and categorised into normal weight 
(BMI < 25 kg/m2) and overweight (BMI t 25 kg/m2). 
Presence of depressive symptoms was scored with the EuroQol 5D.25 We classified 
respondents that indicated to be ‘moderately anxious/ depressed’ or ‘extremely anxious/ 
depressed’ as having depressive symptoms. 
OUTCOMES 
Our primary outcome was presence of gastrointestinal symptoms, which was assessed 
with the question: “Do you experience gastrointestinal complaints?” and had to be 
answered with either “yes” or “no”. Type of gastrointestinal symptoms was the secondary 
outcome measure.
DATA ANALYSIS
Data from the questionnaires were entered into a database using Teleform automated 
scanning software, and statistical analyses were performed with IBM PAWS Statistics 
SPSS, version 18.0. Presence of gastrointestinal symptoms in antidepressant users 
and non-antidepressant users was analyzed with a Pearson’s chi-square (Ȥ2) test. In 
respondents with gastrointestinal symptoms, type of symptoms was compared between 
antidepressant users and non-users with Pearson’s chi-square (Ȥ2) test. Continuous 
variables were compared with Student’s t-test or Mann-Whitney U method whenever 
appropriate. 
Univariable logistic regression analysis was performed to determine which variables 
were associated with the primary outcome. Variables were included in the multivariable 
regression analysis if a significant association with gastrointestinal symptoms was found 
(p < 0.01) and/or if a biological plausibility for an association between antidepressant 
use and gastrointestinal symptoms was present. We included the following variables in 
the multivariable regression analysis: demographic factors (age and gender), lifestyle 
factors (overweight, smoking, and excessive coffee consumption), comorbidity (rheu-
matoid arthritis, asthma/COPD, IBS, and depressive symptoms), history of peptic ulcer 
disease and peptic ulcer bleeding, and medication use.
Subgroup analyses were conducted to assess presence of gastrointestinal symptoms in 
the subgroups of respondents with and without IBS using regression analysis. Use of 
antidepressants in these groups was assessed using Pearson’s chi-square (Ȥ2) test. 
Class of antidepressant and its association with gastrointestinal symptoms was calculated 
using univariable and multivariable regression analysis.
Due to the large number of respondents, a p-value < 0.01 was the cut-off point for sta-
tistical significance. Odds ratios were presented with 95% confidence intervals (CI).
 
RESULTS
We received a total of 18,317 questionnaires (response rate 35.3%), and 742 (4.1%) 
were returned to sender for various reasons (Figure 1). Of the remaining questionnaires 
(n = 17,575), an additional 817 questionnaires (4.6%) were excluded based on pre-
defined exclusion criteria, leaving 16,758 questionnaires eligible for analyses. Mean age 
of respondents was 49.8 years (SD 15.7) and 43% was male.
Antidepressant use was reported by 701 respondents (4.2%), of which 60% used SSRIs 
(n = 423), 19% TCAs (n = 133), 13% SNRIs (n = 89), and 8% reported use of another 
antidepressant (n = 56). Table 1 depicts the baseline characteristics of the included 
population categorised by antidepressant use. Antidepressant users were older, more 
often female, and reported more frequently additional medication use such as proton 
pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs) and anxiolytics. 
Gastrointestinal symptoms were more frequently among antidepressant users compared 
to non-users (40% vs. 25%, p < 0.01) with an unadjusted odds ratio (OR) of 1.96 (95% CI 
1.68 - 2.29). Amongst others, antidepressant users more frequently reported: flatulence 
(78% vs. 70%), bloating (71% vs. 63%), and epigastric pain during daytime (54% vs. 
39%) compared to non-users (all p < 0.01). Symptoms that were more common in anti-
depressant users are depicted in Figures 2A and 2B. 
A total of 18% of the examined population (n = 2,894) reported depressive symptoms. 
Antidepressant users more frequently reported depressive symptoms compared to 
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non-users (56% vs. 16%, p < 0.01). Presence of gastrointestinal symptoms was in-
creased among respondents who reported depressive symptoms (46% vs. 22%, p < 
0.01). Depressive symptoms were more prevalent in respondents with IBS (36% vs. 
17%, p < 0.01). 
After multivariable regression analysis, the difference in gastrointestinal symptoms between 
antidepressant users and non-users was not statistically significant (adjusted OR 0.94, 
95% CI 0.74 - 1.18). We found that use of PPIs, H2 receptor antagonists (H2RAs), laxatives, 
and presence of IBS was strongly associated with gastrointestinal symptoms (Table 2).
We performed several predefined subgroup analyses. First, none of the antidepressant 
classes was independently associated with an increased or decreased risk on gastroin-
testinal symptoms (Table 3). Secondly, we studied the subgroup of respondents with 
IBS (n = 895) and found no association between antidepressant use and gastrointestinal 
symptoms after correction for confounding (adjusted OR 0.99, 95% CI 0.45 - 2.16). We 
also performed a subgroup analysis after exclusion of respondents with IBS, and found 
that antidepressant users more often reported gastrointestinal symptoms compared to 
non-antidepressant users (34% vs. 23%; unadjusted OR 1.77, 95% CI 1.49 - 2.10). 
However, after adjusting for confounders, this was no longer significant (adjusted OR 
0.95, 95% CI 0.75 - 1.21). Finally, we assessed antidepressant use in the subgroup of 
respondents with gastrointestinal symptoms. In this group with symptoms, respondents 
with IBS significantly more frequently reported use of antidepressants compared to respon-
dents without IBS (10.1% vs. 5.8%, p < 0.01).
 
Figure 1: Flowchart
* Some respondents fulfilled more than 1 exclusion criterion
51,869 questionnaires sent
18,317 questionnaires returned
(response rate 35.3%)
17,575 completed questionnaires 
received
16,758 questionnaires analysed
16,057 (95.8%)
Other respondents
701 (4.2%)
Antidepressant users
817 questionnaires excluded*
284 all baseline variables missing
308 primary outcome missing
413 gastrointestinal symptoms missing
111 medication unreadable 
742 questionnaires returned to sender
360 no reason
298 moved
 47 deceased
 37 not interested
Table 1: Baseline characteristics of antidepressant and non-antidepressant users
Variable Antidepressant 
users
n = 701
Non-antidepressant 
users
n = 16,057
p-value
Mean age in years (± SD) 52.9 (13.6) 49.7 (15.7) < 0.01
Female gender (%) 485 (71.1) 8,747 (56.0) < 0.01
Body mass index t 25 kg/m2 (%) 388 (56.6) 7,228 (45.8) < 0.01
Smoking (%) 210 (30.5) 2,719 (17.2) < 0.01
Excessive coffee consumption (%)a 78 (12.8) 1,515 (11.0) 0.162
Medication use (%)
PPIs 162 (23.1) 1,609 (10.0) < 0.01
H2RAS 32 (4.6) 255 (1.6) < 0.01
Antacids 71 (10.1) 954 (5.9) < 0.01
NSAIDs 186 (26.5) 3,047 (19.0) < 0.01
Paracetamol 207 (29.5) 3,974 (24.7) < 0.01
Anxiolytic agents 100 (14.3) 252 (1.6) < 0.01
Antipsychotic agents 45 (6.4) 61 (0.4) < 0.01
Laxatives 39 (5.6)   235 (1.5) < 0.01
ȕ2-sympathicomimetics 58 (8.3) 657 (4.1) < 0.01
Anti-migraine medications 15 (2.1) 171 (1.1) < 0.01
Parasympathicomimetics 19 (2.7) 192 (1.2) < 0.01
Sleep medicationsb 60 (8.6) 191 (1.2) < 0.01
Comorbidity (%)
Reported depressive symptoms 382 (55.5) 2,512 (16.0) < 0.01
Rheumatoid arthritis 74 (10.6) 699 (4.4) < 0.01
Asthma/COPD 75 (10.7) 969 (6.0) < 0.01
Irritable bowel syndrome 84 (12.0) 811 (5.1) < 0.01
History (%)
Peptic ulcer disease 52 (7.6) 834 (5.3) < 0.01
Peptic ulcer bleeding 14 (2.0) 268 (1.7) 0.491
COPD: chronic obstructive pulmonary disease, H2RA: H2-receptor antagonist, NSAID: nonsteroidal anti- 
inflammatory drug, PPI: proton pump inhibitor 
aExcessive coffee consumption: 42 cups a week and more 
bBrotizolam, flunitrazepam, flurazepam, loprazolam, lormetazepam, melatonin, midazolam, nitrazepam,  
temazepam, zolpidem, zopiclon, non specified sleep medications
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Figure 2A: Upper gastrointestinal symptoms reported significantly more frequently by antidepressant users 
compared to other respondents
Figure 2B: Lower gastrointestinal symptoms reported significantly more frequently by antidepressant users 
compared to other respondents
Antidepressant users
Non-antidepressant users
Antidepressant users
Non-antidepressant users
Table 2: Unadjusted and adjusted odds ratio for presence of gastrointestinal symptoms
Variable Unadjusted OR 
(95% CI)
Adjusted OR
(95% CI)
Antidepressant use 1.96 (1.68 – 2.29) 0.94 (0.74 – 1.18)
Age (per advancing year) 1.00 (0.99 – 1.00) 0.98 (0.98 – 0.98)
Female gender 1.70 (1.58 – 1.83) 1.52 (1.38 – 1.67)
Body mass index t 25 kg/m2 1.15 (1.07 – 1.23) 1.07 (0.97 – 1.18)
Smoking 1.20 (1.10 – 1.31) 1.04 (0.92 – 1.17)
Excessive coffee consumptiona 0.83 (0.74 – 0.95) 1.01 (0.87 – 1.18)
Medication use
PPIs 7.14 (6.43 – 7.94) 7.80 (6.76 – 9.01)
H2RAs 8.52 (6.53 – 11.1) 9.12 (6.48 – 12.8)
Antacids 4.33 (3.81 – 4.93) 4.30 (3.63 – 5.08)
NSAIDs 1.58 (1.46 – 1.72) 0.96 (0.85 – 1.08)
Paracetamol 1.29 (1.20 – 1.40) 1.04 (0.94 – 1.16)
Anxiolytic agents 3.03 (2.46 – 3.75) 1.54 (1.12 – 2.11)
Antipsychotic agents 1.62 (1.09 – 2.41) 0.63 (0.36 – 1.13)
Laxatives 6.43 (4.98 – 8.32) 4.82 (3.27 – 7.09)
ȕ2-sympathicomimetics 1.61 (1.37 – 1.88) 0.67 (0.50 – 0.90)
Anti-migraine medications 1.60 (1.18 – 2.16) 1.24 (0.82 – 1.89)
Parasympathicomimetics 1.67 (1.26 – 2.21) 1.13 (0.74 – 1.72)
Sleep medicationsb 2.52 (1.96 – 3.24) 1.62 (1.13 – 2.32)
Comorbidity
Reported depressive symptoms 3.07 (2.82 – 3.34) 2.35 (2.09 – 2.63)
Rheumatoid arthritis 2.07 (1.79 – 2.40) 1.06 (0.85 – 1.31)
Asthma/COPD 1.82 (1.59 – 2.07) 1.47 (1.15 – 1.88)
Irritable bowel syndrome 10.8 (9.26 – 12.7) 9.98 (8.12 – 12.28)
History
Peptic ulcer disease 4.02 (3.50 – 4.61) 2.25 (1.85 – 2.74)
Peptic ulcer bleeding 3.73 (2.94 – 4.73) 1.80 (1.29 – 2.52)
 
COPD: chronic obstructive pulmonary disease, H2RA: H2-receptor antagonist, NSAID: nonsteroidal anti- 
inflammatory drug, PPI: proton pump inhibitor 
aExcessive coffee consumption: 42 cups a week and more 
bBrotizolam, flunitrazepam, flurazepam, loprazolam, lormetazepam, melatonin, midazolam, nitrazepam,  
temazepam, zolpidem, zopiclon, non specified sleep medications
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Table 3: Unadjusted and adjusted odds ratios for presence of gastrointestinal symptoms in antidepressant 
subgroups
Class of antidepressant Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
TCAs 1.57 (1.10 – 2.25) 0.60 (0.35 – 1.04)
SSRIs 1.90 (1.56 – 2.32) 0.91 (0.68 – 1.21)
SNRIs 2.54 (1.67 – 3.86) 1.24 (0.67 – 2.30)
Other antidepressantsa 2.58 (1.52 – 4.37) 1.63 (0.75 – 3.56)
 
SNRI: serotonin and norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor, TCA: tricyclic 
antidepressants 
aTetracyclic antidepressants, MAO inhibitors, and class of antidepressants not specified
DISCUSSION
In our large general population-based study, antidepressant users more frequently reported 
gastrointestinal symptoms. However, after adjustment for potential confounders, there 
remained no association between antidepressant use and gastrointestinal symptoms. 
No previous studies have assessed the association between antidepressant use and 
gastrointestinal symptoms in the general population. However, depression and gastroin-
testinal symptoms were studied before:  a survey from the general population assessed 
frequency of gastrointestinal symptoms in respondents with and without depressive 
symptoms, and found that 54% of respondents with depression frequently reported 
abdominal pain, diarrhoea, constipation, dyspepsia, or IBS compared to 29% of non-
depressed controls.26 Unfortunately, this study did not assess antidepressant use in re-
lation to gastrointestinal and depressive symptoms, but noted the frequent co-occurrence of 
depression and somatic complaints. 
We found that depressive symptoms are an important confounder in the association 
between antidepressant use and gastrointestinal symptoms. In our study, respondents 
with depressive symptoms had a 24% increased risk for presence of gastrointestinal 
symptoms. This is in line with other studies in the field.26-28 An ongoing study that compares 
the effectiveness of SSRIs, TCAs, and placebo in patients with functional gastrointestinal 
disorders (with or without concomitant depression) will hopefully add knowledge to the 
understanding of the complex interplay between depression and functional gastrointestinal 
symptoms.29 
Our study has a number of strengths and limitations. First, we studied the presence of 
gastrointestinal symptoms in antidepressant users in a large randomly selected sample 
of the general population. Most other similar studies included patients from primary, 
secondary, and/or tertiary care centres that had strict inclusion criteria.13,14,30 Second, 
we were able to adjust for confounders using multivariable analysis with many covariates. 
This supported the assumption that the univariable association between antidepressant 
use and gastrointestinal symptoms is attributable to bias.
In our study the possibility of selection bias cannot be excluded. We tried to minimize this 
by sending a personalized invitation letter and ask all invitees to complete the questionnaire, 
irrespective of the presence of gastrointestinal symptoms. Of all respondents returning 
the questionnaire, 26% experienced gastrointestinal symptoms, which is similar to another 
study that assessed prevalence of upper gastrointestinal symptoms in the Netherlands.31 
This suggests that presence of selection bias in our study might be limited. Due to our 
study design we were unable to send reminders or to perform non-responder research. 
Another limitation is that we do not have detailed information about antidepressant dose and 
duration of use. Lower dosages of SSRIs seem to be associated with fewer side effects32-34, 
while the association between dosages of TCAs and adverse effects is ambiguous.35-37 
The lack of information on duration of antidepressant therapy may have confounded 
the association between antidepressant use and gastrointestinal symptoms, because 
adverse effects may predominate the first weeks of therapy. We assume that the 
majority of antidepressant users are long-term users, as was shown by Moore et al.3
The results of our study have clear implications for clinical practice. As known, patients 
using antidepressants are at risk of developing gastrointestinal symptoms, because these 
symptoms are frequently reported adverse effects. These side effects develop shortly after 
initiation of therapy, and usually precede the desired clinical effect by several weeks. This 
profile is inherent to this class of drugs and should be discussed with the patient prior to 
the start of antidepressant treatment. Another implication is that the evaluation of this class 
of drugs should include assessment of psychiatric but also gastrointestinal symptoms. 
In case a depressive patient develops gastrointestinal symptoms during therapy, emphasis 
should be put on adequate treatment of depression rather than alleviating the gastroin-
testinal symptoms. In practice this may result in increasing the dosage of antidepressants 
rather than tapering. For a treating physician this is a rather counterintuitive approach.
In conclusion, we found that antidepressant users more frequently reported presence of 
gastrointestinal symptoms than non-users. However, after adjusting for confounders, no 
association between antidepressant use and gastrointestinal symptoms was observed. 
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Gastrointestinal symptoms are very common and the majority of upper gastrointestinal 
symptoms in the community can be broadly classified as functional dyspepsia. The current 
thinking is that the causes and contributing factors for functional dyspepsia are manifold. 
Similarly, there is no universal treatment for functional dyspepsia. At the individual level, 
gastrointestinal symptoms greatly impact health-related quality of life and at macro-
economical level, these symptoms have profound implications for our healthcare system.1-4 
In this thesis we studied the current prevalence of gastrointestinal symptoms in a random 
sample of the population. 
We assessed which factors are associated with presence of gastrointestinal symptoms 
with a focus on medication use. In addition to assess the mere presence of gastrointestinal 
symptoms, we also addressed health-related quality of life as an outcome measure. We 
are aware that multiple studies focusing on presence of gastrointestinal symptoms have 
been performed in the past. However, the prevalence of risk factors for gastrointestinal 
symptoms, such as Helicobacter pylori and use of gastrotoxic medication, has changed 
considerably. This calls for a critical reassessment of the older data in view of the 
changed environment.5-7
ANSWERS TO QUESTIONS ADDRESSED IN THIS THESIS
1. What is the current prevalence of gastrointestinal symptoms in the Dutch general 
population? 
We studied this question by sending a questionnaire to more than 50,000 randomly 
selected Dutch adult inhabitants. 
We found that the current prevalence of gastrointestinal symptoms was 26%. We found 
that females more frequently reported gastrointestinal symptoms, which is in line with 
other similar studies.8-10 In our study, presence of asthma or COPD was independently 
associated with gastrointestinal symptoms. Asthma is associated with GERD, although 
the exact mechanism remains to be elucidated.11,12 Recent studies in patients with 
COPD also report an increased prevalence of GERD symptoms.13-15 
Medication use, and especially paracetamol, antidepressants, and acid-suppressive 
medication contributed significantly to presence of gastrointestinal symptoms in our 
large population-based survey. The independent association detected for paracetamol 
probably stems from the use of paracetamol as a panacea for gastrointestinal symptoms. 
We surmise that this hypothesis also applies to the relation between acid-suppressive 
medication and gastrointestinal symptoms. The association between antidepressants 
and gastrointestinal symptoms is complex due to the interactions between: 1) depression 
and gastrointestinal symptoms, 2) depression and antidepressant use, and 3) antidepres-
sant use and gastrointestinal symptoms.16-24 In this thesis we found that the association 
between gastrointestinal symptoms and antidepressant use was not statistically significant 
after correction for multiple confounders.
Plain low-dose aspirin and carbasalate calcium are frequently used in the Netherlands for 
the secondary prevention of cardiovascular events. Based on studies in healthy volunteers 
and following pharmacological principals, it is thought that carbasalate calcium possesses 
a safer gastrointestinal profile. We, however, were not able to confirm this hypothesis in 
clinical practice.  
2. What is the consequence of gastrointestinal symptom presence on health-related 
quality of life? 
In addition to prevalence of gastrointestinal symptoms, we also studied health-related 
quality of life. In our general population survey we assessed health-related quality of life 
using the EuroQoL EQ-5D.25 We found that the reported health-related quality of life in 
respondents with gastrointestinal symptoms was significantly lower compared with 
those without these symptoms. We did not use a disease-specific quality of life ques-
tionnaire. These questionnaires focus on specific disease entities, such as dyspepsia, 
gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS) etcetera.26-30 
The disadvantage is that these questionnaires are highly disease focused and less sensitive 
to detect general gastrointestinal symptoms. For the aim of thesis, which was to assess 
gastrointestinal symptoms in general, these disease-specific questionnaires were not 
suitable. 
We also assessed health-related quality of life in our Internet survey of respondents with 
GERD. Health-related quality of life was significantly decreased in respondents with 
more gastrointestinal symptoms. 
3. What is the role of NSAIDs on gastrointestinal symptoms and complications?
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause a large variety of gastrointestinal 
events, from dyspepsia to life-threatening bleeding. We found that NSAID users more 
frequently reported gastrointestinal symptom presence compared with respondents that 
did not use NSAIDs. Users of prescribed NSAIDs more frequently reported gastrointes-
tinal symptoms compared with over-the-counter (OTC) NSAID users, but this difference 
disappeared after statistical correction with multivariable regression analysis. This impli-
cates that NSAID use, irrespective of used dose, is a determinant for gastrointestinal 
symptoms. 
4. What is the role of PPIs in the treatment of gastrointestinal symptoms?
We demonstrated that proton pump inhibitor (PPI) use relieves NSAID-associated 
gastrointestinal symptoms. We also found through our (large paper-based) questionnaire 
study that PPI use was independently associated with presence of gastrointestinal 
symptoms. We assume this is caused by the cross-sectional design that does not allow 
us to detect and establish causal links. Previous studies demonstrated that PPIs and 
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H2-receptor antagonists (H2RAs) have a better efficacy than antacids and placebo in the 
treatment of functional dyspepsia.31-34 It is currently a matter of debate whether the 
efficacy of PPIs in functional dyspepsia could be explained by the existence of overlap 
syndromes with GERD.35,36 A Dutch primary care study that assessed cost-effectiveness 
of different strategies in the treatment of dyspepsia, concluded that starting with an antacid 
was cost-effective.37 However, since the patent of PPIs has expired, the argument of 
cost-effectiveness no longer holds. The newest version of the Dutch guideline “dyspepsia” 
still recommends starting pharmacologic treatment of patients with upper gastrointestinal 
symptoms with antacids. Reasons for this recommendation are the equal efficacy of 
antacids and PPIs, the rebound gastric acid hypersecretion after PPI withdrawal, and the 
drawbacks of long term PPI use, as increased risk for pneumonia and hip fractures.38-42 
However, in clinical practice, many patients visiting a general practitioner with upper 
gastrointestinal symptoms, frequently have already taken OTC antacids and H2RAs prior 
to consultation.  
In addition, PPIs are also frequently prescribed in GERD. In our cohort of individuals with 
GERD that we followed via the internet, we found that two-thirds of those without PPI 
use reported symptom improvement. This is a very interesting observation, because this 
supports reserve with PPI prescription if a patient presents with symptoms of GERD for 
the first time. It would be interesting to examine this population into detail. Did they 
change their dietary habits; did they lose weight, etcetera? This would be fertile ground 
for an interesting future study. 
IMPLICATIONS
Based on the findings of this thesis, we conclude that gastrointestinal symptoms are still very 
common and negatively impact health-related quality of life. Other studies demonstrated 
a decreased work efficacy, and high healthcare costs due to these symptoms.1,2 This 
suggests that strategies focused on improvement of gastrointestinal symptoms may be 
worthwhile. 
Based on these results, we recommend changes in the current Dutch guideline for upper 
gastrointestinal symptoms. PPI should be the first recommended pharmacological inter-
vention when lifestyle modifications are insufficient in patients with upper gastrointestinal 
symptoms. This recommendation follows the current daily practice. 
Our data are in line with the Dutch guideline “dyspepsia” that NSAID users at advanced 
age, with a history of peptic ulcer disease, or with concomitant use of low-dose aspirin, 
anticoagulants of systemic corticosteroids should adhere to a gastroprotective strategy.42 
However, we do not agree with the weight assigned to the risk factors that we will discuss 
below. Presence of severe reumatoid arthritis, severe diabetes mellitus or severe heart 
failure is seen as a bonafide indication for gastroprotection but we disagree. Concomitant use 
of venlafaxine, duloxetine, trazodone or spironolactone also qualifies for gastroprotective 
strategy and we think that this is unwarranted. The evidence that these risk factors affect 
‘general’ NSAID users is scant, and only further complicates the adherence of this guideline 
by individual physicians. 
We do not recommend PPI co-prescription in all NSAID users but favour a targeted 
strategy and offer PPI to those at risk. Although PPIs are generally safe, they can have 
serious side effects.40-42 Another argument against a policy that favours PPI co-prescription 
in all NSAID users is that this strategy promotes polypharmacy, which negatively affects 
compliance. Therefore, we advise the concomitant prescription of a PPI only in NSAID 
users at increased risk for gastrointestinal complications.
We favour the use of a structured GERD questionnaire for symptom assessment. A 
structured questionnaire can support the assessment of symptom severity, in addition 
to history taking. 
FUTURE PERSPECTIVES
Ongoing research is needed to unravel the aetiology of dyspepsia on a molecular basis. 
Although this has not been matter of study in this thesis, we believe that a successful 
treatment can only be found after elucidation of its aetiology. 
If we would have the possibility to repeat our large population survey, we would use a 
validated questionnaire and we would also perform non-responder research. In the ide-
al study, we would perform upper endoscopy and determination of Helicobacter pylori 
presence in every participant. To assess the association between medication use and 
gastrointestinal symptoms into more detail, we would question medication use into 
more detail; what drugs; what dose; how was the compliance, when was the drug started 
etc. To assess symptoms over time, we would send a second questionnaire 1 year after 
the first questionnaire. 
Future studies on NSAID use and gastrointestinal complications should also focus on 
lesions in the lower gastrointestinal tract, as there is experimental evidence that suggests 
an increased proportion of lower gastrointestinal tract lesions in users of concomitant 
PPIs and NSAIDs.43 Ideally, an individual risk profile in NSAID users should be constructed 
based on gastrointestinal risk and cardiovascular risk scores. This is in line with the strategy 
of risk assessment in cardiovascular disease. 
We expect that the role of Internet in our healthcare system will grow further in the future, 
which creates many new opportunities. We have shown a proof of principle, by studying 
feasibility to capture individuals with GERD symptoms through a dedicated website. 
We assume that this concept can be used for many other diseases. Another promising 
option, associated with our follow-up via the Internet, is monitoring of outpatients. This 
concept of telemonitoring has been most extensively studied in patients with heart 
failure.44-47 Results regarding improvement of hospital admission rates and overall 
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mortality are currently still ambiguous, but we believe that this method of follow-up will 
be optimized the next years and will be added to the arsenal of methods for patient-doctor 
communication. 
REFLECTION
We believe a Discussion section of a thesis can also be used to reflect on the work we 
have done over the past few years. Although large questionnaire-based studies have 
been performed multiple times in the past and were widely accepted, we faced several 
struggles. As discussed in the section above, we would certainly change the study design 
if we would be able to perform this study again. 
Due to a changed research environment in gastroenterology with advent of novel tech-
nologies, gene studies and new drugs, we experienced that epidemiological studies on 
gastrointestinal symptoms have low priority for Journal editors. We also experienced 
that the willingness of randomly selected Dutch inhabitants to complete and return the 
questionnaire was limited, which resulted in a response rate of 35%. This percentage 
consistently raised questions about selection bias by reviewers, which we were not able 
to refute due to our study design. The design did not allow us to perform non-responder 
research. Therefore, we will be reluctant to use this study model again in future epide-
miological studies. 
We used a non-validated questionnaire, which was used in several studies in the past 
and was improved step-by-step. However, use of a validated questionnaire to assess 
gastrointestinal symptoms would have improved the use and incorporation of widely 
accepted diagnostic criteria for functional gastrointestinal diseases, as the Rome III 
criteria. It would have facilitated the positioning of our results in respect to others. 
As we focused on medication use as determinant of gastrointestinal symptoms, we 
could have further improved our data by asking respondents to report their current AND 
past drug use, preferably by attaching a printout of their pharmacy report. In addition, 
we would still add questions on OTC medication use.
Despite all these considerations, we feel that an update about the gastrointestinal symptom 
prevalence was warranted and this thesis adds valuable knowledge about this topic.  
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ENGLISH SUMMARY
We studied the current prevalence of gastrointestinal symptoms in the general population 
and the contribution of certain risk factors. In the past, similar studies have been performed, 
but factors associated with presence of gastrointestinal symptoms have changed over 
time, making these results outdated. Although gastrointestinal symptoms do not imme-
diately lead to mortality, they are responsible for a decreased health-related quality of 
life. In addition, gastrointestinal symptoms significantly impact at a macro-economical 
level by healthcare visits, medication use, and additional investigations. 
PART 1 PREVALENCE AND IMPACT OF GASTROINTESTINAL SYMPTOMS
Chapter 1 (General Introduction) describes background information regarding gastroin-
testinal symptoms, including pathogenesis, clinical evaluation and therapeutic options. 
We also describe the three models that we have employed to answer our research 
questions: a questionnaire-based model, a systematic review, and a prospective inter-
vention study. In Chapter 2 we describe the results of 51,869 questionnaires, which we 
sent to randomly selected Dutch inhabitants of five municipalities: Nijmegen, Wijchen, 
Malden, Den Haag and Almere. We chose these communities to obtain a representative 
geographical distribution; east versus west, village versus city. In total, 18,317 question-
naires were returned (response rate 35%) of which 16,758 were eligible for analysis. A 
total of 26% reported presence of gastrointestinal symptoms. Individuals with these 
symptoms reported a decreased health-related quality of life compared to individuals 
without gastrointestinal symptoms (EQ 5D score 0.81 (SD 0.21), vs 0.91 (SD 0.14), p < 
0.01). After correction by multivariable analysis, female gender and asthma/COPD were 
independently associated with gastrointestinal symptoms. Also, use of paracetamol, 
antidepressants and acid-suppressive medication was associated with these symptoms. 
Advanced age and use of statins were associated with a decreased risk for gastrointestinal 
symptoms. 
In Chapter 3 we describe the results about presence of gastroesophageal reflux disease 
(GERD) in website visitors of a dedicated GERD website (www.maagzuur.nl, “maagzuur” 
is “gastric acid”) who completed the GerdQ self-assessment questionnaire. A GerdQ 
score of t 8 is suggestive for GERD. In 2.5 years, more than 150,000 individuals completed 
this questionnaire, and 80% did not report proton pump inhibitor (PPI) use. In this group 
of non-PPI users, 64% had a GerdQ score t 8, of which almost half (48%) reported high 
impact of GERD symptoms on daily life by use of over-the-counter (OTC) acid-suppressive 
medications and sleep problems do to heartburn and/or regurgitation. In the group of 
PPI users, 88% reported GERD symptoms more than one day per week. Respondents 
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with GERD symptoms reported a decreased health-related quality of life compared to 
individuals without symptoms. 
In Chapter 4 we describe the results of a prospective observational study among 
respondents who completed the GerdQ self-assessment questionnaire at baseline, and 
after 4, 12 and 24 weeks. Our main finding is that 66% of respondents who did not use 
PPIs at baseline reported symptom improvement after 24 weeks. Based on these findings, 
we recommend adherence to the Dutch guideline ‘GERD’, which advises lifestyle changes 
as first step in patients who present with symptoms suggestive for GERD, instead of 
prescription of acid-suppressive medication. We also followed PPI users and found that 
over 90% reported persistence of symptoms for more than one day per week after 24 
weeks. A drawback of online research, we experienced, is a high dropout of respondents 
during follow-up. 
PART 2 DETERMINANTS OF GASTROINTESTINAL SYMPTOMS
Chapter 5 describes the results of a systematic review of current guidelines and consen-
sus agreements regarding risk factors for gastrointestinal complications in nonsteroidal 
anti-inflammatory drug (NSAID) users. Nine guidelines were eligible for inclusion. We found 
that a history of (complicated) peptic ulcer disease, older age, concomitant anticoagulant, 
low-dose aspirin and systemic corticosteroid use and use of multiple NSAIDs were clearly 
defined as a risk factor in all guidelines. A history of gastrointestinal symptoms, use of 
high dose NSAIDs, concomitant use of clopidogrel or selective serotonin reuptake inhibitors 
(SSRIs), presence of severe rheumatoid arthritis disability, and cardiovascular disease 
were seen as risk factor for gastrointestinal complications in one or more guidelines. 
Presence of Helicobacter pylori is regarded an additive risk factor, as the exact role of 
this factor in the aetiology of NSAID-associated gastroduodenal ulceration is still under 
debate. We also assessed statements regarding OTC NSAID use in the studied guide-
lines and concluded that the information regarding OTC NSAID use was limited. 
We assessed gastrointestinal symptoms in prescribed and OTC NSAID users in Chapter 
6. NSAID users more frequently reported gastrointestinal symptoms compared with 
respondents that did not use NSAIDs (33% vs 24%, p < 0.01). We did not find a difference 
in gastrointestinal symptom presence between users of prescribed and OTC NSAIDs 
after adjustment for confounders. In users of prescribed NSAIDs at risk for gastrointes-
tinal complications, only 51% concomitantly used a PPI. In Chapter 7 we report on the 
effectiveness of PPIs to reduce NSAID-associated upper gastrointestinal symptoms in 
a prospective, open-label study in primary care. Eighty-one percent of participants reported 
complete or partial response with PPI therapy. This study demonstrates that PPIs can 
be used to reduce NSAID-associated upper gastrointestinal symptoms in daily clinical 
practice. 
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In Chapter 8 we studied gastrointestinal symptoms in users of plain aspirin and carbasalate 
calcium through a large questionnaire-based study in the general population. We could not 
confirm the hypothesis that use of carbasalate calcium is associated with less gastroin-
testinal symptoms. Based on our results, plain aspirin remains the drugs of first choice 
for secondary prevention in cardiovascular disease. 
Antidepressants are frequently used medications and gastrointestinal symptoms are 
frequently reported side effects. Simultaneously, antidepressants are also a treatment 
modality in functional gastrointestinal disorders. In Chapter 9 we assessed the association 
between antidepressant use and gastrointestinal symptoms in the general population. 
Gastrointestinal symptoms were more frequently reported by antidepressant users com-
pared to non-users (40% vs. 25%, p < 0.01). However, after correction for confounding 
by multivariable analysis, no association between antidepressant use and gastrointestinal 
symptoms was found. We assume that the univariable association may be attributable 
to bias, for example by the presence of depressive symptoms. 
In conclusion, the current population prevalence of gastrointestinal symptoms is still 
high and is associated with a decreased health-related quality of life. Given the large in-
dividual and societal impact, improvement of treatment options of these symptoms would 
be worth pursuing. Gastrotoxic drugs, as NSAIDs, are associated with presence of gas-
trointestinal symptoms. When patients present with these symptoms, we suggest that 
medication use deserves careful evaluation. If possible, gastrotoxic drugs should be 
stopped or the dose of these agents should be lowered. 
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Dit proefschrift beschrijft de huidige prevalentie van maag- en darmklachten (gastro- 
intestinale klachten) in de algemene bevolking. In het verleden zijn er meerdere studies 
geweest die het voorkomen van deze klachten in de populatie onderzocht hebben. Echter, 
veel factoren die van invloed zijn op deze klachten, zijn in de loop van de tijd veranderd, 
zoals de prevalentie van Helicobacter pylori en het gebruik van gastrotoxische medicatie. 
Hierdoor zijn de oude cijfers wellicht niet meer toepasbaar. Gastro-intestinale klachten 
zijn gelukkig niet geassocieerd met een verhoogde mortaliteit, maar ze gaan wel gepaard 
met een verlaagde kwaliteit van leven. Tevens zijn ze verantwoordelijk voor substantiële 
gezondheidszorgkosten, onder andere door artsbezoek, medicijngebruik, en aanvullend 
endoscopisch onderzoek.
DEEL 1 PREVALENTIE EN GEVOLGEN VAN GASTRO-INTESTINALE KLACHTEN  
Hoofdstuk 1 (Introductie) geeft een overzicht van de achtergronden van gastro-intestinale 
klachten, de theorieën over de etiologie van deze klachten en de behandelmogelijkheden. 
Tevens worden in dit hoofdstuk de drie modellen beschreven die in dit proefschrift gebruikt 
zijn om de onderzoeksvragen te beantwoorden: vragenlijstonderzoek, een systematische 
review, en een prospectieve interventiestudie. In Hoofdstuk 2 beschrijven we de uitkom-
sten van de 51.869 vragenlijsten die gestuurd zijn naar willekeurig selecteerde inwoners 
van Nijmegen, Wijchen, Malden, Den Haag en Almere om een goed beeld te krijgen van 
de huidige prevalentie van gastro-intestinale klachten in Nederland. Een totaal van 
18.317 vragenlijsten is teruggestuurd (respons van 35%), waarvan er 16.758 geschikt 
zijn voor analyse. Zesentwintig procent van deze respondenten meldde gastro-intestinale 
klachten. Individuen die klachten rapporteerden, hadden een lagere kwaliteit van leven 
in vergelijking met respondenten die geen klachten ervoeren (EQ-5D score 0,81 (SD 0,21), 
vs 0,92 (SD 0,14), p < 0,01). Na aanpassing voor verstorende factoren (confounding) via 
multivariaat analyse, vonden we dat vrouwelijk geslacht en astma/COPD geassocieerd 
zijn met aanwezigheid van klachten. Dit was ook het geval bij het gebruik van paracetamol, 
antidepressiva en maagzuurremmende medicatie. Hogere leeftijd en het gebruik van 
cholesterolverlagende medicijnen (statines) verminderden daarentegen de kans op gastro-
intestinale klachten.
Voor Hoofdstuk 3 hebben we gebruik gemaakt van een website waarop informatie te 
vinden is over gastro-oesofageale refluxziekte (GERD) (www.maagzuur.nl). Op deze 
website, die voor iedereen toegankelijk is, hebben we de GerdQ vragenlijst geplaatst. 
Aan de hand van deze vragenlijst, kan met redelijke betrouwbaarheid worden vastgesteld 
of sprake is van refluxziekte. In een tijdsbestek van 2,5 jaar hebben meer dan 150.000 
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individuen deze vragenlijst ingevuld, waarvan 80% geen maagzuurremmers (PPIs) 
gebruikte. Van deze groep zonder PPI gebruik voldeed 64% aan de criteria voor reflux-
ziekte (gedefinieerd als GerdQ score t 8). Bijna de helft van niet-PPI gebruikers met 
refluxklachten (48%) gaf aan dat de klachten veel invloed hadden op het dagelijks leven. 
Van de respondenten die wel een PPI gebruikten, rapporteerde 88% minimaal 2 dagen 
per week klachten. We vonden in deze studie dat refluxklachten geassocieerd zijn met 
een verminderde kwaliteit van leven in vergelijking met respondenten zonder klachten. In 
Hoofdstuk 4 beschrijven we de resultaten van de studie waarbij we respondenten die de 
GerdQ vragenlijst invulden, gedurende 24 weken hebben gevolgd. Onze belangrijkste 
bevindingen zijn dat 66% van de respondenten die geen PPI gebruikten, een vermindering 
van klachten rapporteerden aan het einde van de follow-up. De overgrote meerderheid van 
de PPI gebruikers daarentegen had na 24 weken nog steeds klachten. Op basis van 
deze getallen, raden wij aan de Nederlandse richtlijn te volgen, zodat patiënten die voor 
de eerste maal met refluxklachten bij de huisarts komen, niet direct maagzuurremmers 
voorgeschreven krijgen. Tijdens deze studie ondervonden we dat bij online onderzoek een 
groot deel van de respondenten de vervolgvragenlijsten niet invult. Hierdoor  voldeden 
helaas veel respondenten niet aan de inclusie criteria voor deze follow-up studie. 
DEEL 2 DETERMINANTEN VAN GASTRO-INTESTINALE KLACHTEN
In Hoofdstuk 5 beschrijven we de resultaten van een systematische review naar Engels-
talige richtlijnen en consensus documenten over risicofactoren bij NSAID gebruik (NSAID 
staat voor “nonsteroidal anti-inflammatory drug”). Negen richtlijnen voldeden aan onze 
selectiecriteria en werden geïncludeerd. Op basis van deze richtlijnen, concluderen we 
dat bij een voorgeschiedenis met ulcuslijden, een hogere leeftijd, het gelijktijdig gebruik 
van anticoagulantia, systemische corticosteroïden, lage dosis aspirine en het gebruik 
van meerdere soorten NSAIDs uniform geadviseerd wordt om een maagbeschermende 
(gastroprotectieve) strategie toe te passen. Een voorgeschiedenis van gastro-intestinale 
klachten, een hoge dosis NSAIDs, gelijktijdig gebruik van clopidogrel of een selectieve 
serotonine-heropnameremmer (SSRI), ernstige reumatoïde arthritis en hart- en vaatziekten 
waren risicofactoren voor gastro-intestinale complicaties die in een of meerdere richtlijnen 
genoemd werden. Een infectie met Helicobacter pylori beschouwen we als een bij komende 
risicofactor. De specifieke bijdrage van deze bacterie in het ontstaan van NSAID-geasso-
cieerde gastroduodenale ulceraties en bloedingen is nog niet geheel uitgekristalliseerd. 
We onderzochten tevens in hoeverre het gebruik van vrij verkrijgbare (over-the-counter; 
OTC) NSAIDs in deze richtlijnen geïntegreerd is. In de bestudeerde richtlijnen was hierover 
echter weinig informatie te vinden. In Hoofdstuk 6 hebben we gastro-intestinale klachten 
bij NSAID gebruikers onderzocht, waarbij we gebruikers van deze medicatie op recept 
hebben vergeleken met respondenten die OTC NSAIDs gebruiken. NSAID gebruikers 
hebben vaker gastro-intestinale klachten dan mensen die geen NSAID gebruiken (33% 
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vs 24%, p < 0,01). We vinden echter geen verschil tussen beide soorten NSAID gebruikers 
(voorgeschreven vs. OTC) na correctie voor confounders. Slechts 50% van de gebruikers 
van voorgeschreven NSAIDs met een verhoogd risico op gastro-intestinale complicaties 
gebruikte gelijktijdig een PPI. We hebben in Hoofdstuk 7 via een prospectieve open-label 
studie in de huisartsenpraktijk onderzocht of PPIs effectief zijn in de behandeling van 
NSAID-geassocieerde gastro-intestinale klachten. We vonden dat bij 81% van de patiënten 
sprake was van verbetering of zelfs volledig verdwijnen van de klachten. PPIs kunnen 
dus in de dagelijkse praktijk gebruikt worden voor reductie van gastro-intestinale klachten 
bij NSAID gebruikers.  
In Hoofdstuk 8 hebben we onderzocht of er verschil is in gastro-intestinale klachten tussen 
gebruikers van lage dosis aspirine en ascal via de vragenlijststudie in de algemene bevolking. 
De hypothese dat ascal minder gastro-intestinale klachten veroorzaakt dan aspirine, 
omdat dit geneesmiddel minder lokale maagschade zou geven, kon niet worden bevestigd. 
Wij zijn dan ook van mening dat ascal niet het middel van eerste keuze dient te zijn bij 
secundaire preventie voor hart- en vaatziekten.
Antidepressiva zijn veelgebruikte geneesmiddelen, die enerzijds gastro-intestinale klachten 
kunnen induceren, aangezien dit vaak gerapporteerde bijwerkingen zijn. Anderzijds worden 
antidepressiva tegenwoordig ingezet als tweedelijns behandeling bij functionele klachten 
van het maagdarmstelsel. In Hoofdstuk 9 hebben we onderzocht of antidepressivagebruik 
in de algemene bevolking geassocieerd is met gastro-intestinale klachten. Bij univariate 
analyse vinden we dat antidepressivagebruikers significant vaker klachten rapporteren 
dan niet gebruikers (40% vs. 25%, p < 0,01). Echter, na multivariaat analyse verdwijnt de 
associatie tussen antidepressiva gebruik en gastro-intestinale klachten. We denken dan 
ook dat de univariate associatie veroorzaakt wordt door bias, zoals de aanwezigheid van 
depressieve klachten.
Samenvattend concluderen we dat de populatieprevalentie van gastro-intestinale klachten 
nog steeds hoog is en geassocieerd is met een verminderde kwaliteit van leven. Gezien 
de grote individuele en maatschappelijke impact, is winst te behalen door een verbeterde 
behandeling van deze klachten. Aangezien gastrotoxische medicijnen, zoals NSAIDs, een 
rol kunnen spelen bij de etiologie van deze klachten, dient geëvalueerd te worden, of 
deze medicatie gestaakt of verminderd kan worden in het geval dat een patiënt zich met 
deze klachten presenteert. 
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ook voor een groot deel uit enveloppen openen en vragenlijsten inscannen. Tijdens deze 
werkzaamheden en de ‘onderzoeksflow’ die in de kelder aanwezig was, werd mijn 
interesse voor het onderzoek bij de afdeling Maag-, Darm- en Leverziekten gewekt. 
Bedankt voor je vertrouwen en voor de kansen die ik gekregen heb om te starten met 
dit promotieonderzoek. 
 
Prof. dr. J.P.H. Drenth, beste Joost, jij nam het stokje over van prof. Jansen. Je scherpe 
analytische vermogen, je uitgebreide onderzoekservaring, je onverzadigbare werklust, 
waarbij artikelen regelmatig per omgaande weer in mijn mailbox verschenen en zeker 
ook je begeleiding tijdens de afrondende fase van dit proefschrift, waardeer ik zeer. Zonder 
jouw ondersteuning had het zeker langer geduurd voordat dit proefschrift voltooid zou 
zijn. Bedankt!
 
Dr. M.G.H. van Oijen, beste Martijn, onder jouw supervisie startte ik met mijn weten-
schappelijke stage, die uitmondde in dit promotieonderzoek. Jouw enthousiasme werkte 
aanstekelijk. Gekscherend zei ik weleens dat jij met dit enthousiasme in staat zou zijn 
poep te verkopen en dat denk ik nog steeds. Helaas heb ik maar kort van je directe 
aanwezigheid mogen genieten; eerst ging je in Utrecht werken en daarna in Los Angeles. 
Ondanks het tijdsverschil, het feit dat jij volop nieuwe uitdagingen in Amerika kreeg en 
dat ik weer in het Jeroen Bosch Ziekenhuis werkte, ben jij tot aan het einde toe betrokken 
geweest. Dank hiervoor. 
 
Zonder manuscriptcommissie en corona geen promotie. Bedankt dat jullie bereid waren 
deze taak op jullie te nemen.
Dankwoord
Leo en Ewald, jullie waren mijn redders in nood bij computer- en database problemen! 
Super bedankt! 
 
Jeroen en Ties, jullie hebben mij de eerste maanden geholpen met het invoeren van 
meer dan 18.000 vragenlijsten en het handmatig controleren van de data. Dat was een 
immens karwei. Dank voor jullie hulp.  Jeroen, ik wil je ook bedanken voor je kritische blik 
op de artikelen en onze ‘spar’- momenten. 
 
Co-auteurs, jullie wil ik bedanken voor de kritische input. Zonder jullie was het eindresultaat 
minder goed geworden. 
 
Stagiaires Bernadette en Bryan, jullie hielden me scherp en lieten me zien dat het lastig 
kan zijn om aan anderen precies uit te leggen waarom en hoe je dingen doet. Bernadette, 
super dat jouw stage onderdeel van dit proefschrift is geworden.
 
Mijn collega-onderzoekers van “de Kelder” en “de Buitenhoek”: Karin, Serena, Mieke, 
Bjorn, Melissa, Evelyn, Wybrich, Polat, Tom, Ria, Geert, Mark, en Robin bedankt! Andere 
onderzoekers, stafleden, aios, laboratoriummedewerkers en secretaresses van de afdeling 
MDL van het UMC Radboud: allen bedankt voor de gezelligheid en prettige samenwerking! 
Ik wil ook de stafleden, aios en onderzoekers van het UMC Utrecht bedanken waar ik tijdens 
mijn fulltime onderzoeksjaar één dag in de week werkzaam was. Nicolette, dank je wel 
dat je mij op sleeptouw nam.
 
Ik wil alle collega’s uit het JBZ bedanken voor de fijne leeromgeving en gezelligheid.
 
Lieve vrienden en vriendinnen, het combineren van opleiding, promotie, muziek en daar-
naast ook nog jullie willen zien, is lastig. Dank voor al jullie gezelligheid, interesse, steun 
en ook flexibiliteit als ik weer eens afspraken wilde verzetten. Laten we er de 28e een 
mooi feestje van maken!
Saxofoonmaatjes Trudy, Eveline, Frank, Liesbeth en andere HKW-leden: wat is het fijn 
om samen met jullie prachtige muziek te mogen maken. Geert, zonder jouw hulp was 
het voor mij onmogelijk geweest om wekelijks te repeteren. 
Lieve papa en mama, jullie konden af en toe niet meer bijbenen waar ik mee bezig was; 
onderzoek, opleiding, voorbereiden voor congres etc...... Jullie hebben me altijd gestimu-
leerd om het beste uit mezelf te halen. Een van de lessen die jullie me hebben meegegeven, 
is dat het belangrijk is om dingen waar je aan begint, ook af te maken. Dat is zeker van 
pas gekomen.
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Chapter 11
Myrte, lieve zus, met wie ik vroeger slootje sprong, in de boomhut sliep en samen naar 
school fietste. Later gingen we beiden geneeskunde studeren, jij in Maastricht en ik in 
Nijmegen. En wie had gedacht dat we allebei zelfs promotieonderzoek zouden gaan 
doen. Blijkbaar kruipt het bloed toch waar het niet gaan kan… Fijn dat jij, samen met 
Bjorn, mijn paranimf wilt zijn. Ik ben erg blij met je als kleine zus!
Lieve Jeroen, je moest het allemaal aanhoren en meemaken; mijn gemopper als het niet 
wilde vlotten, alle uren in avonden, weekenden en zelfs vakanties waarbij ik achter de 
computer aan mijn onderzoek zat te werken (in plaats van gezellig met jou op de bank 
of in de kroeg), alle presentaties waar je naar mocht luisteren. Dank je wel voor al je 
steun en liefde. Het is heerlijk samen met jou!  
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Ziekenhuis te ‘s-Hertogenbosch (opleider: dr. P.M. Netten). Deze werd gedurende een 
jaar onderbroken om fulltime promotieonderzoek te doen. Sinds 1 december 2012 is 
Merel werkzaam als AIOS Maag-, Darm-, en Leverziekten in het Jeroen Bosch Ziekenhuis 
(opleider: dr. I.P. van Munster).
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